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The objective of this study is to compare approaches for the regulatory screening, testing 
and assessments of substances for the endocrine disrupting properties within the 
European Union (EU) and among relevant international trading partners, as well as the 
results of these approaches, in order to establish commonalities and differences and 
assess the drivers for these differences. 
To create a basis for the analyses of this study, an inventory of completed and on-going 
activities related the screening, priority setting, testing and assessment of chemicals for 
their endocrine disrupting properties in the EU (including within the Member States) and 
relevant international trading partners (US, Canada, Australia, Japan, China) was 
created. This was complemented by an expert consultation about ongoing activities, and 
resulted in a high level overview summary of the regulatory approaches for endocrine 
disrupting chemicals in the various legalities. 
This overview summary showed a common concern about the harmful effects of 
endocrine disrupting properties across the legalities. However, significant differences 
relate to the question whether endocrine disrupting chemicals require dedicated 
regulatory systems and structures to capture their effects appropriately, or whether the 
adverse effects produced by endocrine disrupting chemicals can be dealt with adequately 
within the existing regulatory structures. 
Case studies of eight chemicals, ethinylestradiol and estradiol, nonylphenol, bisphenol A, 
di-ethyl-hexyl phthalate (DEHP), mancozeb, prochloraz, procymidone and 
benzophenone-3, were conducted for a deep analysis of the commonalities and 
differences in screening, priority setting and testing of chemicals for their endocrine 
disrupting properties in the EU and among its international trading partners. The case 
studies served to address the following study questions: 
 Are the differences and commonalities in the different legalities due to differences 
in scientific approaches, or are they an expression of the different features of the 
respective legal systems? 
 What impact do differences in approach have on the final outcome of the 
derivation of regulatory values (e.g. water quality standards, acceptable daily 
intakes and similar)? 
To facilitate systematic comparisons between the case studies, a common structure was 
adopted, covering: Discovery of endocrine disrupting properties of the chemical in 
question, its regulatory status across the different legalities, assessment endpoints used 
for hazard characterisation, the derivation of assessment values (acceptable daily intakes 
or water quality criteria), and exposure and risk assessments. 
The comparative analysis of the case studies revealed that the endocrine disrupting 
properties of five of the chemicals were discovered in the context of scientific research 
activities; only three (two pesticides, prochloraz, procymidone and a cosmetic ingredient, 
benzophenone-3) were identified through regulatory testing efforts. This suggests that 
the framework of established regulatory testing is ill-equipped for identifying chemicals 
with endocrine disrupting properties. It also gives an impression of the potential benefits 
of international harmonisation in the regulatory domains dealing with pesticides and 
cosmetic ingredients. 
While all the pesticides analysed in the case studies (mancozeb, prochloraz, and 




this project, a more varied picture emerged for industrial chemicals such as bisphenol A 
and DEHP. For bisphenol A, restrictions apply in some jurisdictions (e.g. EU and China), 
while in others, it is essentially unregulated (USA, Canada, Japan, Australia). This is a 
reflection of differences in the regulatory regimes and of differences in the level of 
concern with which bisphenol A is regarded (higher in the EU than anywhere else). The 
use of DEHP is restricted in the EU, the USA and Australia, but not in Canada, Japan or 
China. 
The environmental regulatory status of the industrial chemical nonylphenol varies 
considerably across the legalities considered, with water quality criteria implemented in 
the EU, the USA and Canada, but not in China, Japan and Australia. In contrast, the 
status of the pharmaceutical ethinylestradiol is rather uniform. With the exception of 
Canada, which has established water quality criteria, there are no environmental 
standards implemented in any of the other legislations. 
The assessment values (acceptable daily intakes) that are applied for the pesticides 
considered in the case studies are rather uniform across all legislations, except for 
procymidone where the values vary by a factor of approximately 30. This appears to be a 
result of the internationally harmonised procedures of hazard characterisation that have 
evolved over the years in the regulatory domain of pesticides. It is of note that the 
assessment values derived for prochloraz are based on toxicities unrelated to endocrine 
disruption. A similar, rather uniform picture also emerged for DEHP where the 
assessment values utilised in the different countries and legislations do not differ much, 
with the exception of the EU where a range of values is applied. 
Greater differences became obvious for the environmental standards used for 
ethinylestradiol and nonylphenol, and for bisphenol A. The water quality criteria (or 
equivalent) that are in use for risk assessments for ethinylestradiol vary by a factor of 
approximately 15. These differences are explained by the use of different experimental 
studies for the derivation of the values, and by the application of differing assessment 
factors. 
In the case of nonylphenol, the differences between the various assessment values 
(factor of approximately 60) are due to the fact that their derivation was based on 
distinct chemical entities (nonylphenol with linear or branched side chain), with quite 
different toxic properties. 
The greatest variations became apparent with bisphenol A where the assessment values 
in use internationally differ by no less than 10,000-fold. This is driven by the use of a 
variety of assessment endpoints, not all of which relate to endocrine disruption, and the 
application of widely differing assessment factors, reflecting differences in the evaluation 
of adversity, and a lack of scientific agreement about the basis for hazard 
characterisations. 
In summary, the differences and commonalities in the different legalities in dealing with 
endocrine disruptors are mainly an expression of the features of the respective legal 
systems. In some cases, diverging scientific approaches also play a role. The impact of 
these differences on the final outcome of the derivation of regulatory values (e.g. water 
quality standards, acceptable daily intakes and similar) varies from compound to 
compound, but can be considerable. 
The differences in the respective assessment values could diminish if more consistent 




transparent and agreed criteria as to the selection of studies for hazard characterisations, 
and more transparency in the choice of assessment factors. 
To discuss the commonalities and differences in screening, testing and evaluating 
endocrine disruptors across the EU and its international trading partners, an international 
workshop with risk assessment practitioners from competent authorities was held on 19-
20 September 2016 in Brussels. Four working groups were set up, as follows: 
Working Group 1: The scope for data sharing on ED hazards and exposures at the 
international level 
Working Group 2: Setting priorities for screening and testing for ED properties – 
commonalities and differences and scope for common principles 
Working Group 3: Research needs and horizon scanning in the ED arena – prospects 
for international cooperation? 
Working Group 4: Harmonisation of hazard and risk assessment for endocrine 
disruptors at the international level – opportunities and limitations 
There was widespread recognition among workshop participants of the need for 
international cooperation in promoting the chemical safety of chemicals with endocrine 
disrupting properties. There was also a willingness to move towards an international 
harmonisation of approaches. This found expression in four recommendations from 
workshop participants, which concerned the 
 development of international guidance for harmonised hazard assessment of 
endocrine disruptors, 
 development of a strategy for the testing of endocrine disruptors 
 implementation of existing tests and assays for the identification of endocrine 
disruptors, as described in the OECD Conceptual Framework, Level 2 and 3, and 
 creation of an institutional platform for international harmonisation of hazard and 
risk assessment for endocrine disruptors, and for the exchange of data and 
assessments 
The implementation of the last of these recommendations would appear to be essential 
to initiate the process of international harmonisation in the assessment of endocrine 
disruptors. However, it is beyond the scope of this project to elaborate the finer 
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This document is the Final Report for the project Mapping commonalities and differences 
in approaches for testing and assessment of endocrine disruptors within the EU and 
among relevant international trading partners. It incorporates the 2nd interim report for 
this project. 
The objective of this project is to compare approaches for the regulatory screening, 
testing and assessments of substances for the endocrine disrupting properties within the 
European Union (EU) and among relevant international trading partners, as well as the 
results of said approaches, in order to establish commonalities and differences and 
assess the drivers for these differences. 
Accordingly, the project addresses the following specific objectives: 
1. To gain an overview of regulatory screening, priority setting, testing and 
assessment approaches applied to identify and assess endocrine disruptors in EU Member 
State, at EU level and by relevant international trading partners (US, Canada, Australia, 
Japan, China) focusing in particular on case studies of application; 
2. To map out commonalities and differences in the screening, priority setting, 
testing and assessments approaches addressing the used methodologies, type of data 
considered, technical assessments of specific cases and interpretation of results of 
specific cases; 
3. To ascertain the extent to which differences are due to variations in scientific 
approaches or in different legislative frameworks and regulatory culture; 
4. To identify opportunities to foster international cooperation on scientific issues 
related to promoting chemical safety in regards to potential for endocrine disruption. 
1.1 Tasks 
In line with the technical specifications for this project, and on the basis of the above 
specific objectives, the study includes the following tasks: 
Task 1: Collate an inventory of completed and on-going activities related the screening, 
priority setting, testing and assessment of chemicals for their endocrine disrupting 
properties in the EU (including within the Member States) and relevant international 
trading partners (US, Canada, Australia, Japan, China); 
Task 2: Elaborate a descriptive overview of results of regulatory screening, priority 
setting, testing and assessments as regards endocrine disruptors in the EU (including 
within the Member States) and relevant international trading partners (US, Canada, 
Australia, Japan, China); 
Task 3: Identify, describe and assess commonalities and differences in screening 
approaches, priority setting approaches, testing approaches and assessments of 
chemicals as regard their endocrine disrupting properties; 
Task 4: Identify opportunities to foster international cooperation on scientific issues 
related to promoting chemical safety in regards to potential for endocrine disruption; 
Task 5: Organise an international workshop on commonalities and differences in 
approaches for testing and assessment of endocrine disruptors within the EU and among 




1.2 Contents of this report 
This report describes all the results obtained in relation to all tasks of the project, under 
the following headings: 
  Inventory of concluded and on-going activities regarding the screening, priority 
setting, testing and assessment of chemicals for their endocrine disrupting 
properties in the EU and relevant international trading partners 
  Descriptive overview of results of regulatory screening, priority setting, testing 
and assessment in the EU and relevant international trading partners 
  Identification and assessment of commonalities and differences in screening 
approaches, priority setting approaches, testing approaches and assessments of 
chemicals regarding their endocrine disrupting properties 
  The international workshop on commonalities and differences in approaches for 
testing and assessment of endocrine disruptors within the EU and among relevant 
trading partners 
  Possibilities for fostering international cooperation on scientific issues related to 
promoting chemical safety in regards to the potential for endocrine disruption. 
 
2. INVENTORY OF CONCLUDED AND ON-GOING ACTIVITIES 
REGARDING THE SCREENING, PRIORITY SETTING, TESTING AND 
ASSESSMENT OF CHEMICALS FOR THEIR ENDOCRINE DISRUPTING 
PROPERTIES IN THE EU AND RELEVANT INTERNATIONAL TRADING 
PARTNERS 
In this section of the report we present an inventory of completed and on-going activities 
related the screening, priority setting, testing and assessment of chemicals for their 
endocrine disrupting properties in the EU (including within the Member States) and 
relevant international trading partners (US, Canada, Australia, Japan, China). This work 
was subdivided into 4 separate work steps: 
Step 1: Literature searches 
Step 2: Expert consultation 
Step 3: Overview summaries 
Step 4: Summary of commonalities and differences in the various legislations 
2.1 Step 1: Literature searches 
Web-based searches via search engines yielded more than 200 relevant documents from 
EU and non-EU countries, as well as relevant authorities. In addition to these documents, 
the expert consultation (see below) produced more than 60 documents which have been 
added to a document inventory as Annex 1 “EDC assessment documents” to this report. 
2.2 Step 2: Expert consultation 
Experts from EU and non-EU countries were consulted in order to prepare for the project 
workshop and to develop an overall picture of the legislative frameworks and regulatory 
activities related to endocrine disruption of selected member states and international 
trading partners. 
The aims of this consultation exercise were 
 to ensure that the international workshop takes note of all relevant current, 
ongoing or planned activities and approaches regarding identification, testing and 




 to ensure that all points considered critical and important by experts are properly 
discussed during the workshop and reflected in the workshop report. 
 The consultation took the form of collection of expert views via structured written 
responses to questions. To this end an expert consultation guide was developed 
which covered the list of topics below: 
 Definition of Endocrine Disruptors (EDs) – requirements for regulatory 
purposes 
 Identification of EDs – overview of regulatory activities related to the 
screening, priority setting, testing and assessment 
 Completeness and fitness-for-purpose of different approaches 
 Regulatory assessment of EDs 
 Evidence based assessment of EDs 
 Research and regulatory needs 
 Data sharing 
 Comparative case studies 
The expert consultation guide can be found in Annex 2 “Expert consultation guide”. 
Among international trading partners (non-EU countries), we contacted 22 experts (from 
5 countries), of which: 
  6 completed interviews: 1 from Australia, 1 Canada, 2 Japan, 2 US 
  2 promised they would complete the questionnaire but did not have sufficient time 
before the extended deadline (end of May 2016) (one submitted some comments 
by email, Australia) 
  4 were undeliverable to given email addresses 
  8 did not reply despite 3 attempts of contact (one because he had retired) 
  2 refused because questions were not pertinent to their organisations 
From EU Member States 16 experts from 8 MS were contacted, of which: 
  7 completed interviews from Austria (2), Belgium (1), Denmark (1), Germany (2), 
Italy (1) 
  4 promised they would complete the questionnaire but did not have sufficient time 
before the extended deadline (2 submitted some comments by email, France and 
UK) 
  3 did not reply despite 3 attempts of contact 
  2 refused altogether (UK) 
Among EU Institutions 2 experts were contacted, of which: 
  ECHA replied 
  EFSA promised to send completed questionnaire but then failed to respond to 
reminders 
Altogether, we obtained 14 responses.  An anonymised compilation of these responses 
can be found in Annex 3 “Compilation of anonymised expert responses”. 
2.3 Step 3: Overview summaries 
The outcomes of Steps 1 and 2 were distilled into overview summaries. These summaries 






The Toxic Substances Control Act 1976 (TSCA) authorises the US Environmental 
Protection Agency (USEPA) to require reporting, record-keeping and testing, and to 
enforce restrictions related to the importation, use, and disposal of specific chemicals and 
mixtures. Until recently, efforts have been focused on making basic screening level 
information on the toxicity of existing chemicals publicly available by maintaining the 
TSCA Chemical Substance Inventory which compiles information about more than 84,000 
chemicals. There are no fixed data requirements for industrial chemicals, and 
accordingly, no requirements for reporting endocrine disrupting properties of chemicals. 
New chemicals can be added to the TSCA Chemical Substance Inventory through the 
submission of a Pre-manufacture Notice, in which all currently available data should be 
included. After submission, USEPA can request further information (EPA, 2016a).  In April 
2010, Senator Lautenberg introduced new legislation aiming to reform the TSCA by 
placing the burden of proof on chemical manufacturers. The ‘‘Frank R. Lautenberg 
Chemical Safety for the 21st Century Act’’ was approved by the US Senate on the 8th 
June 2016.  
Food, drugs, cosmetics and pesticides, amongst others, are excluded from TSCA. The 
Federal Food, Drug, and Cosmetic Act and Federal Insecticide, Fungicide, and Rodenticide 
Act was amended by the passage of the Food Quality Protection Act (FQPA) in 1996 that 
allows USEPA to use and require data on endocrine disrupting properties of pesticides. In 
addition, the Safe Drinking Water Act (SDWA) provides USEPA with the authority for 
testing any substance that may be found in sources of drinking water. 
The US has not yet taken any legal action to restrict use of a chemical on the basis of its 
endocrine disrupting properties, but authorities have used ‘soft’ regulatory action such as 
voluntary programmes with industry and recommendations to consumers (e.g. the Food 
and Drug Administration (FDA) is supporting industry’s action to replace or minimise 
exposure to bisphenol A (BPA)). 
Activities related to the screening, testing and assessment of endocrine disrupters 
Passage of the FQPA required the EPA to develop a screening and testing program to 
determine human health effects of endocrine disrupting chemicals. The Endocrine 
Disruptor Screening and Testing Advisory Committee was established to make 
recommendations on how to develop the Endocrine Disruptor Screening Program (EDSP). 
The EDSP is a two-tiered screening and testing process that addresses both potential 
human and environmental effects. Tier 1 screening aims to identify chemicals with the 
potential to interact with the estrogen, androgen and thyroid hormone systems. The 
purpose of Tier 2 testing is to identify and establish a quantitative dose-response 
relationship for any resulting adverse effects, on the basis of which risk can be assessed 
and risk mitigation measures developed for the protection against adverse effects in 
humans and wildlife. The EPA began issuing test orders for the first list of 52 chemicals 
for Tier 1 screening in October 2009, mainly focused on active substances used in plant 
protection products. Eighteen of those will now undergo Tier 2 testing.  The EPA 
published a second list of 109 chemicals for Tier 1 Screening in May 2013, focussing on 
possible water pollutants.  
The National Toxicology Program (NTP) Tox21 is a federal collaboration among the 
National Institute of Health, USEPA and the FDA with the aim of applying high-
throughput methods in the hazard identification for chemicals. The EPA’s contribution to 
Tox21 is ToxCast, is a battery of in vitro endocrine disruption assays used to develop 
activity signatures of chemicals. It is used for prioritisation for testing under EDSP (Reif 
et al. 2010). The Interagency Centre for the Evaluation of Alternative Toxicological 
Methods (ICCVAM) is another NTP program that supports the scientific development and 




use in chemical testing. For example, the ToxCast estrogen receptor (ER) model for 
bioactivity integrates the results of 18 high-throughput in vitro screening assays with a 
computational model to predict the potential of a chemical to interact with the estrogen 
receptor that has been accepted by the USEPA as an alternative to the three test 
methods currently used in the EDSP Tier 1 battery. 
The NTP’s Office of Health Assessment and Translation (OHAT) has also led the 
development of a systematic review process to standardise the collection, assessment 
and synthesis of scientific evidence of hazardous properties to support evidence-based 
hazard assessments. 
Finally, the National Institute for Environment and Health Studies (NIEHS) offers financial 
support to studies investigating the potential human health effects related to exposure to 
endocrine disrupters.  
Canada 
Legislative Framework 
The Government of Canada’s legal tool for assessing and managing chemical substances 
in the environment is the Canadian Environmental Protection Act, 1999 (CEPA 1999), 
jointly administered by Environment and Climate Change Canada and Health Canada.  
Health Canada is responsible for the assessment of potential risks to human health posed 
by existing substances, i.e. those on the Domestic Substances List, a compilation of 
about 23,000 substances used, imported or manufactured in Canada for commercial 
purposes between January 1, 1984, and December 31, 1986, at a quantity of greater 
than 100 kg per year. The Existing Substances Division conducts this work within Health 
Canada, jointly with Environment and Climate Change Canada. If a substance is found to 
be CEPA-toxic as defined in Section 64 of the Act, it is added to Schedule 1 (the List of 
Toxic Substances) of the Act and options for controlling risks to human health and/or the 
environment are reviewed. 
Environment and Climate Change Canada oversees the New Substances Notification 
Regulations created to ensure that no new chemicals are introduced into the Canadian 
marketplace before completion of an assessment of their potential toxicity has been 
completed, and before any appropriate or required control measures have been taken. 
Any company or individual who plans to import or manufacture a substance subject to 
notification under the Regulations must provide a New Substances Notification (NSN) 
package containing all information prescribed in the Regulations prior to import or 
manufacture. This NSN Package is jointly assessed with Health Canada to determine 
whether there is a potential for adverse effects of the substance on the environment and 
human health. When this process identifies a new substance that may pose a risk to 
human health or the environment, CEPA 1999 empowers Environment and Climate 
Change Canada to intervene prior to or during the earliest stages of its introduction into 
Canada.  
CEPA 1999 not only defines ‘hormone disrupting substances’ but also requires that 
research is carried out on ‘methods related to their detection, methods to determine their 
actual or likely short-term or long-term effects on the environment and human health, 
and preventive, control or abatement measures to deal with those substances to protect 
the environment and human health’. 
Activities related to the screening, testing and assessment of endocrine disrupters 
Since 2001, Health Canada maintains an active research program related to exposure 
and biomonitoring, toxicological and epidemiological studies of substances suspected of 
having effects on the endocrine system, with the aim of supporting the risk assessment 




Research on Environmental Chemicals (MIREC) and Plastics and Personal-care Product 
use in Pregnancy (P4). 
Environment and Climate Change Canada has also been investigating hormone-disrupting 
substances for over 15 years. Research has included work on individual priority 
substances, wildlife toxicity studies and method development to improve the detection of 
substances, targeted at pulp mill and municipal wastewater effluents, as well as research 
in priority ecosystems such as the Great Lakes Areas of Concern. 




Since the early 1990s, new chemicals have undergone an assessment of their potential 
environmental and health impacts, and many of the older chemicals have been revised 
and, in some cases, phased out of production. At the Commonwealth level, chemicals are 
regulated according to four categories; 
  The National Industrial Chemicals Notification and Assessment Scheme (NICNAS) 
is responsible for the regulation of non-agricultural chemicals such as industrial 
chemicals regulated by the Industrial Chemicals (Notification & Assessment) Act 
1989, 
  The Australian Pesticides and Veterinary Medicines Authority (APVMA) oversees 
the permit process of agricultural and veterinary chemicals (such as pesticides) 
regulated by the Agricultural and Veterinary Chemicals (Administration) Act 1992, 
Agricultural and Veterinary Chemicals Act 1994, Agricultural and Veterinary 
Chemicals Code Act 1994, and Agricultural and Veterinary Chemical Products 
(Collection of Levy) Act 1994 
  The Therapeutic Goods Administration (TGA) is responsible for registering 
pharmaceuticals and medicinal products regulated by the Therapeutic Goods Act 
1989, and 
  The Food Standards Australia and New Zealand (FSANZ) is responsible for 
developing standards for food related issues including food additives regulated by 
Food Standards Australia New Zealand Act 1991, Australia New Zealand Food 
Standards Code. 
From a regulatory perspective, the current Australian position is that although endocrine 
disrupters present concerns equivalent to carcinogens, mutagens, reproductive toxicants 
or persistent and bio-accumulative agents, endocrine disruption is not an adverse end-
point per se, but rather a mode or mechanism of action of a chemical that can potentially 
lead to adverse toxicological or eco-toxicological outcomes. The existing legislation is 
considered to provide adequate protection and approaches devoted to the explicit 
screening and testing of EDCs are not currently proposed. 
NICNAS is currently going through reforms. Known EDCs are proposed to receive a 
similar regulatory treatment to that proposed for CMR and PBT chemicals and require a 
pre-market assessment. NICNAS is not requiring the generation of new data and 
information, but rather that applicants confirm whether their chemical is known to be an 
EDC by checking specified authoritative lists. It is anticipated that such lists can be 
developed by the time the reforms are due to be implemented (July 2018) with the 




Activities related to the screening, testing and assessment of endocrine disrupters 
Australia contributes to ongoing international work, particularly through the OECD Test 
Guidelines program, to further refine the methods used to identify the risks and to 
develop even more sensitive assessment methods. 
Additionally, NICNAS monitors the scientific literature and liaises with other regulators 
nationally and internationally to maintain an up-to-date understanding of research. This 
includes incorporation of new tools for characterising the hazard and exposure to 
endocrine disrupters, as these are progressively validated and gain international 
regulatory acceptance. 
Furthermore, organisations such as the CSIRO, universities, and regional water 
authorities have research and monitoring projects aimed at better understanding the 
presence, behaviour and fate of EDCs in aquatic environments. 
China 
Legislative Framework 
Industrial chemicals are mainly regulated by the following regulations: 
  Decree 591 - Regulations on Safe Management of Hazardous Chemicals entered 
into force on 1 Dec 2011. It implements the Global Harmonised System for 
Classification and Labelling of Chemicals and regulates hazardous chemicals 
through the entire supply chain by operating a license system and HazChem 
registrations. 
  MEP Order 7 - The Measures for Environmental Management of New Substances 
came into force on 15 Oct 2010. This regulation is similar to EU REACH and 
requires that manufacturers and importers of new substances notify new 
substances and obtain approval. 
  SAWS Order 53 - The Measures for the Administration of Registration of 
Hazardous Chemicals came into force on 1 Aug 2012 and sets out detailed 
requirements on HazChem registrations with the State Administration of Work 
Safety (SAWS). 
  MEP Order 22 - The Measures for Environmental Administration Registration of 
Hazardous Chemicals came into force on 1 March 2013. This regulation requires 
that manufacturers and companies who use hazardous chemicals to manufacture 
products (“user”) in China shall register hazardous chemicals listed in the 
Catalogue of Hazardous Chemicals with local environmental protection authorities 
and obtain environmental administration registration certificates. 
There is no dedicated regulation focusing on endocrine disruptors in China. The Ministry 
of Environmental Protection and the Ministry of Agriculture are taking the lead for 
controlling endocrine disruptors within their own jurisdictions. According to China’s action 
plan for water pollution prevention issued by the state council in 2015, the Chinese 
government plans to organize a national survey on the production and uses of 
Environmental Endocrine Disruptors before the end of 2017. Measures will be taken to 
eliminate, restrict or substitute endocrine disrupters. Both industrial chemicals and 
pesticides are affected. 
In Dec 2015, the Ministry of Agriculture announced the publication of industry standard 
NY/T2873-2015 Evaluation Method of the Endocrine Disruption Effects of Pesticides. The 
standard will be implemented from 1 April 2016. NY/T2873-2015 consists of 7 testing 
methods given in two tiers (in vitro and in vivo) to screen pesticides for endocrine 






The Ministry of Economy, Trade and Industry (METI) has overall responsibility for the 
management of chemicals. The Chemical Substances Control Law regulates the 
manufacture and import of bioaccumulative, persistent and toxic chemical substances. It 
was first enacted in 1973, and Japan pioneered the introduction of a pre-manufacturing 
evaluation and regulation system for new chemical substances.  
Under the Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances 
in the Environment and Promotion of Improvements to the Management Thereof, 
business operators are required to provide the Material Safety Data Sheet when 
transactions of Class I and II designated chemical substances (and products containing 
them) occur. The list of Class I Designated Chemical Substances is determined based on 
advice given by the Pharmaceutical Affairs and Food Sanitation Council (Ministry of 
Health, Labour and Welfare), the Chemical Substances Council (METI), and the Central 
Environment Council (Japan Environment Agency). Hazardous substances are selected 
based on their degree of hazard and the possibility of exposure.  
Other relevant laws applicable to the control of chemical substances include Food 
Sanitation Law, Agricultural Chemicals Regulation Law, Water Pollution Control Law, none 
of which specifically mentions endocrine disruption.  
Activities related to the screening, testing and assessment of endocrine disrupters 
The Ministry of Health, Labour and Welfare (MHLW) established a Committee on Health 
effects of Endocrine Disruptors in 1998. The Committee developed a framework for 
testing of possible endocrine disrupters consisting of two tiers; screening and definitive 
tests. Screening tests were carried out on a number of chemicals and a priority list for 
future definitive testing was established based on those results. MHLW is widening its 
research interest to signal toxicity, to encompass disruption of signalling of any neuro-
immuno-endocrine system suggesting a wider range of molecular mechanisms not 
limited to nuclear receptor systems and including epigenetic alterations.   
The Ministry of Economy, Trade and Industry (METI) established an advisory body – the 
Endocrine Disruptive Effect Subcommittee and by 2009 had funded 15 studies on hazard 
assessment of 15 chemicals of potential concern as endocrine disrupters which did not 
identify significant risks to human health. 
The Ministry of the Environment (MOE) established the Strategic Programme on 
Environmental Endocrine Disruptors 98 (SPEED 98). Simultaneously, the MOE carried out 
an Environmental Monitoring Survey of suspected endocrine disrupters as listed in the 
SPEED ’98 report and in air, water and wildlife. In addition, the ExtEND 2005 and later 
ExTEND 2010 were established to research mechanisms of endocrine disruption, 
environmental monitoring, development of test methods, hazard and risk assessment, 
risk management and communication. Within the scope of the OECD Conceptual 
Framework for testing and assessment, they contributed substantially to development of 
test protocols such as the Medaka Extended One Generation Reproductive Toxicity assay 
(TG 240) and the Larval Amphibian Growth and Development Assay (TG 241). MOE is 
now preparing a new program titled ‘ExTEND 2016’ to be published in June 2016. 
Moreover, the MOE has established a Joint Research Program on Endocrine Disrupters 
with the United Kingdom.  
OECD 
Endocrine disruption has figured highly on the chemical regulation agenda of regulatory 
authorities in most OECD countries, and it has been proposed by UNEP as a SAICM policy 
emerging issue. In turn, this is reflected in the OECD Test Guidelines Programme that 




guidelines and other tools, to support member countries’ needs in relation to the testing 
and screening of chemicals for endocrine disrupting properties. 
The work on endocrine disrupters testing and assessment is overseen by the Working 
Group of National Coordinators of the Test Guidelines Programme (WNT) and managed 
by four main expert groups: 
 An advisory group on endocrine disrupters testing and assessment (EDTA AG) 
  A validation management group (VMG) on ecotoxicity testing 
  A VMG on non-animal testing 
  A VMG for mammalian testing (Expert group on development and reproductive 
toxicity) 
The EDTA AG is an advisory group to the WNT and to the VMGs. National experts 
nominated by the National coordinators and the European Commission, and 
representatives from the Business and Industry Advisory Committee, Environmental 
NGOs, and International Council on Animal Protection in OECD Programmes participate in 
the work. 
Between 2007 and 2012, the OECD has published 12 Test guidelines specifically 
developed or updated for the screening or testing of chemicals for endocrine disruption. A 
further 11 adopted test guidelines were reviewed and found to provide useful 
information, although not specifically developed for screening/testing chemicals for 
endocrine disruption. Additionally, there are currently 16 projects for the screening or 
testing of chemicals for endocrine disruption, on the work plan. 
Following the Workshop on OECD Countries’ Activities Regarding Testing, Assessment 
and Management of Endocrine Disrupters, held in September 2009 in Copenhagen, to 
take stock of over 10 years of activity, further work was recommended and completed, 
namely: 
  The revision of the 2002 Conceptual Framework for Testing and Assessment of 
Endocrine Disrupters, approved by the WNT in April 2012. It includes all published 
Test Guidelines; test methods for which inclusion in the Test Guidelines work plan 
has been approved by the WNT; some existing Test Guidelines not specifically 
developed for screening/testing of chemicals for endocrine disruption, and a few 
non OECD test methods. The CF is not a testing strategy and simply reflects the 
type of information the tests provide at the different levels. 
  The development of a guidance document on standardised test guidelines for 
evaluating chemicals for endocrine disruption (GD 150) to support regulatory 
authorities’ decisions when they receive test results from a Test Guideline or draft 
Test Guideline for the screening/testing of chemicals for endocrine disruption. The 
guidance is worded to permit flexible interpretation in the context of different 
domestic legislation, policies and practice and provides guidance on how to 
interpret the outcome of individual tests, taking into account existing information, 
and how to increase evidence on whether or not a substance may be an endocrine 
disrupter. 
  A detailed review paper on endpoints not included in existing Test Guidelines (DRP 
178). To date, OECD work related to endocrine disrupters focused on 
oestrogen/androgen thyroid signalling processes and steroidogenesis. However, 
other endocrine and neuro-endocrine pathways may also have adverse outcomes, 
such as symptoms of metabolic syndrome, reproductive dysfunction, altered foetal 
development. 
Other relevant OECD activities not solely concerned with endocrine disruption include a 
new programme on the development of Adverse Outcome Pathways (AOP) initiated in 
2012. Several projects on the work programme are related to endocrine disrupters’ 




  the AOP for Embryonic Vascular Disruption and Developmental Defects 
  the AOP on Xenobiotic Induced Inhibition of Thyroperoxidase and Depressed 
Thyroid Hormones Synthesis and Subsequent Adverse Neurodevelopmental 
Outcomes in Mammals 
  the AOPs linking Aromatase Inhibition, Androgen Receptor Agonism, Estrogen 
Receptor Agonism, or Steroidogenesis Inhibition, to Impaired Reproduction in 
Small Repeat-Spawning Fish Species 
Quantitative Structure-Activity Relationships (QSARs) are methods for estimating 
properties of a chemical from its molecular structure. They have the potential to provide 
information on hazards of chemicals, while reducing time, monetary cost and animal 
testing currently needed. To facilitate practical application of (Q)SAR approaches in 
regulatory contexts by governments and industry and to improve their regulatory 
acceptance, the OECD (Q)SAR project has developed principles for the validation of 
(Q)SAR models, guidance documents as well as the QSAR Toolbox including some 
relevant to endocrine mechanisms of toxicity. 
Europe 
Legislative Framework 
Due to growing concerns about the potential detrimental effects of endocrine disruptors 
(EDs) on human and animal health, and the environment, the Commission adopted the 
'Community strategy for endocrine disruptors' in 1999, to identify the risks posed by 
endocrine disruptors.  
Legislative actions of the Strategy introduced rules relevant to EDs in major pieces of EU 
chemical legislation regarding industrial chemicals (REACH), pesticides (PPPR), biocides 
(BPR), cosmetics and media-oriented regulations such as the Water Framework Directive 
(WFD). Several industrial substances and pesticides have been assessed for their 
endocrine disrupting properties. 
Under REACH, endocrine disrupters may be addressed under processes for dossier and 
substance evaluation and identified as Substances of Very High Concern (SVHC) based 
on article 57(f) (substances of equivalent concern to CMR or PBT/vPvB substances). The 
‘SVHC Roadmap’ gives an EU-wide commitment for having all relevant currently known 
SVHCs included in the candidate list by 2020. As of May 2016, five substances or 
substances group had been placed on the candidate list for authorisation due to 
endocrine disrupting properties. Following a review, the Commission concluded that 
companies applying for authorisation of endocrine disrupters will only be able to go via 
the adequate control (risk assessment) route if they can demonstrate that a safe 
threshold exists. When a threshold cannot be determined, a socio-economic analysis of 
the substance and any alternative must be carried out. 
Under the Biocidal Products Regulation and the Plant Protection Product Regulation, 
endocrine disrupting properties are explicitly cited as an exclusion criterion for approval 
of active substances. However, a number of derogations, where an approval may be 
granted for five years, do exist in case of public health concerns, negligible exposure or 
socio-economic consequences. Until the criteria for the identification of endocrine 
disrupters are adopted, interim criteria are in place. 
Activities related to the screening, testing and assessment of endocrine disrupters 
European Chemical Agency (ECHA) 
Under REACH, criteria for the prioritisation of substances for evaluation include suspected 
endocrine disruption. Currently, the databases for registration under REACH and for CLP 
(Classification, Labelling and Packaging) are screened for alerts for endocrine disruption 




substances have been included in the Community Rolling Action Plan (CoRAP) on such as 
basis for initial concern. For a further 15 substances whose evaluation had been initiated 
by other concerns, endocrine disruption was identified as an additional concern. 
Evaluations (manual screening) are carried out by Member States and the substances 
can be identified case-by-case as SVHC on the basis of equivalent concern. In the 
absence of regulatory criteria, the IPCS definition for endocrine disrupters has been used 
and interpreted in the light of expert judgment.  
Since February 2014, ECHA also coordinates an Endocrine Disrupter Expert Group 
(EDEG) to provide informal, non-binding scientific advice on questions related to the 
identification of endocrine disrupters. It consists of experts nominated by Member State 
competent authorities, the European Commission and accredited stakeholders. The 
expert group focuses on; 
  Screening methods and activities to identify potential endocrine disrupters 
  Integrated approaches to testing and assessment of endocrine disrupting 
properties 
  Complex scientific issues related to information and testing needs 
  Interpretation of test data and other relevant information 
European Food Safety Agency (EFSA) 
EFSA collected any indication for ED (both human and other organisms) in the 
Conclusions of the risk assessment of 41 active substances since 2014. From the 
available information, hazard or risk-based concerns were identified for 15 substances. 
For some substances, the interim criteria were not met, but EFSA highlighted evidence 
suggesting possible concerns and recommended additional studies to finalise their 
assessment of potential endocrine-mediated adverse effects.  
DG Joint Research Centre (JRC) 
The Commission’s Joint Research Centre (JRC) is engaged in activities for establishing 
the technical basis for the large-scale in vitro screening of substances for endocrine 
disrupting properties. 
EU Member States 
Member States (MS) experts and competent authorities play an active role in regulatory 
and scientific activities at the EU and international level under the auspices of the OECD.  
Several MS have also taken unilateral national legislative measures to restrict the use of 
some chemicals, despite the impact of such measures on the functioning of the internal 
market. Their major motivation for doing so is borne out of frustration with progress at 
EU level. Bisphenol A is undoubtedly the most pertinent example; its use has been 
banned in specific consumer products aimed at babies or young children in France, 
Denmark, Austria, Belgium and Sweden. Some Member States, such as Italy and 
Denmark, have also taken ‘soft’ measures at the national level such as providing advice 
to the public, creating incentives for industry for the development of safer alternatives or 
the promotion of voluntary agreements. 
Several Member States provide national funding for research and have established 
specific research programmes and collaboration. For example, The Danish Centre for 
Endocrine Disrupters formed in 2008 as a network of scientists and relevant institutions. 
Together with the results of Task 2, the material gathered in Task 1 will form the basis of 
the core of this project, the case studies in Task 3. 




In order to map the commonalities and differences in approaches to testing and 
assessment of endocrine disrupting substances within the European Union and with 
international trading partners, an expert consultation exercise was carried out and 
completed by web searches. Overviews of the different legislative frameworks and 
activities relevant to endocrine disruption are described in the rest of this document.  
Preliminary findings suggest that; 
  Most jurisdictions have had to address chemical hazards retrospectively. There are 
generally separate provisions to deal with existing chemicals (already placed on 
the market) and new substances. In some instances, this results in different 
information requirements for new and existing chemicals. 
  It is also common for certain uses of chemicals, e.g. as pesticides, food additives, 
medicinal drugs, cosmetics, or chemical pollution in a given environmental media 
to be regulated by specific chemical legislation in addition to general chemical 
legislation. This is generally translated by more stringent pre-market information 
requirements or post-market monitoring. 
  A notable difference between trading partners is related to whether the burden of 
proof resides mainly with the regulator or the manufacturer/applicant. There are 
however indications of a tendency to shift that burden to the latter. This has 
potential implications for sharing data along the supply chain and with the public. 
  There appears to be a general consensus that endocrine disrupters raise a level of 
concern equivalent to that of Carcinogens, Mutagens and Reproductive toxicants 
(CMRs) or Persistent, Bioaccumulative and Toxic chemicals (PBT). 
  There are however different stances on whether the concerns above require 
additional or complementary regulatory approaches or whether these concerns 
are adequately addressed by current legislation. 
When legal action has been taken, approaches also vary widely from soft voluntary 
programmes with industry or recommendations to consumers, to implementation of 







3. DESCRIPTIVE OVERVIEW OF RESULTS OF REGULATORY SCREENING, 
PRIORITY SETTING, TESTING AND ASSESSMENT IN THE EU AND 
RELEVANT INTERNATIONAL TRADING PARTNERS 
In this section we give a descriptive overview of results of regulatory screening, priority 
setting, testing and assessments as regards endocrine disruptors in the EU (including 
within the Member States) and relevant international trading partners (US, Canada, 
Australia, Japan, China). 
Additionally, some non-governmental organisations (NGO) such as the Endocrine 
Disruption Exchange (TEDX) and ChemSec have published their own lists of endocrine 
disruptors (e.g. SINList 2.1) that may be used to prioritise or include chemicals in the 
candidate list of Substances of Very High Concern under REACh (Annex XIV). These may 
therefore also be of relevance and are also been considered. 
To develop a descriptive overview of the different approaches, the OECD conceptual 
framework and related guidance documents will be used as a frame of reference, 
whereby the activities ongoing in non-EU and EU countries will be mapped onto the 
Framework. Particular attention will be given to the following aspects as they may drive 
the outcomes of different approaches to testing, prioritisation, etc.: 
  The selection criteria for chemicals to be screened, whether related to specific 
legislative imperatives or existing information such as in silico data, peer-reviewed 
literature, or a measure of potential exposure. 
  The test or battery of assays employed and the endocrine modalities and 
taxonomic groups covered. This will include consideration of whether results for 
human health and environmental receptors are integrated.  
  The interpretation of results of individual tests and integration of evidence from 
different tests and whether expert judgment is used on a case-by-case basis or 
other criteria-based methods such as decision trees or weight-of-evidence 
approaches are recommended. 
The following insights are emerging from the material gathered: 
3.1 Selection criteria for the screening of chemicals for ED properties 
With the Endocrine Disrupter Screening Programme (EDSP), the USA seems to have the 
most advanced and elaborated screening programme for endocrine disrupting properties. 
Prioritisation for screening is derived on the basis of biological activity and monitoring 
data which includes quantitative structure-activity relationships (QSAR) and test 
outcomes of the ToxCast programme. 
A similar approach, with biological activity as the driver for prioritisation and screening is 
taken in the Japanese ExTEND 2010 programme. 
Several other efforts, particularly in the EU, have used information available from the 
literature. Examples are the RPS BKH Endocrine Disrupter Database for the European 
Commission and the SIN list. 
3.2 Assays, endocrine modalities and taxonomic groups 
The assay systems used in the various screening and testing programmes will be mapped 
onto the OECD Framework, as shown in the Table below. 
Most testing and screening activities do not go beyond the familiar estrogen, 
(anti)androgen and thyroid modalities (EAT); some also encompass steroidogenesis. It is 
notable that the US activities encompass a large number of in vitro assays for these 
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In vitro assays providing 
data about selected 
endocrine mechanism(s) / 
pathways(s) 
 yes yes 
Level 3 
In vivo assays providing 
data about selected 
endocrine mechanism(s) / 
pathway(s) 
 yes yes 
Level 4 
In vivo assays providing 
data on adverse effects on 
endocrine relevant 
endpoints  
yes yes  
Level 5 
In vivo assays providing 
more comprehensive data 
on adverse effects on 
endocrine relevant 
endpoints over more 
extensive parts of the life 
cycle of the organism  
yes yes  
 
3.3 Interpretation of results, decision trees 
The interpretation of test results has been aided by the use of decision trees, such as the 
one developed by the German BfR in the context of EU pesticide legislation1. The 
development of weight-of-evidence approaches is making progress with the SYRINA 
method2 . 
  
                                                 
1
 Described in Kortenkamp A, Martin OV, Faust M, Evans R, McKinlay R, Orton F and Rosivatz E 2012, State of the art 
assessment of endocrine disrupters. Final Report.[Online] Available at: http://ec. europa. 
eu/environment/endocrine/documents/4_SOTA% 20EDC% 20Final% 20Report  
2
 Vandenberg LN, Ågerstrand M, Beronius A, Beausoleil C, Bergman Å, Bero LA, Bornehag CG, Boyer CS, Cooper GS, 
Cotgreave I, Gee D, Grandjean P, Guyton KZ, Hass U, Heindel JJ, Jobling S, Kidd KA, Kortenkamp A, Macleod MR, Martin 
OV, Norinder U, Scheringer M, Thayer KA, Toppari J, Whaley P, Woodruff TJ, Rudén C. A proposed framework for the 
systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals. Environ Health. 2016 Jul 





4. IDENTIFICATION AND ASSESSMENT OF COMMONALITIES AND 
DIFFERENCES IN SCREENING APPROACHES, PRIORITY SETTING 
APPROACHES, TESTING APPROACHES AND ASSESSMENTS OF CHEMICALS 
REGARDING THEIR ENDOCRINE DISRUPTING PROPERTIES 
This section reports the results of a deep analysis of the commonalities and differences in 
screening, priority setting and testing of chemicals for their endocrine disrupting 
properties in the EU and among EU trading partners. In accordance with the technical 
specifications for this project, we have chosen the method of case studies for the 
analysis. 
The goals of this work were to address the following issues: 
  Are the differences and commonalities in the different legalities due to differences 
in scientific approaches, or are they an expression of the different features of the 
respective legal systems? 
  What impact do differences in approach have on the final outcome of the 
derivation of regulatory values (e.g. water quality standards, acceptable daily 
intakes and similar)? 
The case studies were chosen to represent both human health and the environment and 
to cover several regulatory domains, including media-oriented regulation (e.g. water) 
and several chemical-oriented regulations (pesticides, chemicals in consumer items, 
general chemicals). With this in mind, the following substances were selected for the 
case studies: 
  Ethinylestradiol and estradiol (environmental risk assessment) 
  Nonylphenol (environmental risk assessment) 
  Bisphenol A (human health) 
  Di-ethylhexyl phthalate (human health) 
  Mancozeb (human health) 
  Prochloraz (human health) 
  Procymidone (human health) 
  Benzophenone-3 (human health) 
To facilitate a systematic comparison between the case studies, which would help 
identifying commonalities and differences in the assessments, a common structure was 
developed, with the following subheadings: 
  Discovery as an endocrine disruptor 
  Regulatory framework in selected jurisdictions 
  Assessment and measurement endpoints for hazard characterisations 
  Assessment values and their derivation 
  Exposure assessments 
  Risk assessments 
The presentation of the eight case studies is followed by an analysis of commonalities 






4.1 Case Study: 17α-Ethinylestradiol and 17β-Estradiol in the Aquatic Environment 
Summary 
The endocrine disrupting properties of 17α-ethinylestradiol (EE2) and 17β-estradiol (E2) 
on fish have been discovered not through screening exercises, but through chance 
observations by anglers of hermaphroditism in fish in the United Kingdom. Today, the 
endocrine disrupting effects of EE2 and E2 at low ng/L concentrations on individual fish 
are well established and are not controversial. What is unresolved is whether there are 
negative impacts on the ability of fish to reproduce at environmental exposures to EE2 
and E2. For the purpose of environmental risk assessments, various assessment values 
for EE2 and E2, so-called Predicted No-Effect Concentrations (PNECs), have been derived 
in Canada, the USA, China and Europe by using deterministic approaches and by 
constructing Species Sensitivity Distributions (SSDs). For EE2, these values range from 
0.016 – 0.5 ng/L and for E2 from 0.1 – 2 ng/L. The differences are explained mainly by 
the choice of assessment factors that were used to convert experimental values into 
PNECs. Although of lesser importance in the case of EE2, the choice of experimental 
studies and fish species also had an impact on the different PNECs for E2. While non-
endemic, sometimes very sensitive, species are used to construct SSDs for European 
PNECs, only resident species are considered in the USA, Canada and Australia. Due to the 
smaller water flow available for dilution of sewage treatment discharges in Europe, 
considerable proportions of river stretches cannot comply with various EE2 and E2 
PNECs. In the USA, the proportion of river segments that exceed PNECs is considerably 
smaller. Risk management options for reducing the discharge of EE2 and E2 are limited 
to upgrading sewage treatment technologies, at considerable cost. This is currently 
opposed by the pharmaceutical and water industries, with the argument that detrimental 
effects on the ability of fish populations to reproduce have not been shown, despite 
evidence for signs of endocrine disruption at current exposure levels. 
Scope of this case study 
Most of the studies addressing 17α-ethinylestradiol (EE2) or 17β-estradiol (E2) as 
environmental endocrine disruptors have focused on effects on aquatic wildlife. The risks 
to human health e.g. via drinking water are generally considered negligible (Laurenson et 
al. 2014). Accordingly, this case study focuses on the effects of EE2 and E2 on wildlife, 
especially fish. The considerable literature on cancer risks associated with the therapeutic 
use of steroidal estrogens e.g. in hormone replacement therapy is deemed out of scope. 
Discovery as an endocrine disruptor 
The discovery of EE2, E2 and other steroidal estrogens as endocrine disruptors in fish 
was accidental; it was not the result of systematic screening, nor were the endocrine 
disrupting properties of EE2 or E2 in fish predicted on the basis of their biological activity 
in humans.  
Rather, it was the accidental observation in the 1980s by anglers of hermaphrodite fish in 
the settlement lagoons of some sewage treatment works (STWs) in south-east England 
that triggered research into the effects of STW effluents on fish. In subsequent studies 
with caged fish in UK rivers near STW outlets, the observation was made that male fish 
exhibited feminised phenotypes, characterised by the production of the female yolk 
protein precursor vitellogenin and an intersex state where the reproductive tracts 
contains male and female gonads (Purdom et al. 1994).  
Systematic field studies in the UK then revealed that this kind of endocrine disruption 
was widespread in wild fish caught near STW outlets (Jobling et al. 1998). The effect 
could be traced to steroidal estrogens in STW effluents. The most potent components of 
these effluents were identified as EE2 and E2 (Desbrow et al. 1998), present at 




Experimental exposures under controlled laboratory conditions demonstrated that EE2 
and E2 could induce the intersex state with sometimes near complete reproductive failure 
(Lange et al. 2001, 2009, Nash et al 2004). Exposure to EE2 for 3 years in a Canadian 
Lake led to the collapse of the residing fathead minnow population (Kidd et al. 2007). 
Similar observations have since been repeated in numerous studies throughout the 
world. Accordingly, the endocrine disrupting effects of EE2 and E2 at low ng/L exposure 
concentrations on individual fish are not controversial. What is currently under 
investigation is the impact of feminisation on the ability of fish to reproduce at 
environmental exposures to EE2 and E2. 
The consequences of feminisation on the reproductive capability of breeding groups of 
wild fish were shown to be significant in wild caught roach with relatively severe intersex. 
However, mild intersex had little impact on the ability of the fish to reproduce (Harris et 
al. 2011). Essentially the same results were obtained in a study where roach were 
exposed in the lab to STW effluent for 3 years (Hamilton et al. 2015). A field study 
investigating the impact of endocrine disruption in wild roach in the UK found that fish 
populations in river stretches exposed to EE2 and E2 were able to reproduce, despite 
being affected by intersex (Hamilton et al. 2014). However, the authors of that study 
highlight several factors that might have obscured the detection of reproductive impacts 
in the wild, including migration of fish and the introduction of populations to certain river 
stretches. 
Regulatory framework in selected jurisdictions 
With the exception of Canada (British Columbia), no environmental quality standards for 
EE2 or E2 exist in any jurisdiction in the world, although various risk assessment 
exercises have been conducted on the basis of draft or provisional reference values. 
European Union 
The Water Framework Directive and its daughter directives, the 2008/105/EC 
Environmental Quality Standards Directive (EQSD) and the 2013/39/EU Directive with 
the latest amendment of the list of Priority Substances (PS), are the existing body of 
legislation for the protection and sustainable use of European water resources in which 
chemicals in the aquatic environment are regulated. The Water Framework Directive 
articulates a holistic ‘response’ principle – Good Ecological Status – and a chemical-
related assessment - Chemical Status. The latter is based on Environmental Quality 
Standards for selected PS which all Member States need to adhere to. The European 
Commission had developed draft Environmental Quality Standards (EQS) for EE2 and E2 
(European Commission 2011 a, b), but this was replaced by a watch list mechanism 
established for emerging pollutants. The 1st EU Watch List was launched in 2015; it 
encompasses EE2 and E2. For chemicals on the Watch List, monitoring data will be 
acquired at European Union-wide level and these data will be used to support future 
chemical prioritization initiatives. 
United States of America 
The National Environmental Policy Act requires the US Food and Drug Administration 
(FDA) to assess environmental impacts that result from the approval of individual drug 
applications. An exemption from the requirement for an environmental assessment is 
possible when the estimated concentration of the substance at the point of entry into the 
aquatic environment is below 1 part per billion (i.e. 1 µg/L, which is higher than the 
derived PNECs in the table below) or when the application does not increase the use of 
the active substance. Most drug applications for pharmaceutical estrogens, including EE2, 
have qualified for this exemption. Nevertheless, the Center for Drug Evaluation and 
Research (CDER) at the FDA has conducted a risk assessment exercise for EE2 in US 
aquatic environments which showed that approximately 1% of river stretches exceed a 




Canada (British Columbia) 
The Ministry of the Environment of British Columbia has established ambient water 
quality guidelines for EE2 (Nagpal and Meays 2009). To protect freshwater aquatic life 
from adverse effects, these guidelines recommended that the 30-d average concentration 
of EE2 in water should not exceed 0.5 ng/L, with no single value above 0.75 ng/L. 
Japan 
Japan’s basic Environmental Law establishes two kinds of Environmental Quality 
Standards relevant to water pollution – standards for the protection of human health, 
and standards for protecting the living environment. Environmental Quality Standards 
have been set for many water-borne pollutants, but there are currently no such 
provisions for EE2 or E2.  
China 
In China, a “black” list of 68 priority pollutants was developed for regulatory purposes, 
mainly based on existing priority lists in the USA and the EU. Based on this list, regional 
priority pollutants were selected for Beijing, Tianjin, and Zhejiang (Jin et al. 2014). There 
are currently no binding standards for EE2 or E2. 
Assessment and measurement endpoints for hazard characterisations 
In aquatic communities exposed to EE2 and E2, fish are generally considered to be the 
most sensitive taxa. The assessment endpoint in hazard characterisations is fish 
reproduction, with the aim of ensuring exposure levels low enough to maintain self-
sustaining fish populations. Widely selected measurement endpoints for this assessment 
endpoint include the induction of vitellogenin in male fish, changes in the presence of 
secondary sexual features, intersex status, skewed sex ratios from male to female, and 
endpoints relevant to reproductive success, such as sperm quality. Of these, vitellogenin 
induction is generally considered as a biomarker of the effects of estrogenic chemicals on 
fish, rather than a measurement endpoint for adverse effects for the derivation of 
regulatory standards. 
Assessment values and their derivation 
Ecotoxicological hazard characterisations aim to establish Predicted No-effect 
Concentrations (PNECs). For EE2 and E2, two different approaches have been used for 
this purpose: The “deterministic” approach focuses on a single experimental study 
considered to be “critical”, which is then used to derive a No-Observed-Effect-
Concentration (NOEC). Alternatively, a Species Sensitivity Distribution (SSD) is used to 
establish a hazardous concentration (HC) that affects 5% of relevant taxa (HC05). NOECs 
and HC05 values are then combined with assessment factors (AF) to yield a PNEC. Often, 
both approaches are used side-by-side. 
The deterministic and the SSD approach have been used widely, and have produced 
PNECs ranging from 0.016 to 0.5 ng/L for EE2 and 0.1 to 2 ng/L for E2 (Table 1). The 






Table 1: EE2 PNECs 
PNEC 
(ng/L) 
Approach Basis (points of departure) AF Source and year 
0.5 Deterministic LOEC of 1.0 ng/L from 3 
experimental studies in fish for 
chronic reproductive effects and 
egg production 
2 British Columbia, 
Nagpal and Meays 
(2009) 
0.35 SSD Based on chronic NOECs for 26 
species; HC05 = 0.35 ng/L, but see 
update by Caldwell et al. (2012) 
below 
none Caldwell et al. 
(2008) 
0.1 Deterministic NOEC = 0.57 ng/L from a full life 
cycle study in zebrafish (Wenzel et 
al. 2001) 
5 UK Environment 
Agency (2004) 
0.1 Deterministic LOEC = 0.19 ng/L for mortality in 
fertilised zebrafish eggs (Soares et 
al. 2009) 
2 CDER commissioned 
study, see 
Laurenson et al. 
(2014) 
0.1 SSD As Caldwell et al. (2008), but 
updated taking account of new data 
in Chinese rare minnows, Zha et al. 
(2008), with an extrapolated NOEC 
of 0.1 ng/L (from a LOEC of 0.2 
ng/L); HC05 = 0.06 – 0.08 ng/L 
< 1 Caldwell et al. 
(2012) 
0.035 SSD Based on chronic reproductive 
NOECs, HC05 = 0.07 ng/L 
2 European 
Commission 
(2011 a), draft 
EQS 
0.016 Deterministic Based on a LOEC = 0.32 ng/L for 
decreased egg fertilisation and 
skewed sex ratios in the fathead 





2 SSD Based on 21 NOECs for chronic 
reproductive toxicity, HC05 = 4.3 
ng/L 
2 Caldwell et al. 
(2012) 
1 Deterministic LOEC = 10 ng/L, toxicity on early 
life stages of the medaka (Nimrod 
and Benson 1998) 
10 UK Environment 
Agency (2004) 
0.73 SSD Based on 31 NOECs for chronic 
reproductive toxicity and other 
endpoints, HC05 = 1.46 ng/L 
2 Wu et al. (2014) 
0.4 SSD Based on NOECs for chronic 




(2011 b), draft 
EQS 
0.1 Deterministic Based on extrapolated NOEC = 0.5 
ng/L for semen quality in rainbow 









The following issues, which all impact to varying degrees on the numerical value of these 
PNECs, have been debated in the literature: 
The choice of critical experimental studies and selection criteria 
Different experimental studies were chosen for the various PNECs listed in Table 1, and 
criteria for the selection of these studies were not always made explicit, nor were they 
consistent. For EE2, Caldwell et al. (2008, 2012), a publication by the pharmaceutical 
industry, selected studies according to Klimisch scores, with a requirement for a score of 
1. The quality criteria for the studies that underpinned the derivation of all other EE2 
PNECs are unclear. For E2, Wu et al. (2014) and the European Commission (2011 b) 
used studies with Klimisch scores of 1 and 2, but which quality criteria were used to 
select studies for all the other E2 PNECs is unclear. 
Despite the fact that different sets of NOECs were used to construct the EE2 SSDs by 
Caldwell et al. (2012) and by the European Commission (2011 a), the respective HC05 
values were very similar (0.06-0.08 ng/L in Caldwell and 0.07 ng/L in European 
Commission). The lowest NOEC in Caldwell was 0.1 ng/L, an extrapolated NOEC from 
Zha et al. (2008) (LOEC = 0.2 ng/L). The lowest NOEC in the European Commission SSD 
was 0.16 ng/L, extrapolated from the LOEC of 0.32 ng/L by Parrot and Blunt (2005), 
which was also used by Caldwell et al. (2012). The study by Soares et al. (2009), with a 
LOEC of 0.19ng/L, was critical for the EE2 PNEC derived by CDER, but this value was not 
used for constructing the European Commission SSD. The Soares study was erroneously 
assigned a NOEC of 1 ng/L in the SSD by Caldwell et al. (2012), but use of the correct 
value would have had little impact on the Caldwell HC05, because here the Zha study 
with an extrapolated NOEC of 0.1 ng/L was used. 
Different studies were also chosen to build SSDs for E2, but here, this had a greater 
impact on the respective HC05 values. The lowest value in Caldwell et al. (2012) was 5 
ng/L, from a study by Nash et al. (2004), which in fact is not a NOEC. The smallest NOEC 
used by the European Commission (2011 b) for constructing their SSD was 0.5 ng/L from 
Lahnsteiner et al. (2006), not used by Caldwell et al. (2012). The Lahnsteiner study was 
also the lowest NOEC in Wu et al. (2014), but assigned a NOEC of 1 ng/L. Furthermore, 
Wu et al. used a variety of endpoints, not strictly limited to reproductive toxicity, 
including vitellogenin induction. These differences and inconsistencies readily explain why 
the SSDs from Caldwell, Wu and the European Commission produced HC05 values of 4.3, 
1.46 and 0.8 ng/L, respectively. 
The choice between the deterministic and the SSD approach 
In general, the NOECs derived by the deterministic approach tended to be higher than 
the HC05 derived from SSDs, with the exception of the 0.5 ng/L E2 NOEC from the 
Lahnsteiner study. However, since the SSD approach is also sensitive to the choice of 
NOECs, this does not necessarily mean that it generally produces more conservative 
PNEC estimates. 
Consequently, the argument about whether to use one or the other approach for deriving 
PNECs turns on matters of principle. The use of the SSD approach is rejected by some 
(e.g. by the British Columbia Environment Ministry, Nagpal and Meays, 2009) and 
favoured by others (e.g. the pharmaceutical industry, Caldwell et al. 2008, 2012). 
Arguments against the SSD approach are (Nagpal and Meays, 2009): 
  The results of an SSD are sensitive to the choice of NOECs.  
  NOECs are literature values which are influenced by the experimental design (e.g. 
concentration levels and concentration spacings used in toxicity studies). A 
benchmark approach based on critical effect concentrations (e.g. EC10) would be 




  NOECs vary according to the end point employed in the toxicity test. A PNEC 
derived from NOECs with mixed end points is regarded by many scientists as less 
desirable than a PNEC obtained from NOECs with single end points (e.g. critical 
reproductive effects).  
  SSDs do not necessarily protect the most sensitive species and life stage, and 
there is the issue of representativity of the selected species.  
 
Conversely, the advantage of the SSD method is seen in its use of the entire sensitivity 
distributions of species in an ecosystem for the establishment of a PNEC instead of taking 
always the lowest long-term NOEC. Accordingly, if appropriate data are available, SSDs 
are favoured in the USA and the EU. In the EU, deterministic and SSD approaches can be 
used side-by-side. 
Use of non-endemic species for the derivation of HC05 values from SSDs 
The European Commission (2011 a, b) as well as the pharmaceutical industry (Caldwell 
et al. 2012) have included fish species not endemic in Europe for their SSDs. In contrast, 
in Canada, the USA and Australia only endemic wildlife species are used as test species 
to derive water quality values (Nagpal and Meays, 2009, USEPA 1985, Hose and Van den 
Brink 2004). 
The choice of assessment factors 
As can be seen from Table 1, the choice of assessment factors (AF) can have a 
considerable impact on the numerical value of PNECs for EE2 and E2. With the 
deterministic approach, AFs of between 2 and 20 were used, while with the SSD 
approach AFs between 1 and 5 were applied, in line with ECHA guidance. 
Only the PNEC for EE2 proposed by the pharmaceutical industry was derived directly 
from an SSD, without application of an AF (Caldwell et al. 2012). The pharmaceutical 
industry opposes the application of an AF > 1 in this case, with the argument that a 
PNEC of 0.1ng/L is smaller than the NOECs for commonly tested fish species. As a result, 
so the argument goes, this PNEC will be protective for fish species commonly found in 
Europe. 
In contrast, the European Commission (2011 a, b) and the European Commission 
Scientific Committee on Health and Environmental Risks (SCHER 2011 a,b) regard the 
application of an AF as essential, to compensate for the fact that most NOECs used in the 
various SSDs are not from multi-generation studies. According to SCHER, this is 
particularly relevant in view of evidence that the toxicity of EE2 and E2 increases from 
generation to generation. Furthermore, the endpoints included in the NOECs used for 
constructing the various SSDs are not always the most sensitive.  
Other issues 
Of all the PNECs derived for E2, the one suggested by the pharmaceutical industry 
(Caldwell et al. 2012) is the highest (2ng/L). The values used by all other authorities and 
authors are by a factor of 2 to 20 lower than the industry value. The lowest PNEC for E2 
(0.1 ng/L) has been derived by the European Commission, using a deterministic 
approach based on a NOEC of 0.5 ng/L for semen quality and other reproductive 
endpoints from a 35 day study in the rainbow trout (Lahnsteiner et al. 2006). However, 
this value was not chosen as the basis for the draft EQS. 
The HC05 of 0.8ng/L in the European Commission SSD approach was driven by inclusion 
of the Lahnsteiner study. The pharmaceutical industry opposed consideration of the 
Lahnsteiner study for deriving a PNEC for E2, however, the European Commission SCHER 





Exposure assessments for EE2 and E2 in rivers have been conducted in numerous 
countries and economic areas, including the European Union, the USA, China, Canada, 
Japan and Australia. These were based on either Measured Environmental Concentrations 
(MECs) or on values derived through hydrological modelling, Predicted Environmental 
Concentrations (PEC). 
Measured Environmental Concentrations (MECs) 
There are significant technical problems with measuring EE2 and E2 levels in riverine 
waters, due to the detection limits often being higher than the biologically effective 
concentrations or the various proposed PNECs. Despite the fact that many studies 
returned non-detects, the EE2 and E2 concentrations measured in locations in the 
European Union, the USA, or China were in the range of several ng/L, depending on 
location (Laurenson et al. 2014, Wu et al. 2014, European Commission 2011 a,b). 
Predicted Environmental Concentrations (PECs) 
The use of models has helped to overcome the difficulties with measuring EE2 and E2 in 
surface waters. On the basis of assumptions about per capita EE2 usage and E2 
excretion, per capita wastewater outputs, metabolic and wastewater treatment removal 
rates, and instream dilution and loss processes in water bodies, models can provide 
estimates of EE2 and E2 concentrations in surface waters. The models that have been 
used to generate PECs for EE2 and E2 include PhATE (Pharmaceutical Assessment and 
Transport Evaluation) in the USA, GREAT-ER (Geography Referenced Regional Exposure 
Assessment Tool for European Rivers) and GWAVA in the European Union. The models 
differ in their assumptions about per capita use of EE2, per capita water usage and 
available dilution in rivers. 
By using PhATE, approximately 1% of river segments in the USA are estimated to exceed 
an EE2 concentration of 0.1 ng/L. According to GREAT-ER, 23% of river segments in 
Europe exceed that value (see the review in Laurenson et al. 2014). Johnson et al. 
(2013), using GWAVA, estimated that 12% by length of European rivers exceed the 
European Commission Draft EQS for EE2 of 0.035 ng/L, and 1% would reach 
concentrations greater than the Draft EQS of 0.4 ng/L for E2. 
A major factor explaining these differences between the USA and Europe is the water 
flow available for dilution of STW discharges. This is generally larger in the USA than in 
Europe.  
Humans are not the only source of emission of steroidal estrogens to surface waters, 
emissions from life stock and farming have also been recognised as relevant (Laurenson 
et al. 2014). 
Risk assessments 
The possible risks to aquatic life of exposures to EE2 and E2 were assessed in several 
studies, by building risk quotients of MECs or PECs and various PNECs. 
One such assessment, classed as a screening assessment, was conducted by CDER for 
EE2 in the USA (Laurenson et al. 2014), by comparing PECs obtained by modelling 
(PhATE) with the EE2 PNEC of 0.1 ng/L. The mean long-term PECs for EE2 were smaller 
than this PNEC in approximately 99% of US surface waters downstream of STWs, with a 
median PEC more than two orders of magnitude smaller than this PNEC. The 
approximately 1% of exceedances were in localized, effluent-dominated stream 




Due to the smaller water flow available for dilution of discharges into riverine waters, the 
situation in Europe, particularly the UK, is very different. In relation to the PNECs derived 
by the European Commission for EE2 and E2, 0.035 and 0.4ng/L, respectively, long river 
stretches were found to exceed these values (Johnson et al. 2013). Even compliance with 
the higher EE2 PNEC of 0.1 ng/L will be difficult in many areas of the European Union. 
Because the focus on EE2 alone may underestimate the extent of exceedance of PNECs, 
attempts have been made to assess the risks from combined exposures to steroidal 
estrogens, including EE2, E2, estrone and estriol. PECs for these steroids were derived by 
modelling, converted into E2-equivalents, summed up and evaluated in relation to E2-
equivalent PNECs of various magnitudes. 
Williams et al. (2009) presented the first assessment of this kind for the United Kingdom. 
They evaluated the predicted E2-equivalents against an E2-equivalent PNEC of 1 ng/L 
(the value derived for E2 by the UK Environment Agency 2004) and found that only 39% 
of the modelled river segments were not at risk from combined endocrine disruption (E2-
equivalent PEC < 1 ng/L). If the PNEC of 0.4 ng/L for E2 had been used in these 
assessments, an even higher proportion of river stretches would have been declared as 
“at risk”. To illustrate this point, the figure below (Williams et al. 2009) shows the 
distribution of predicted E2-equivalents in the Thames catchment in the London 
metropolitan area. It is evident that only a few stretches would comply with an E2-
equivalent PNEC of 0.4 ng/L, the Draft European Commission EQS for E2 (SB = 
secondary biological filter). 
 
On the basis of short-term and long-term E2-equivalent PNECs of 5 and 2 ng/L, Anderson 
et al. (2012) conducted a similar analysis across 12 US watersheds. They found that only 
0.8% of the segments of these river catchments would exceed 2 ng/L. The authors 
concluded that aquatic species in most US waters are not at risk from the release of 




The question of reproductive ability of fish populations 
While it is not under dispute that individual fish are likely to show signs of endocrine 
disruption such as intersex at EE2 and E2 levels found in many European surface waters, 
the debate has moved to the question whether this degree of endocrine disruption will 
affect fish populations to an extent that compromises their reproduction. Although there 
is evidence that cyprinid fish populations affected by mild intersex are able to sustain 
themselves (Hamilton et al. 2014, Harris et al. 2011), this question cannot currently be 
answered conclusively, especially not in relation to a concentration that will protect from 
population level effect. There is evidence that severe intersex, found particularly in older 
fish with long-term exposures, can compromise reproduction (Harris et al. 2011). 
The pharmaceutical and water industries in the UK and the European Union are strongly 
opposed to implementing controls over the discharge of EE2 or E2 via STW effluents, 
unless clear evidence of significant ecological damage can be provided. 
Risk management options 
The UK Environment Agency has decided that there is a strong case for risk management 
measures (Gross-Sorokin et al. 2006). However, management options are limited: 
Reducing the levels of EE2 and E2 in the aquatic environment will require end-of-pipe 
solutions, with an upgrade of STW to remove steroidal estrogens from effluents. This is 
currently implemented in Switzerland. 
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4.2 Case Study: Nonylphenols in the Aquatic Environment 
Summary 
Nonylphenols were discovered as endocrine disruptors (estrogen mimics) not through 
systematic screening programmes, but by the accidental discovery of unusual estrogenic 
effects of cell culture media stored in laboratory plastic ware from which it leaked and 
contaminated the media. Since then, estrogenic effects of nonylphenols have been 
demonstrated in numerous assays and test systems. Water Quality Criteria (WQC) and 
Environmental Quality Standards (EQS) exist in the European Union, the USA and 
Canada. Chinese scientists have derived equivalent values for China. The various values 
range from 0.1 to 6.6 µg/L, with the USA WQC being the least restrictive. These 
variations are explained by the use of different sets of toxicity data, together with 
different methodologies for their derivation. In the USA, extrapolations from acute 
toxicity data to chronic toxicity were made by using acute-to-chronic ratios. In Canada, 
the European Union and China, WQC and PNECs were derived by using deterministic 
approaches, based on NOECs from critical toxicity studies, with application of an 
assessment factor of 10. The endocrine disrupting properties of nonylphenols were not 
decisive for deriving WQS or Predicted No-effect Concentrations (PNECs); other chronic 
toxicities were critical for setting these values. Nevertheless, European and USA 
authorities have assessed the degree of protection from endocrine disruption afforded by 
these values by comparison with data for endocrine disruptor tests in whole organisms 
and ascertained that such protection was achieved. Risk assessments were commonly 
performed by building risk quotient of measured nonylphenol concentrations and the 
respective WQC or PNECs applicable in the various legislations. These assessments have 
shown that nonylphenol WQC are exceeded in certain areas in Canada, the European 
Union and China. 
Scope of this case study 
This case study focuses on the effects of nonylphenol isomers on aquatic wildlife. In 
many risk assessment efforts this, rather than possible effects on human health, has 
been recognised as critical (ECHA 2014). 
Discovery as an endocrine disruptor 
The endocrine disrupting properties of nonylphenols were discovered accidentally when 
cell culture media stored in laboratory plastic ware was found to induce unusual cell-
proliferative responses in estrogen-receptor positive human mammary gland cell lines 
(Soto et al. 1991). Estrogenic chemicals are capable of producing such effects in these 
cells. In painstaking investigations, nonylphenols were proven to leach from the plastics 
into the cell culture medium, and were shown to be responsible for the estrogenic effects. 
Since then, nonylphenols have been tested in numerous assays and test systems 
relevant for the detection of estrogen-like effects, including the pure steroid receptor, 
estrogen receptor-dependent gene reporter assays, cell lines and whole organisms 
including rats and fish.  
Regulatory framework in selected jurisdictions 
Nonylphenols are a group of different isomers, not a single chemical compound. This 
often complicates the interpretation of toxicological studies, because the precise 
composition and provenance of the material used was not specified. Of importance as 
endocrine disruptors are the para-substituted alkyl phenols, 4-nonylphenols. The alkyl 
side chain can be linear (CAS No 104-40-5) or branched (CAS No 84852-15-3). 4-
nonylphenols with unspecified side chains are assigned CAS No 25154-52-3. Many 





Nonylphenol (defined as CAS No 84852-15-3 and 25154-52-3) is a Priority Substance 
under the Water Framework Directive and is listed in the 2008/105/EC Environmental 
Quality Standards Directive (EQSD) and the 2013/39/EU Directive with the latest 
amendment of the list of Priority Substances (PS). All EU Member States are required to 
adhere to the Environmental Quality Standard (EQS) for freshwater of 0.3 µg/L. Pollution 
from Priority Substances should be progressively reduced. 
United States of America 
Section 304(a)(1) of the Clean Water Act of 1977 requires the US EPA to publish Water 
Quality Criteria (WQC) for pollutants. If these are adopted by States as Water Quality 
Standards (WQS), they become enforceable maximum acceptable pollutant 
concentrations in ambient waters in that State. The WQC for nonylphenol (final chronic 
value for freshwater) is 6.6 µg/L, not differentiating between the various isomers (US 
EPA 2005).  
Canada 
Canada’s Water Quality Guidelines for the protection of aquatic life specify a 
concentration of nonylphenols of 1.0 µg/L in freshwater, and 0.7 µg/L in marine water 
(Canadian Council of Environment Ministers, CCEM 2002). The values apply to 4-
nonylphenols with branched side chains (CAS No 84852-15-3). 
China 
There are currently no water quality criteria for nonylphenols in China, although several 
Chinese scientists have derived such criteria (Lei et al. 2012, Gao et al. 2014). 
To our knowledge, water quality criteria for nonylphenols are not in place in Australia or 
Japan. 
Assessment and measurement endpoints for hazard characterisations 
A wide variety of assessment endpoints have been used for hazard characterisations of 
nonylphenols and these have formed the basis for the various regulatory values. 
Generally, whole organism endpoints were employed to derive water quality criteria. 
Endpoints relevant to endocrine disruption have played a relatively minor role in these 
efforts. Where they were used or where they proved critical for the derivation of WQC or 
EQS, measurement endpoints included reproduction, fecundity and biomarkers of 
estrogenicity such as induction of vitellogenin in fish. Biochemical and cell-based 
endpoints for estrogenicity were generally not employed. 
Often, several toxicity endpoints were integrated, instead of selecting endpoints for 
specific toxicities, including endocrine disruption. 
Assessment values and their derivation 
WQC for nonylphenols and the associated Predicted No-effect Concentrations (PNECs) 
have been derived by a “deterministic” approach and by using Species Sensitivity 
Distributions (SSDs), often side-by-side. The “deterministic” approach focuses on a single 
experimental study considered to be “critical”, which is then used to derive a No-
Observed-Effect-Concentration (NOEC). Species Sensitivity Distributions (SSDs) are 
constructed on the basis of several NOECs for a variety of species with the aim of 
establishing a hazardous concentration (HC) that affects 5% of relevant taxa (HC05). 





Table 1 shows the various PNECs and freshwater Water Quality Criteria (WQC), together 
with values important for their derivation, arranged in descending order. These values 
ranged from 0.1 to 6.6 µg/L. Values based on endocrine disruption endpoints are shaded 
in grey. The PNECs that formed the basis for the European Union EQS are highlighted in 
bold. 




Approach Basis (points of departure) AF Source and 
year 
6.6 deterministic Derived from a Final Acute value of 
55.49 µg/L by using a Final Acute 
Chronic Ratio (FACR) of 8.412 
8.412 
(FACR) 
US EPA (2005) 
1.59 SSD HC5: 1.59 µg/L, based on NOECs for 
chronic reproductive toxicity, 
specific for 4-NP with linear side 
chain CAS No 104-40-5 
1 Lei et al. (2012) 
1.3 deterministic Chronic NOEC: 10.3 µg/L, specific 
for 4-NP with unspecified side chains 
CAS No 25154-52-3 
10 Lei et al. (2012) 
1.34 SSD HC5: 1.34 µg/L, based on NOECs for 
chronic reproductive toxicity, 
specific for 4-NP with unspecified 
side chains CAS No 25154-52-3 
1 Lei et al. (2012) 
1 deterministic 91 day LOEC for growth reduction in 
rainbow trout: 10.3 µg/L 
10 CCEM (2002) 
0.74 deterministic Chronic NOEC: 7.4 µg/L, specific for 
4-NP with unspecified side chains 
CAS No 84852-15-3 
10 Lei et al. (2012) 
0.5 deterministic NOEC: 5 µg/L for chronic 
reproduction, specific for 4-NP with 
linear side chain CAS No 104-40-5 
10 Lei et al. (2012) 
0.5 deterministic NOEC: 5 µg/L for chronic 
reproduction, specific for 4-NP with 
unspecified side chains CAS No 
25154-52-3 
10 Lei et al. (2012) 
0.48 SSD HC5: 1.43 µg/L, based on various 
endpoints which included NOECs 
and LOECs. Lowest value: LOEC = 
0.3 µg/L for fecundity and 
biomarkers of estrogenicity in 
rainbow trout (Giesy et al. 2000) 
3 Gao et al. 
(2014) 
0.42 SSD HC5: 2.12 µg/L based on combined 
marine and freshwater NOECs 
5 ECHA (2014) 
0.3 deterministic Long-term NOEC in freshwater 
algae Scenedesmus subspicatus: 
3.3µg/L 
10 EU EQS, EU 
(2005) 
0.39 deterministic NOEC in marine mysid: 3.9 µg/L 10 ECHA (2014) 
0.16 deterministic Chronic NOEC: 1.65 µg/L, specific 
for 4-NP with linear side chain CAS 
No 104-40-5 
10 Lei et al. (2012) 
0.1 deterministic NOEC: 1 µg/L for chronic 
reproduction, specific for 4-NP with 
branched side chains CAS No 
84852-15-3 
10 Lei et al. (2012) 
 
Selection criteria for the choice of experimental studies  
Different experimental studies were chosen for the various PNECs and WQC listed in 
Table 1, but criteria for their selection were often not made explicit. Lei et al. (2012) 
based their selection on Klimisch scores of 1 as a minimum quality criterion, ECHA 




US EPA (2005) and the Canadian CCEM (2002) only used results from test organisms 
resident in North America. US EPA (2005) excluded studies where the test organisms 
were inadequately described, where dosing was by injection, gavage or an artificial 
medium, and where the experimental model was not an intact organism. 
Gao et al. (2014) used toxicity data from the US EPA ECOTOX database. 
Consideration of specific nonylphenol isomers 
The values listed in Table 1 were generally not derived for specific 4-nonylphenol 
isomers. US EPA did not specify isomers; most other values are for 4-nonylphenol with 
branched side chains and for unspecified side chains, i.e. CAS No 84852-15-3 and 
25154-52-3 considered together. These distinctions are of importance because different 
isomers have different potencies, especially in relation to endocrine disruption. The only 
effort that derived different PNECs for the different CAS No is by Lei et al. (2012). 
Consideration of endocrine disrupting effects 
Where toxicities other than endocrine disruption were decisive for the derivation of 
PNECs or WQC, several regulatory bodies also assessed the degree of protection from 
endocrine disrupting effects that results from the respective PNECs and WQCs by 
comparison with the outcome of critical endocrine disruption endpoints. 
For example, US EPA (2005) stated that the USA WQC protect against endocrine 
disrupting effects because such responses had rarely been reported below the critical 
value of 6.6 µg/L. 
ECHA (2014) noted that the most sensitive fully reliable LOEC in fish was 10 µg/L 
(endpoints: growth in rainbow trout and sex ratio changes in the zebrafish), but pointed 
out that first effects on semen quality may start around 0.75 µg/L. In amphibians, the 
LOEC is smaller than 10 µg/L. Both the EU EQS of 0.3 µg/L and the value of 0.39 used by 
ECHA for their risk assessment would protect against such endocrine disrupting effects. 
The choice between the deterministic and the SSD approach 
All the PNECs and WQC in Table 1 that are applied in jurisdictions (i.e. EU 2005, CCEM 
2002 and US EPA 2005) were derived by deterministic approaches. However, ECHA 
(2014) also constructed SSDs and estimated HC5 values which were then compared with 
the deterministic values. 
The authors of several Chinese efforts of deriving WQC for nonylphenols (Lei et al. 2012, 
Gao et al. 2014) expressed a preference for the SSD approach, with the argument that 
information from a multitude of studies is used, instead of placing a great deal of weight 
on just one critical study, as in the deterministic approach. 
The differences in the various HC5 values derived using the SSD approach are due 
entirely to different sets of NOECS and LOECs employed for constructing the SSDs. 
Across the various efforts, no consistent selection criteria for the sets of toxicity values 
are discernible.  
Use of non-endemic species for the derivation of HC05 values from SSDs 
The EU values were derived by inclusion of species not resident in Europe, such as the 
fathead minnow or the zebrafish. The USA and Canada rely only on species resident in 
North America. 




With the deterministic approach, an AF of 10 was typically used. With the SSD approach 
AFs between 1 and 5 were applied, in line with ECHA guidance. 
Exposure assessments 
Exposure assessments for NP in freshwaters and marine waters have been conducted in 
numerous countries and economic areas, including the European Union, the USA, China, 
Canada and Japan. Mostly, these were based on Measured Environmental Concentrations 
(MECs). Values derived through hydrological modelling, Predicted Environmental 
Concentrations (PEC), were not often used. 
Risk assessments 
The possible risks to aquatic life of exposures to nonylphenols were assessed in several 
studies, by building risk quotients of MECs and the PNECs or WQC applicable in the 
various jurisdictions. 
European Union 
By deriving risk quotients with the PNEC of 0.39 µg/L, ECHA (2014) concluded that there 
is no concern for most surface waters in the European Union, with the exception of some 
Member States where risk quotients exceeding 1 were found. If however, an additional 
factor of 10 was used to produce a value of 0.039 µg/L, with the aim of accounting for 
endocrine disrupting properties of nonylphenols, the measured concentrations in most 
European Union Member States would be of concern. If mixture effects that occur 
through joint action of NP with other estrogenic chemicals would be accounted for, even 
larger risk quotient would be the result (ECHA 2014).  
Canada 
Nonylphenol concentrations in Canadian freshwaters range between < 0.01 and 1.7 µg/L 
(CCEM 2002), thus sometimes exceeding the Canadian WQC of 1 µg/L. It is unclear what 
proportion of Canadian freshwaters exceed the WQC of 1 µg/L. 
China 
Gao et al. (2014) have presented calculations of risk quotients for a variety of Chinese 
rivers using their freshwater PNEC of 0.48 µg/L. The risk quotients in freshwater ranged 
from 0.04 to 69.7, with an average of 6.22. The highest RQ value of 69.7 was recorded 
at the urban riverine water of the Pearl River Delta in Southern China around the 
economically highly developed city of Guangzhou. The main sources of nonylphenol are 
from industrial wastewaters and domestic sewage. 
Risk management options 
In the European Union, nonylphenol is subject to risk management measures; it fulfils 
the criteria for being designated an endocrine disruptor laid down in the REACH 
legislation (ECHA 2014). This means that measures for substitution of nonylphenols 
should be implemented. 
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4.3 Case Study: BPA, Bisphenol A, human health 
Summary 
Bisphenol A (BPA) is an industrial chemical that is widely used as a monomer or additive 
for the manufacture of polycarbonate (PC) plastics and epoxy resins and other polymeric 
materials. It is also used in certain paper products, including thermal paper. 
The endocrine disrupting properties of Bisphenol A (BPA) have been discovered through 
screening exercises back in 1930’s.  
BPA has been the subject of intense research and debate over the last decade, not least 
due to suspected low-dose effects (endocrine disrupting properties and developmental 
neurotoxicity) of the chemical and its presence in food contact materials resulting in 
exposure of vulnerable groups such as infants and young children. 
What is unresolved is whether there are low dose effects and non-monotonic dose 
responses at the levels to which most people are exposed to BPA. Moreover the reference 
doses and the risk management of BPA are different internationally. 
Scope of this case study 
Many studies addressing BPA as endocrine disruptor for humans have focused on effects 
on male and female reproductive development (studies in rodents). Accordingly, this 
case study focuses on the effects of BPA on humans and the effect on aquatic wildlife will 
not be the focus in this report. However, also in the environment effects on BPA in 
several studies are seen3. In a recently published report from the EU commission it is 
stated (on BPA): “With respect to vertebrate wildlife evaluation, a plausible link was 
established since in vitro and in vivo mechanistic data available (binding and agonistic 
activity to thyroid hormone receptor as well as transthyretin transactivation) were 
considered as likely to be responsible for the observed malformations in several frog 
species. Moreover, inhibition of sperm maturation in fish and skewed sex ratio in 
amphibians could be linked to increased vitellogenin synthesis in male fish suggesting 
estrogenic activity”. 
Discovery as an endocrine disruptor 
Chemists synthesized the chemical bisphenol A (BPA) in the laboratory in 1891. In the 
1930’s, scientists were searching for synthetic chemicals that could replace the expensive 
natural oestrogen in pharmacological applications. They identified BPA as a weak 
functional oestrogen. Its use as a pharmaceutical hormone was precluded by the 
invention of another synthetic chemical, DES, with even more potent estrogenic 
properties (Dodds and Lawson, 1938). DES was subsequently used as a pharmaceutical 
that showed severe side effects (Meyers, 1983). Since 1940’s and 1950’s BPA have been 
used to make polycarbonate plastics.  
In 1993 a team of endocrinologists at Stanford University found an unknown oestrogenic 
substance that contaminated their assays. Finally, they identified BPA leaching from their 
polycarbonate cell culture dishes when they were autoclaved (Krishnan et al., 1993). 
BPA has been the subject of intense research and debate over the last decade, not least 
due to suspected low-dose effects (endocrine disrupting properties and developmental 
neurotoxicity) of the chemical and its presence in food contact materials resulting in 
exposure of vulnerable groups such as infants and young children (DK-EPA, 2014). 
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Regulatory framework in selected jurisdictions 
In recent years, the reproductive and developmental toxicity of BPA has been thoroughly 
evaluated at the national, European and international level. Moreover, during the last 10 
years, several risk assessments on BPA have been performed by different regulatory 
bodies and expert groups in Europe, Canada, USA and Japan. The hazard assessments 
were mainly based on a comprehensive range of studies conducted in accordance with 
international testing guidelines and Good Laboratory Practices.  
European Union  
The EU risk assessments under the Existing Chemicals programme concluded that there 
was no consumer risk associated with the use of BPA.  
However, in recognition of the uncertainty as to the effect associated with possible low-
dose exposure of BPA and following pressure from several Member States, an EU ban 
prohibiting the use of BPA for the manufacture of polycarbonate infant feeding bottles 
was adopted in January 2011 and EU states outlawed the manufacture of polycarbonate 
feeding bottles containing the compound from March 2011, and banned their import and 
sale from June 20114. 
EFSA 
In 2015 EFSA concludes that based on the t-TDI of 4 μg/kg bw/day, and using the EFSA 
estimates of the total exposure to BPA, there is no health concern. 
EU Member states  
Germany  
In REACH a Substance Evaluation on BPA (with focus environment) was started in 2012 
with Germany as the rapporteur Member State. One of the initial grounds for concern 
was: Potential endocrine disruptor. The status is that information is requested5 on more 
testing6. 
France 
France suggested a harmonised classification and labelling for BPA (Reprotoxic Category 
1B).  The Committee for Risk Assessment (RAC) has adopted an opinion to strengthen 
the existing harmonised classification and labelling (CLH) of BPA from a category 2 
reproductive toxicant to a category 1B reproductive toxicant regarding the adverse 
effects on sexual function and fertility in line with a proposal from the French competent 
authority7. The classification of bisphenol A (BPA) as a category 1B substance toxic for 
reproduction which will come into force on 1st March 20188. 
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Moreover, in May 2014, the French authorities submitted a proposal to restrict BPA 
because of health risks for pregnant workers and consumers exposed to it in thermal 
paper - for example when they handle cash register receipts. The population identified as 
being at risk is unborn children, who are exposed in the uterus. RAC agreed with the 
French proposal that BPA may have effects on the mammary glands, as well as on 
reproduction, metabolism and neuro-behaviour. In addition, and in line with the opinion 
of the European Food Safety Authority (EFSA), RAC also considered the effects on the 
immune system. 
In September 2015, RAC concluded that the risk for the unborn children of female 
workers e.g. cashiers handling thermal paper, is not adequately controlled. However, the 
Committee did not identify a risk to consumers in handing receipts9. 
Moreover, France have ongoing work to identify BPA as SVHC57(f) for human health (to 
be submitted in the window of early 2017)10. 
Denmark 
In July 1, 2010 Denmark temporarily restricted BPA in baby bottles, sippy cups and 
packaging for baby food and “breast milk substitutes”. The measure, labelled 
“temporary,” is in effect until evidence proves BPA safe to developing nervous system 
and behaviour11. 
United States of America 
FDA’s current perspective, based on its most recent safety assessment, is that BPA is 
safe at the current levels occurring in foods. Based on FDA’s ongoing safety review of 
scientific evidence, the available information continues to support the safety of BPA for 
the currently approved uses in food containers and packaging12. 
FDA’s regulatory Centers and FDA’s National Center for Toxicological Research continue 
to pursue a set of studies on the fate of BPA in the body from various routes of exposure 
and the safety of low doses of BPA, including assessing novel endpoints where questions 
have been raised.  
Research studies pursued by FDA’s National Center for Toxicological Research have 
recently completed a rodent subchronic study (Delclos et al. 2014) intended to provide 
information that would help in designing a long-term study that is now underway 
(CLARITY BPA). The subchronic study was designed to characterize potential effects of 
BPA in a wide range of endpoints, including prostate and mammary glands, metabolic 
changes, and cardiovascular endpoints. The study included an in utero phase, direct 
dosing to pups to mimic bottle feeding in neonates, and employed a dose range covering 
the low doses where effects have been previously reported in some animal studies, as 
well as higher doses where estrogenic effects have been measured in guideline oral 
studies. The results of this study showed no effects of BPA at any dose in the low-dose 
range (Delclos et al. 2014). 
The FDA’s National Center for Toxicological Research is now continuing with an additional 
study. Using the data and design from the rodent subchronic study, the National 
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Toxicology Program/Food and Drug Administration (NTP/FDA) is conducting a long-term 
toxicity study of BPA in rodents to assess a variety of endpoints, including novel 
endpoints where questions have been raised. As an addition to this core study, FDA is 
providing extra animals and tissues to a consortium of grantees (Schug et al. 2013) 
selected and funded by the National Institute of Environmental Health Sciences to 
address other critical questions. 
The 2014 hazard assessment by the FDA’s BPA Joint Emerging Science Working Group 
reconfirms the previously identified NOAEL of 5 mg/kg bw/day for systemic toxicity from 
subchronic/multigenera-tional studies using rodents as the most appropriate NOAEL for a 
safety assessment of oral or dietary exposures. Available pharmacokinetic data and 
comparisons between ages and species further support use of this NOAEL as very 
conservative in extrapolating to humans. Compared to the 90th percentile exposures 
cited above for populations of 2 years old, the margins of safety exceed the uncertainty 
factor of 100013. 
Canada  
In its 2008 risk assessment, the Health Canada’s Food Directorate did not revise the 
provisional TDI for BPA of 0.025 mg/kg bw per day set from the lowest NOEL of 25 
mg/kg bw per day for general toxicity in a rat 90-day study (NTP, 1982), and concluded 
that the current dietary exposure to BPA through food packaging uses was not expected 
to pose a health risk to the general population, including new-borns and young children 
(Health Canada, 2008). Health Canada then estimated the probable daily exposure to 
BPA to vary from as low as 0.21 μg/kg bw for infants 8-12 months of age to as high as 
1.35 μg/kg bw for 0-1 month old infants with the maximum formula intake and the 
maximum concentration of BPA migrating from epoxy lined infant formula cans (EFSA, 
2015). 
Over the years, Health Canada's Food Directorate has conducted periodic reviews of BPA 
as new information has become available relating to its toxicity and/or its potential 
exposure from food packaging applications. The purpose of these reviews was to 
determine whether dietary exposure to BPA could pose a health risk to consumers. 
However, due to the uncertainty raised in some animal studies relating to the potential 
effects of low levels of BPA, the Government of Canada is taking action to enhance the 
protection of infants and young children. It is therefore recommended that the general 
principle of ALARA (as low as reasonably achievable) be applied to continue efforts on 
limiting BPA exposure from food packaging applications to infants and new-borns, 
specifically from pre-packaged infant formula products as a sole source food, for this 
sensitive segment of the population14. 
Health Canada released an “updated assessment of BPA in 2012” and also concluded that 
there were no safety issue at the levels people are exposed to15. 
Australia 
Food Standards Australia New Zealand (FSANZ) is an independent statutory agency 
established by the Food Standards Australia New Zealand Act 1991 (FSANZ Act). FSANZ 
is part of the Australian Government's Health portfolio. In a paper from 2010 FSANZ 
states that:  




 http://www.hc-sc.gc.ca/fn-an/securit/packag-emball/bpa/index-eng.php  
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The weight of scientific evidence indicates that exposure to BPA in food does not present 
a significant human health and safety issue at current exposure levels. A recent FSANZ 
survey of BPA levels in food and beverages in Australia affirms the conclusion that 
consumers are exposed to very low levels of BPA through food and beverage 
consumption. Only a limited number of products were found with detected levels of BPA 
and no detectable levels of BPA were found in infant formula. These results provide 
additional assurance that BPA concentrations in Australian food do not pose a health risk 
to consumers16. 
China 
In April 2011, China's Ministry of Health announced that the production and import of 
infant food containers containing bisphenol A (BPA), including baby feeding bottles, will 
be banned from 1 June, and that sales of such products will be banned from 1 
September. The ministry says that while risk assessment of dietary exposure levels of 
BPA have demonstrated that the substance does not pose a health hazard, taking into 
account the potential of a low dose effect and the uncertainty of animal experiments, 
Canada, the EU and some US states have felt it necessary to introduce restrictions. 
China's production and imports ban will take effect on the same date as the ban on 
polycarbonate baby bottles in the EU17. 
Assessment and measurement endpoints for hazard characterisations 
The scientific debate on the risks for public health of BPA focuses on its endocrine-active 
properties, which might adversely impact physical, neurological and behavioural 
development. In addition, other perturbations of physiology, both in animals and 
humans, have been brought in relationship to the endocrine active properties of BPA. 
Among these are e.g. obesity, modification of insulin-dependent regulation of plasma 
glucose levels, perturbation of fertility, proliferative changes in the mammary gland 
possibly related to the development of breast cancer, immunotoxicity and adverse effects 
on the cardiovascular system (EFSA, 2015).  
In the recent evaluation made by EFSA, both kidney and liver effects and proliferative 
changes in mammary gland were considered likely and were used for hazard 
characterisation (EFSA, 2015). 
Assessment values and their derivation 
In 2006, EFSA set the TDI for BPA at 0.05 mg BPA/kg body weight (b.w.)/day. This is 
based on the No-Observed-Adverse-Effect-Level (NOAEL) of 5 mg/kg b.w./day that has 
been identified in two multi-generation reproductive toxicity studies in rodents, where the 
critical effects were changes in body and organ weights in adult and offspring rats and 
liver effects in adult mice, respectively (EFSA, 2006). The NOAEL for developmental 
toxicity was 50 mg BPA/kg bw/day and 600 mg BPA/kg bw/day for reproductive toxicity 
(Tyl et al., 2006). EFSA reviewed new scientific information on BPA in 2008, 2009, 2010 
and 2011: EFSA’s experts concluded on each occasion that they could not identify any 
new evidence which would lead them to revise the TDI for BPA of 0.05 mg/kg bw/day.  
Based on new scientific findings and possibly triggered by several Member States aiming 
at further restrictions on the use of BPA in food contact materials, EFSA undertook a full 
re-evaluation of the human risks associated with exposure to BPA through the diet, also 










taking into consideration the contribution of non-dietary sources to the overall exposure 
to BPA. After public consultation EFSA published the new evaluation of bisphenol A (BPA) 
in January 21, 201518. The EFSA evaluation of BPA consisted of a summary, Part 1: 
Exposure assessment and part 2: Toxicological assessment and risk characterisation. In 
this opinion EFSA establishes a new temporary TDI for BPA on 4 μg/kg bw/day.  EFSA 
concludes that based on the t-TDI of 4 μg/kg bw/day, and using the EFSA estimates of 
the total exposure to BPA, there is no health concern.  
The t-TDI vas based on a BMDL10 of 8960 µg/kg bw/day based on changes in relative 
kidney weights in the Tyl et al. (2008) study on mice and by using the HEDF of 0.068 
based on the adult mouse. Multiplying the HEDF by the point of departure (i.e. a NOAEL 
or BMDL10) of a toxicity study yields a human-equivalent oral dose that can be used for 
risk assessment. To obtain the equivalent dose in humans, the HEDF of 0.068 is 
multiplied by the BMDL10 of 8960 µg/kg bw/day resulting in a human equivalent dose of 
609 µg/kg bw /day. The overall uncertainty evaluation by EFSA (2015) included the 
effects on mammary gland as well as reproductive, metabolic, neuro-behavioural and 
immune systems (EFSA, 2015). The uncertainty evaluation approached “likely” in the 
(HED) dose range of 100-1000 µg/kg bw/day. EFSA (2015) therefore concluded that the 
uncertainty regarding the abovementioned effects at the HED of 100 µg/kg bw/day and 
higher should be taken into account when establishing a health-based guidance value by 
including an extra factor in establishing the t-TDI. Thus, as the reference point was 609 
µg/kg bw/day based on the mean relative kidney weight and the lower end of the dose 
range for which the uncertainty evaluation for other endpoints approached “likely” is 100 
µg/kg bw/day, a factor of 6 was applied. Applying the remaining assessment factor of 25 
(remaining factor of 2.5 for interspecies differences, and factor 10 for intraspecies 
differences), the resulting t-TDI was 4 µg/kg bw/day (EFSA, 2015) (see table 1). 
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The choice of critical experimental studies and selection criteria 
Different experimental studies were chosen for the various reference values listed in 
Table 1.   
In EFSA, the changes in relative kidney weights in the Tyl et al. (2008) have been used 
for setting the TDI. Moreover, the overall uncertainty evaluation by EFSA (2015) was 
reported to also include the effects on the mammary gland as well as reproductive, 
metabolic, neurobehavioural and immune systems (EFSA, 2015).The same study 
(industry) was chosen for RfD setting in FDA. The DTU evaluation is based on a new 
statistical analysis of the data from Delclos et al. 2014. DTU evaluates that these data 
suggest that increased numbers of female animals with hyperplasia of the mammary 
tissue are found at 80 μg/kg bw/day BPA and higher doses. Such changes indicate an 
increased risk for breast cancer later in life. DTU finds that the study leads to a tentative 
LOAEL of 80 μg/kg bw/dag and a NOAEL of 25 μg/kg bw/day. 
ANSES has chosen different studies on low dose exposure of BPA with neural-, female 
reproductive, metabolic- and mammary gland effects (ANSES, 2013) resulting in low 
internal DNELs. 
The choice of assessment factors 
EFSA 
In deriving a health-based guidance value, the CEF Panel (EFSA) used an uncertainty 
factor of 2.5 for inter-species differences (1 for toxicokinetics and 2.5 for toxicodynamics, 
reflecting the fact that toxicokinetic differences have been addressed by use of the HED 
approach) and an uncertainty factor of 10 for intra-species differences (see table 1). In 
addition, the CEF Panel considered that the extra factor of 6 should be included to take 
into account the uncertainty in the database, i.e. mammary gland, and reproductive, 
neurobehavioural, immune and metabolic systems. The CEF Panel applied, therefore, an 
overall uncertainty factor of 150 to the HED of 609 μg/kg bw per day and established a 
temporary Tolerable Daily Intake (t-TDI) for external oral exposure to BPA in humans of 
4 μg/kg bw, based on the mean relative kidney weight effect in the mouse. The CEF 
Panel designated the TDI as temporary, pending the outcome of the long-term study in 
rats involving prenatal as well as postnatal exposure to BPA, currently being undertaken 
by NTP/FDA. This study will help resolve the uncertainties in the database (EFSA, 2015). 
French Agency for Food, Environmental and Occupational Health & Safety 
(ANSES)  
In September 2011, ANSES published a report on BPA, including one part concerning its 
effects on human health and the other one on its uses (ANSES, 2011). In the hazard 
identification report "Effets sanitaires du bisphénol A” ANSES classified the effects of BPA 
on humans and animals as proven, suspected, controversial, or inconclusive (ANSES, 
2011). Furthermore, it reached the conclusions that BPA exposure was associated with 
proven effects in animals and suspected effects in humans, also at levels of exposure 
below the current regulatory thresholds. These effects were the main focus of the 
subsequent risk assessment that was completed by ANSES in April 2013(ANSES, 2013).  
Specifically, the characterisation of human health risks was conducted considering four 
toxicological endpoints for which the external threshold doses identified in oral studies in 
developing animals are reported: neurobehavioural development (NOAEL: 50 μg/kg bw 
per day from Xu et al., 2010), female reproductive system (NOAEL: 100 μg/kg bw per 
day from Rubin et al., 2001), metabolism and obesity (LOAEL: 260 μg/kg bw per day 
from Miyawaki et al., 2007) and mammary gland proliferation - changes in the structure 




et al., 2008). ANSES used a bioavailability factor of 3% to convert the external 
NOAEL/LOAEL from the experimental data into equivalent internal doses (internal 
NOAEL/LOAEL), taking into consideration the impact of first-pass metabolism on orally 
ingested BPA and assuming that only the unconjugated fraction of BPA was responsible 
for the effects observed. To obtain an internal Derived No Effect Level (DNEL) for each 
critical endpoint, ANSES applied an overall assessment factor of 300 to the internal 
NOAELs (or 900 if the starting critical dose was a LOAEL), consisting of a factor 100 to 
account for inter- and intra-species kinetic and dynamic differences, and an extra factor 
of 3 to account for uncertainties regarding possible low-dose effects of BPA and non-
monotonic dose-response relationships (NMDRs). The resulting internal DNELs that were 
used in risk characterisation were 0.005, 0.01, 0.009 and 0.0025 μg/kg bw per day for 
neural-, female reproductive-, metabolic- and mammary gland effects, respectively (see 
table 1). The sources of BPA considered for BPA (probabilistic) exposure assessment 
were air, sedimented dust, food and beverages. Dietary (external) exposure (99th 
percentile) was estimated to be for children (3-17 yrs) 0.31 μg/kg bw per day, for 
adolescents (11-17 yrs): 0.12 μg/kg bw per day, and for pregnant women: 0.24 μg/kg 
bw per day (ANSES, 2013). 
Other issues 
No risk assessment has taken potential mixture effects due to exposure to other 
chemicals with similar types of effects as BPA into account. This means that the risk can 
be underestimated. 
Moreover, the debate on non-monotonic dose-response relationships and low dose 
effects on BPA is ongoing. In a recent paper by Vandenberg and Prins (2016) it is stated: 
…, some effects are seen at low doses of BPA, but not at higher doses. These may be 
examples of nonmonotonic dose responses, which are common for hormones and EDCs, 
and can be explained by a number of endocrine-mediated mechanisms, including 
receptor down-regulation, receptor competition, and the overlap of competing monotonic 
curves.  
ANSES provided a more lengthy discussion of non-monotonic relationships in their 
evaluation of BPA (ANSES, 2013). As mentioned above, ANSES do include an extra factor 
of 3 to account for uncertainties regarding possible low-dose effects of BPA and non-
monotonic dose-response relationships (NMDRs) when deriving a DNEL (ANSES, 2013). 
Exposure assessments 
Highly exposed humans are according to EFSA’s exposure assessment exposed to 1.01-
1.06 μg/kg bw/day for men and women and 1.26-1.45 μg/kg bw/day for children (3-10 
years) and teenagers. These exposures are around 3-4 times lower than the EFSA t-TDI 
of 4 μg/kg bw/day and EFSA concludes that the aggregated exposure to BPA indicates no 
health concern for BPA (EFSA, 2015). 
However, DTU finds that the TDI for BPA should be 0.7 μg/kg bw/day (see table 1) to be 
sufficiently protective with regards to endocrine disrupting effects of BPA. Highly exposed 
humans including pregnant women and children are according to EFSA’s exposure 
assessment exposed to around 1.4-2 times more than 0.7 μg/kg bw/day BPA. DTU 
concludes that this gives rise to health concern for highly exposed humans (DTU, 
Evaluation, 2015). 
In 2012, a refined (probabilistic) exposure assessment of Canadians was conducted 
based on the collective results of a number of recent Canadian surveys, including results 
from a Total Diet Study. A mean exposure to BPA of 0.055 μg/kg bw per day was 
calculated for the general population, which is approximately 3 times lower than the 
exposure calculated in the risk assessment of 2008. This updated dietary exposure figure 
generally aligns with exposure estimates that are based on the results of population-




amount of BPA. The probable daily exposure to BPA varied from 0.083 μg/kg bw (0-1 
month of age) to 0.164 μg/kg bw (4-7 months old infants). Collectively, also the BPA 
exposure estimates for infants were, on average, approximately 3-fold lower than those 
of 2008. Health Canada recommended the application of the general principle of ALARA 
(as low as reasonably achievable) to limit BPA exposure of new-borns and infants, due to 
uncertainties for low-dose neurodevelopmental and behavioural effects in rodents (EFSA, 
2015). 
In 2005, the Japanese AIST concluded that BPA was unlikely to pose unacceptable risks 
to human health at current exposure levels. Margins of exposure (MOEs) were calculated 
as 85,000-1,800,000 based on realistic exposure scenarios, and as >1,000 for adults and 
children based on worst-case scenarios. For these calculations, the NOAEL or the 
Benchmark Dose Lower Limit (BMDL) for three critical endpoints, namely lower body 
weight gain, liver and reproductive effects, were in the 5 to 50 mg/kg bw per day range. 
AIST updated the Hazard Assessment of BPA in 2011 (AIST, 2011). The oral NOAEL for 
BPA general toxicity was considered to be 3 mg/kg bw per day based on centrilobular 
hepatocyte hypertrophy in the two generation study in mice by Tyl et al. (2008). A total 
uncertainty factor of 25 was applied, consisting of 2.5 for inter-species differences (1 for 
toxicokinetics, and 2.5 for toxicodynamics), and of 10 for intra-species differences. 
According to the BPA exposure estimate in Japanese individuals, exposure was highest in 
1 to 6 years old children with an estimated 95th percentile (in μg/kg bw per day) of 3.9 
(males) - 4.1 (females). In adults, the 95th percentile of BPA intake (estimated from the 
amount of BPA excreted in 24-hour urine samples) was 0.037-0.064 μg/kg bw per day in 
men and 0.043-0.075 μg/kg bw per day in women. The relative margins of exposure 
(MoEs, i.e. ratio between the NOAEL and 95th percentile exposure data) were 730-770 
for 1-6 yr old children and 40,000-81,000 for adults. These values were much larger than 
both the MoE (25) that was considered might possibly result in health effects in humans 
and the standard (conservative) MoE of 100, and thus the AIST concluded that the risk of 
BPA with regard to human health was very small (reported in EFSA, 2015). 
Risk assessments 
EU 
In 2003, the European Chemical Bureau of the European Union published a 
comprehensive Risk Assessment Report (EU-RAR) for BPA in the context of Council 
Regulation (EEC) No. 793/93 on the evaluation and control of existing substances. The 
key health effects of BPA through different exposure routes were considered to be eye 
and respiratory tract irritation, skin sensitisation, repeated dose toxicity to the 
respiratory tract, effects on the liver and reproductive toxicity (effects on fertility and on 
development). With respect to human health risks, a need for further research was 
identified, to resolve the uncertainties surrounding the potential for BPA to produce 
adverse effects on neurological and neurobehavioural development at low doses (EU-
RAR, 2003).  
In 2008, the EU-RAR (EU-RAR, 2008) was updated after evaluation of the two generation 
reproductive study in mice by Tyl et al. (2008) along with the new data on human 
exposure and effects of BPA that had become available since 2003. EU-RAR identified a 
NOAEL of 50 mg/kg/day from the multigenerational study and used it for risk 
characterisation purposes, in relation to effects on fertility. The Rapporteur came to the 
conclusion that there was no need for further information and/or testing and for risk 
reduction measures beyond those which were already being applied. However, Denmark, 




warranted further consideration and expressed a minority view19 concerning this 
toxicological endpoint (EU-RAR, 2008). 
EFSA 
EFSA established in 2015 a temporary Tolerable Daily Intake (t-TDI) of 4 μg/kg bw per 
day. Highly exposed humans are according to EFSA’s exposure assessment exposed to 
1.01-1.06 μg/kg bw/day for men and women and 1.26-1.45 μg/kg bw/day for children 
(3-10 years) and teenagers (EFSA, 2015). These exposures are around 3-4 times lower 
than the EFSA t-TDI of 4 μg/kg bw/day and EFSA concluded that there is no health 
concern for any age group from dietary exposure or from aggregated exposure (EFSA, 
2015).  
Risk management options 
In recognition of the uncertainty as to the effect associated with possible low-dose 
exposure of BPA an EU ban prohibiting the use of BPA for the manufacture of 
polycarbonate infant feeding bottles was adopted in January 2011 and EU states 
outlawed the manufacture of polycarbonate feeding bottles containing the compound 
from March 2011, and banned their import and sale from June 2011.  
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4.4 Case Study: DEHP, human health 
Summary 
DEHP was discovered as a reproductive toxicant several decades ago and later when 
relevant endpoints for endocrine disruption became investigated, experimental exposures 
during development have demonstrated that DEHP can cause endocrine disrupting effects 
on male sexual development. The critical effect, assessment factor (AF) and the 
assessment values, e.g. DNEL or TDI, appear rather similar in Europe, the US and 
Canada and the values range from 34-60µg/kg bw/day.  No additional AFs are included 
to address uncertainties related to endocrine disruption (e.g. threshold).  Estimated 
exposures to DEHP also appear similar in Europe, the US and Canada and range from 1-
30 µg/kg bw/day. Both Canada and the US have concluded that there is concern for 
human health, especially for children. In the EU it has been concluded that the combined 
exposure to DEHP, BBP, DBP and DIBP reaches levels that constitute a risk to children. 
The regulatory actions include a ban on DEHP in toys and childcare products at 
concentrations greater than 0.1% in EU and US as well as recommendations in the EU, 
US and Japan with regards to medical devices used for infants. In the EU, there is a 
proposal to ban also articles intended for use indoors in unsealed applications and articles 
that may come into direct contact with the skin or mucous membranes containing one or 
more of the 4 phthalates DEHP, DBB, BBP or DIBP in a concentration greater than 0.1 % 
by weight of any plasticised material. 
Scope of this case study 
This case study focuses on the endocrine disrupting effects of DEHP on male reproductive 
development in humans. Effects of DEHP on the environment are also relevant, but this 
is not the scope of this case study. 
Discovery as an endocrine disruptor 
The discovery of DEHP as an endocrine disruptor was not the result of systematic 
screening, nor was the endocrine disrupting property of DEHP predicted on the basis of 
the biological activity in animals or humans. DEHP was discovered as a reproductive 
toxicant several decades ago and gradually, as relevant endpoints for endocrine 
disruption became investigated, experimental exposures during development 
demonstrated that DEHP can affect male sexual development. The type of effects seen in 
male offspring, especially decreased anogenital distance, increased nipple retention and 
malformation of the external genitalia (hypospadias) clearly points to an anti-androgenic 
mode of action of DEHP. This is supported by mode of action studies showing decreased 
testosterone levels in male foetuses during sensitive periods of sexual development.  
Regulatory framework in selected jurisdictions 
European Union 
DEHP is classified as toxic to reproduction in category 1B according to the CLP Regulation 
because it induces effects on reproductive organs and fertility in experimental animals 
exposed prenatally. The toxicological mode of action was later recognized to be the anti-
androgenic properties of DEHP (ECHA/NA/14/56). 
Under the REACH Regulation (EC) No. 1907/2006, the European Chemicals Agency 
(ECHA) has proposed adding DEHP to the list of substances for inclusion in Annex XIV for 
authorisation procedures. A restriction dossier was therefore submitted in 2011. 
In 2014, Denmark proposed DEHP to be identified as a substance of very high concern 
(SVHCs) due to the endocrine disrupting properties for human health and the 
environment. The Member State Committee (MSC) unanimously agreed with the 
identification of DEHP as a substance giving rise to equivalent level of concern due to its 




acknowledged that for DEHP there is scientific evidence of endocrine activity and of a link 
between this activity and adverse effects to human health. However, the MSC did not 
reach unanimous agreement on whether this constitutes an equivalent level of concern to 
CMRs (majority view), as a minority of members were of the view that the concern 
related to endocrine disruption is already covered by the existing identification as SVHC 
due to toxicity to reproduction. This MSC opinion with majority and minority views on the 
SVHC proposals will be sent to the European Commission for final decision.   
DEHP is subject to a ban on use (0.1%) in toys and childcare articles, in cosmetics and in 
plastic materials and articles intended to come into contact with foodstuffs.  
The risks posed by toys and childcare articles have to an extent been covered by the 
European Commission (Decision 1999/815/EC) temporary ban on DEHP in toys and 
childcare articles intended to be put into the mouth by children under three years of age. 
In September 2004, the EU Competitiveness Council replaced this temporary ban with 
permanent legislation within the framework of Directive on Restrictions on the Marketing 
and Use of Certain Substances and Preparations (76/769/EEC), which banned DEHP in 
toys and children's articles for all children because of the classification of DEHP as a 
reproductive toxicant. 
Similar restrictions on DEHP, as one of many substances classified as Carcinogenic, 
Mutagenic and Reproductive Toxicants (CMR), have been adopted in the Cosmetics 
Directive 2003/15/EEC by European Parliament in February 2003. "The Scientific 
Committee on Cosmetics concluded that CMR substances pose a significant threat to the 
health of consumers when used in cosmetic products. Although the exposure routes are 
not the same, toys, food packaging materials and medical devices may be seen as 
parallel cases giving rise to direct exposure of (the) consumers." 
In 2012, France became the first country in EU to ban the use of DEHP in paediatrics, 
neonatal and maternity wards in hospitals (http://healthierhospitals.org/media-
center/news-updates/france-first-eu-country-ban-use-dehp-paediatrics-neonatology-and-
maternity).  
United States of America 
Federal Government (2012) 
The federal government both regulates and continues to study phthalates. Federal 
entities involved in phthalate management and research include: 
Consumer Products Safety Commission (CPSC) – Among other provisions, the Consumer 
Product Safety Improvement Act of 2008 (CPSIA) banned the use of DEHP in toys and 
child care articles at concentrations greater than 0.1 percent. The CPSIA tasks the CPSC 
with appointing a Chronic Hazard Advisory Panel and examining the cumulative health 
risks of phthalates and phthalate substitutes.  
Food and Drug Administration (FDA) – The FDA regulates phthalates in food contact 
substances (such as plastic wrap), cosmetics, pharmaceuticals and medical devices. FDA 
announced in June 2008 that it is conducting a comprehensive inventory of regulated 
products that contain phthalate and is reviewing available use and toxicology information 
associated with phthalate exposure from FDA regulated products to better characterize 
any potential risk from these uses. 
Environmental Protection Agency (EPA) – Existing EPA Actions affecting DEHP (and other 
phthalates) include:  
  DEHP is regulated under the Safe Drinking Water Act. The highest concentration 
allowed, the maximum contaminant level (MCL), is 0.006 mg/L. 




  Under the Resource Conservation and Recovery Act (RCRA), phthalates are 
regulated as a hazardous waste if discarded as a commercial chemical product. 
  DEHP is reportable to the Toxic Release Inventory (TRI) under section 313 of the 
Emergency Planning and Community Right-to-know Act (EPCRA). 
  DEHP is included in the first group of 67 chemicals to be screened as part of the 
Endocrine Disruptor Screening Program (EDSP). 
  Phthalates that are listed on the TSCA Inventory are subject to TSCA section 8(e) 
Inventory Update Reporting (IUR) requirements, including production and use 
information for sites having production volumes of at least 25,000lbs/yr. All eight 
Phthalates (10 CASRNs) included in this Action Plan are listed on the TSCA 
Chemical Substance Inventory. 
  In 1989, EPA entered an Enforceable Consent Agreement under TSCA section 4 
with six companies to perform certain chemical fate and environmental effects on 
certain Alkyl Phthalates (54 FR 618). 
  In 2001, under the voluntary HPV Challenge Program, the Phthalate Esters Panel 
Testing Group of the American Chemical Council sponsored a phthalates ester 
category. The panel has submitted to EPA robust study summaries or other 
information for 26 phthalates, including DEHP. 
US State Governments 
California, Vermont and Washington have established standards for the content of certain 
phthalates in children’s articles. California prohibits the manufacture, sale, or distribution 
in commerce of any toy or child-care article that contains DEHP at greater than 0.1%.  
Vermont prohibits the manufacture, sale, or distribution in commerce of any toy or child-
care article intended for use by a child younger than three years old that contains DEHP, 
DBP, or BBP in concentrations greater than 0.1% (CRS, 2008). 
As part of a statute concerning chemicals in children’s products generally, Washington 
prohibits a manufacturer, wholesaler, or retailer from manufacturing, knowingly selling, 
offering for sale, or distributing for sale or for use in the state a children’s product or 
product component containing phthalates (DEHP, DBP, BBP, DINP, DIDP, DnOP) 
individually or in combination, at a concentration exceeding 0.1% by weight (CRS, 2008).  
Other States such as Hawaii have introduced legislation to prohibit the manufacture, 
sale, or distribution of certain toys and child care articles containing certain types of 
phthalates (Hawaii House of Representatives, 2009; CRS, 2008). 
Proposition 65 California Proposition 65: The Office of Environmental Health Hazard 
Assessment (OEHHA) of the California Environmental Protection Agency added DEHP to 
the list of more than 750 chemicals known to the state to cause reproductive toxicity for 
the developmental and male reproductive endpoints. 
Japan 
In 2002, the Japanese Ministry of Health, Labour and Welfare recommended that 
healthcare professionals do not use medical devices made of PVC in which the plasticiser 
DEHP is used; alternative devices should be used instead. 
Australia 
In 2006, the Australian Government declared the phthalates DEHP, DIDP, DMP, DINP, 
DBP, BBP, DnOP, DEP and bis(2-methylethyl) phthalate as Priority Existing Chemicals 
and initiated public risk assessments for these phthalates. Phase 1 "the development of 




2008a-h). Phase 2 "the development of the risk assessments" is currently in progress 
(Australian Government, 2009). 
Assessment and measurement endpoints for hazard characterisations 
Developmental toxicity manifested as effects on male sexual development is used as 
critical effect. The endpoints considered include among others AGD, NR and testicular 
toxicity in rat offspring and these effects are generally recognized to be due to endocrine 
disruption.  
Assessment values and their derivation 
In the EU, the Tolerable Daily Intake (TDI) value of DEHP was previously established 
(RAR 2008 and ECB 2008) at 48 µg per kg bw per day, based on a NOAEL of 4.8 
mg/kg/d for reproductive toxicity in rats and applying an assessment factor of 100. 
Based on the same studies, EFSA rounded the TDI to 50 µg/kg bw/d (EFSA 2005). The 
current derived No Effect Level (DNELs) adopted by ECHA for DEHP is 35 µg/kg bw/day 
(ECHA 2013). 
In 2015, SCENIHR supported the TDI value of 50 µg/kg bw/d, considering that the new 
studies are in line or not sufficiently robust to justify the derivation of a new TDI 
(SCENIHR, 2015). The assessment values, i.e. DNEL, TDI, are shown in table 1. They 
appear rather similar, i.e. range from 0.03-0.06 mg/kg/d, and generally an AF of 100 for 
intra- and interspecies differences is used. Although the effects of DEHP are generally 
recognized to be due to endocrine disruption, no additional AFs are included to address 
uncertainties related to endocrine disruption (e.g. threshold, non-monotonic dose-
response).   
Table 1 Assessment values and their derivation 









ECHA (2013) testicular toxicity 
in rat offspring 
NOAEL = 4.8 mg/kg/d; 
NOAEL (corrected, 
absorption) = 3.36 
mg/kg/d 
100 0.034  
EFSA (2005) testicular toxicity 
in rat offspring 










NOAEL = 44 mg/kg/d 1000 0.044 
 
ECHA has rejected claims by a group of NGOs that there are “procedural and substantive 
flaws” in the draft opinions, adopted by its Committees on Risk Assessment (RAC) and 
Socio-Economic Analysis (SEAC), which concluded that authorisations for the use of the 
phthalate DEHP should be granted. NGOs have argued that it is wrong to set a DNEL for 
DEHP, because REACH does not allow them to be set for endocrine disruptors, and 
DEHP’s classification as a reprotoxicant “is mediated by an endocrine mode of action” 
(https://chemicalwatch.com/22717/echa-defends-its-views-on-dehp-authorisation, 28 




to be set for reproductive toxicants. The RAC acknowledges that the reproductive toxicity 
of DEHP is mediated by an endocrine mode of action but finds that it is appropriate to 
establish the reference DNEL because the substance has been identified according to 
Article 57(c) and not (f).  
Exposure assessments 
In the EU RAR from 2008, the mean DEHP intake in one year-old children estimated 
using the dietary concentration in 2001 was 5.7-6.1 μg/kg/day (5 to 95 percentiles: 0.8 
to 17.5 μg/kg/day). The mean DEHP intake in all age groups was 1.8-1.9 μg/kg/day (5 to 
95 percentiles: 0.4 to 5.4 μg/kg/day). 
NTP in the US has estimated that the general population of the United States is exposed 
to DEHP levels ranging from 1 to 30 µg/kg bw/day (NTP 2006). 
Estimated daily intake of DEHP for the general population in Canada is 9-19 µg/kg 
bw/day (Canada 1994). 
Based on Danish biomonitoring data on urinary phthalate metabolite excretion in 
pregnant women and collected in 2011-12, the estimated mean daily intake was 1.54 
µg/kg/day (25 to 95 percentiles: 0.7 to 3.4 μg/kg/day). This is very similar to the levels 
in the DEMOCOPHES study (Frederiksen et al. 2013). Here, the intake levels in pregnant 
women were estimated to be 2.6 µg/kg/day (25 to 95 percentiles: 1.1 to 5.1 μg/kg/day). 
The intake levels in children were estimated to be higher, i.e. 4.1 µg/kg/day (25 to 95 
percentiles: 1.6 to 10.3 μg/kg/day). 
Risk assessments 
EU 
EU Risk Assessments have been made for DEHP individually. 
The ANNEX XV RESTRICTION REPORT (Danish EPA 2011) concludes that the combined 
exposure to DEHP, BBP, DBP and DIBP from food, dust and indoor air combined with 
normal handling and use of a few selected articles containing one or several of these 
phthalates reaches levels that constitute a risk to children. A comparison with 
biomonitoring data of urine metabolites further confirmed that risk. 
For DEHP, DBP, BBP and DIBP a ban is proposed on the placing on the market of articles 
intended for use indoors and articles that may come into direct contact with the skin or 
mucous membranes containing one or more of these phthalates in a concentration 
greater than 0.1 % by weight of any plasticised material. The proposal is to ban the 
placing on the market of articles intended for use indoors in unsealed applications and 
articles that may come into direct contact with the skin or mucous membranes containing 
one or more of the 4 phthalates DEHP, DBB, BBP or DIBP in a concentration greater than 
0.1 % by weight of any plasticised material. 
NTP US  
The National Toxicology Program (NTP) Center for the Evaluation of Risks to Human 
Reproduction (CERHR) has reached the following conclusions on the possible effects of 
exposure to DEHP on human development and reproduction (NTP 2006). (Note that the 
possible levels of concern, from lowest to highest, are negligible concern, minimal 
concern, some concern, concern, and serious concern): 
 There is serious concern that certain intensive medical treatments of male infants 
may result in DEHP exposure levels that adversely affect development of the male 
reproductive tract. DEHP exposure from medical procedures in infants was 




  There is concern for adverse effects on development of the reproductive tract in 
male offspring of pregnant and breastfeeding women undergoing certain medical 
procedures that may result in exposure to high levels of DEHP.  
  There is concern for effects of DEHP exposure on development of the male 
reproductive tract for infants less than one year old. Diet, mouthing of DEHP-
containing objects, and certain medical treatments may lead to DEHP exposures 
that are higher than those experienced by the general population.  
  There is some concern for effects of DEHP exposure on development of the 
reproductive tract of male children older than one year. As in infants, exposures of 
children to DEHP may be higher than in the general population.  
  There is some concern for adverse effects of DEHP exposure on development of 
the male reproductive tract in male offspring of pregnant women not medically 
exposed to DEHP. Although DEHP exposures are assumed to be the same as for 
the general population, the developing male reproductive tract is sensitive to the 
adverse effects of DEHP.  
  There is minimal concern for reproductive toxicity in adults exposed to DEHP at 1–
30 µg/kg bw/day. This level of concern is not altered for adults medically exposed 
to DEHP.  
  U.S. Environmental Protection Agency’s (EPA’s) current management plan (2012) 
includes DEHP 
Canada (British Columbia) 
Based on limited available data on concentrations of bis(2-ethylhexyl) phthalate in food, 
indoor air, ambient air, drinking water, soil, and children's products, the total average 
daily intakes of bis(2-ethylhexyl) phthalate have been estimated for various age groups 
in the general population (Canada 1994) . The estimated average daily intakes of bis(2-
ethylhexyl) phthalate for some age groups of the general population in Canada may 
slightly exceed the tolerable daily intake developed on the basis of studies in laboratory 
animals. Based on these considerations, there is insufficient information to conclude 
whether bis(2-ethylhexyl) phthalate is entering or may enter the environment in a 
quantity or concentration or under conditions that are having a harmful effect on the 
environment. It has been concluded, however, that bis(2-ethylhexyl) phthalate is not 
entering the environment in a quantity or concentration or under conditions that 
constitute a danger to the environment on which human life depends. It has also been 
concluded that bis(2-ethylhexyl) phthalate may enter the environment in a quantity or 
concentration or under conditions that may constitute a danger in Canada to human 
health. 
References 






NTP 2006. NTP-CERHR Monograph on the Potential Human Reproductive and 
Developmental Effects of Di(2-Ethylhexyl) Phthalate (DEHP), 
https://ntp.niehs.nih.gov/ntp/ohat/phthalates/dehp/dehp-monograph.pdf  





Opinion on the safety of medical devices containing DEHP-plasticized PVC or other 





4.5 Case Study: Mancozeb 
Summary 
Mancozeb and its metabolite ethylene thiourea (ETU) were known thyroid toxicants 
before the endocrine disruption hypothesis emerged. Plant protection products undergo 
broadly comparable registration process in all jurisdictions and the substance-specific 
monographs produced by the WHO/FAO Joint Meeting on Pesticide Residues (JMPR) play 
an important role in the harmonisation of acceptable daily intakes (ADI = 0.05 mg/kg 
bw/day) for human health risk assessment. Full reports or summaries of the evaluation 
of mancozeb were made publicly available (in English) by Canada (2013), the United 
States (2005) and the European Union (2005, revised in 2009). As the latest JMPR 
evaluation of mancozeb is now 23 years old, the more recent reregistration proposal by 
Health Canada (2013) has derived a lower ADI of 0.008 mg/kg bw/day. This did not 
however influence the results of risk assessments which find no concern related to the 
thyroid toxicity of mancozeb or ETU via food or drinks. Another shift probably more likely 
to be related to the passage of time and expansion of knowledge than fundamental 
differences in regulatory processes is that the ecotoxicological effects of mancozeb are 
more readily attributed to endocrine disruption (Health Canada 2013). Evidence for 
endocrine-disrupting properties of mancozeb has recently been reviewed as part of a 
screening exercise related to the impact assessment of various options for science-based 
criteria required by European legislation. Mancozeb was found to be an endocrine 
disrupter under all options but the interim criteria currently in place. 
Scope of this case study 
This case study focuses on the consideration of the thyroid disrupting effects of 
mancozeb in humans and wildlife during authorisation of its uses as a pesticide or 
biocide. In many risk assessment efforts, thyroid toxicity has been recognised as the 
critical endpoint. Media-oriented legislation that may have addressed the potential 
human or ecological effects of mancozeb or its degradation product was considered 
beyond the scope of this case study. 
Discovery as an endocrine disruptor 
Mancozeb is a broad-spectrum ethylene(bis)dithiocarbamate (EBDC) fungicide launched 
in 1961 by Rohm and Haas (Klittich, 2008). It is a complex of two dithiocarbamates, 
zineb and maneb, that controls many fungal diseases in a wide range of field crops, 
fruits, nuts, vegetables, and ornamentals grasses. It is also used as a slimicide in water-
cooling systems, in sugar, pulp, and paper manufacturing, as antioxidant in rubber, and 
as a scavenger in waste-water treatment. It plays an important role in the management 
of pest resistance and is still the largest selling fungicide in the world. 
Discovery of thyroid toxicity of ethylene(bis)dithiocarbamates (EBDCs) predates the 
launch of mancozeb as a pesticide. Smith et al. (1953) reported thyroid changes in rats 
fed mancozeb throughout their lives in 1953. Most of this toxicity is thought to be 
associated with one of the principal metabolites of EBDCs, ethylenethiourea (ETU). ETU is 
readily formed in soil and water, during storage, processing and cooking of produce, and 
as a catabolite in mammals. Both mancozeb and ETU have been found to inhibit thyroid 
peroxidase (Hurley et al. 1998). Although this mechanism of thyroid disruption is not 
species-specific, marked differences between rodents and primates in inhibition of thyroid 
peroxidase in vitro underlie to the assumption that rodents are much more sensitive than 
humans (IARC Monograph 1987). 
As a recognised thyroid toxicant, mancozeb was included in some early priority lists of 
chemicals to be screened for endocrine disrupting properties. The Japanese SPEED’ 98, 




Regulatory framework in selected jurisdictions 
Residues of mancozeb are currently analysed following non-specific acid digestion of 
whole samples, converting all dithiocarbamates to carbon disulphide (CS2), which is then 
quantified by spectrophotometry or gas chromatography. As a result, limit values at the 
national or international level are commonly set for any dithiocarbamate, determined as 
CS2. Several problems arise with this quantification method. Firstly, the samples 
themselves may contain sulphides leading to an overestimation of dithiocarbamate 
residues or false-positive results. Secondly, this method does not allow attribution of any 
contravention to a specific dithiocarbamate. 
As a result, a group Acceptable Daily Intake (ADI) and Maximum Residue Limit (MRLs) 
are generally set for all or selected dithiocarbamates, and separately for their common 
metabolite ETU.  
Joint FAO/WHO Meeting on Pesticide Residues (JMPR) 
Before considering specific jurisdictions, it is worth noting that two United Nations 
institutions, the Food and Agriculture Organisation (FAO) and the World Health 
Organisation (WHO), jointly develop their own scientific risk assessments as part of the 
JMPR. The purpose of this ad hoc expert meeting is to provide advice on the acceptable 
levels of pesticide residues in food moving in international trade. The focus of these 
activities is therefore on the protection of human health. 
The WHO Core Assessment Group is responsible for reviewing pesticide toxicological data 
and estimating Acceptable Daily Intakes (ADI), acute reference doses (ARfDs) and 
characterizes other toxicological criteria. 
The FAO Panel is responsible for reviewing pesticide data residue and for estimating 
maximum residue levels, supervised trials median residue values (STMRs) and highest 
residues (HRs) in food and feed. Maximum residue levels (MRLs) are recommended to 
the Codex Committee on Pesticide Residues for consideration to be adopted by the Codex 
Alimentarius Commission. MRLs take account both of good agricultural practice and 
toxicological data and should be understood as the minimum quantity required to achieve 
effective protection against plant pathogen infections, and still be acceptable for 
consumer intake. 
Mancozeb was repeatedly evaluated by the JMPR in 1967, 1970, 1974, 1977, 1980 and 
1993. A temporary ADI of 0.025 mg/kg bw/day set 1967 was reduced to 0.005 mg/kg in 
1974. An ADI of 0.05 mg/kg bw/day was finally established at the 1980 Meeting for 
mancozeb or the sum of maneb, mancozeb and zineb, of which not more than 0.002 
mg/kg bw may be present as ETU. This was then reduced to 0.03 mg/kg at the 1993 
Meeting (JMPR, 1993). 
European Union 
Use of mancozeb as a plant protection product is currently authorised in the European 
Union until 31/01/2018 according to the Plant Protection Product Regulation (EC) No 
1107/2009 (a two years extension was granted in 2013 to allow applicants to complete 
the renewal procedure). Currently, the ADI is set at 0.05 mg/kg bw, the ArfD at 0.6 
mg/kg bw and the acceptable occupation exposure level (AOEL) at 0.035 mg/kg bw/day. 
MRLs set for individual food items are publicly available via the EU pesticide database. 
United States of America 
The US Environmental Protection Agency published its Reregistration Eligibility Decision 
on mancozeb in 2005. The chronic Population Adjusted Dose (cPAD) used its risk 
assessment of dietary exposure of the general population, a dose metric equivalent to 




equivalent to the ArfD was determined as 1.3 mg/kg bw/day. Maximum residue limits are 
referred to as ‘tolerances’. The United States and Canada, along with other OECD 
member countries, use the OECD MRL Calculator to calculate pesticide tolerances or 
MRLs. The OECD MRL Calculator replaces and supersedes the (North American Free 
Trade Agreement (NAFTA) MRL Calculator.  
Australia 
The Australian Pesticides and Veterinary Medicines Authority is a government statutory 
authority established in 1993 to centralise the registration of all agricultural and 
veterinary chemical products into the Australian marketplace. Previously each State and 
Territory government had its own system of registration. The APVMA is responsible 
regulating ‘agvet’ chemicals up to—and including—the point of retail sale. Beyond this 
point the state and territory governments are responsible, including controlling the use of 
these chemicals. Dithiocarbamates are listed under Schedule 20 of the Australia New 
Zealand Food Standards Code – Standard 1.4.2 – Agvet chemicals that commenced on 1 
March 2016. As such MRLs have been set for dithiocarbamates measured as CS2 
(https://www.legislation.gov.au/Details/F2016C00812). 
Summaries of registration applications are made publicly available for individual products 
but no public record of decisions of evaluation could be located by our online searches. 
Canada 
Mancozeb is currently under re-evaluation by Health Canada's Pest Management 
Regulatory Agency (PMRA), under the authority of the Pest Control Products Act. A 
consultation document proposing continued registration of most mancozeb uses in 
Canada and phase-out of certain uses with risk concerns was made publicly available. 
The online consultation is now closed and the report considering comments received is 
being finalised. (http://www.hc-sc.gc.ca/cps-spc/pest/part/consultations/_prvd2013-
01/prvd2013-01-eng.php#a4).  
Canadian MRLs are also calculated using the OECD MRL Calculator. Under NAFTA, 
Canada, the United States and Mexico are committed to resolving MRL discrepancies to 
the broadest extent possible. Canadian MRLs are specified in the proposed re-evaluation 
report of mancozeb (Health Canada 2013) and differences with US tolerances are 
presented in Annex IX of the same document. MRLs may vary from one country to 
another for a number of reasons, including differences in agricultural practices and the 
locations of the field crop trials used to generate residue data.  
Japan 
Under the Law to Partially Revise the Food Sanitation Law (Law No. 55, 2003), the 
Ministry of Health, Labour and Welfare (MHLW) introduced the positive list system for 
agricultural chemicals remaining in foods. This system prohibits the distribution of foods 
that contain agricultural chemicals above a certain level if MRLs have not been 
established. MRLs for sum of residues of dithiocarbamates as CS2 are established 
(http://www.m5.ws001.squarestart.ne.jp/foundation/agrdtl.php?a_inq=28700 ). 
China 
China operates a pesticide registration system under the Regulations on Pesticide 
Administration 2001. No substance specific publicly available information in English could 
be retrieved during our online searches. 
Assessment and measurement endpoints for hazard characterisations 
Mancozeb and its metabolite ETU are recognised thyroid toxicants and in line with the 




toxicity and thereby human health. Mancozeb is classified as toxic for the (aquatic) 
environment. The extent to which effects seen in fish, birds and other taxa are 
considered to be related to the endocrine system appears to be itself correlated with the 
date of the evaluation.  
Whilst some effects on fish, birds and other taxa have been noted in earlier available 
evaluations and risk assessments (DG SANCO 2005, USEPA 2005), these could not be 
clearly related to the endocrine system. No mention of amphibians was found in either 
document despite the fact that ETU is known to alter metamorphic development and 
thyroid gland histology in the amphibian metamorphosis assay. The focus of the following 
sections will therefore be limited to human health. 
Assessment values and their derivation 
Human health: acceptable daily intakes (ADI) 
The review report by the European DG SANCO and the USEPA’s Reregistration Eligibility 
Decision for mancozeb were both published in 2005 and were consistent with the last 
JMPR evaluation in 1993. The ADI (or cPAD) in all three evaluations were derived from a 
two-year dietary study in rats. The No Observable Adverse Effect Level (LOAEL) was 125 
ppm, equal to 4.8 mg/kg bw/day, based on decreased body-weight gain, decreased T3, 
T4 values, increased TSH values, increased absolute and relative thyroid weight, thyroid 
follicular cell hypertrophy, hyperplasia, and nodular hyperplasia, in both sexes at 750 
ppm. 
Under the Food Quality Protection Act, USEPA did consider the application of an 
additional tenfold (10X) safety factor, to account for potential pre-and postnatal toxicity 
and completeness of the data with respect to exposure and toxicity to infants and 
children. As the dataset did include acceptable reproductive and developmental toxicity 
studies that did not show any indication of increased susceptibility to fetuses or offspring, 
this special safety factor was reduced to 1. No additional uncertainty factors were 
deemed necessary to account for uncertainties in the toxicology database. As a result, all 
three evaluations applied a safety factor of 100 and supported an ADI of 0.05 mg/kg 
bw/day. 
The only difference was that the JMPR decided to establish a lower group ADI of 0-0.03 
mg/kg bw for mancozeb, alone or in combination with maneb, metiram, and/or zineb, 
because their parent residues cannot be differentiated using presently-available 
analytical procedures. 
The more recent Proposed Re-evaluation Decision by Health Canada departs from these 
evaluations. The ADI was derived from a one-year dog toxicity study with a NOAEL of 2.3 
mg/kg bw/day based on thyroid hormone effects. In addition to the standard uncertainty 
factors of 100-fold for interspecies extrapolation and intraspecies variability, an 
additional 3-fold factor for database uncertainty (lack of ETU DNT and mancozeb 
immunotoxicity studies) was applied. The additional Pest Control Product Act factor for 
the protection of infants and children was reduced to one-fold as the selected endpoint 
was deemed to provide adequate margins to the reproductive and developmental 
endpoints of concern yielding a composite assessment factor is 300. The ADI derived by 
Health Canada by this method is equal to 0.008 mg/kg bw/day. 
Environment: consideration of endocrine disrupting effects 
Mancozeb is classified as dangerous to the environment. While there are notable 
differences between the USEPA Reregistration Eligibility Decision and the European 
Review Report (USEPA 2005, DG SANCO 2005) such as the presence or absence of 
effects in birds, both reports concurred that there was little evidence that any observed 




amphibians, despite the fact that the ETU is known to alter metamorphic development 
and thyroid gland histology in the amphibian metamorphosis screening assay. 
By contrast, the more recent Canadian Proposed Re-evaluation Decision (Health Canada 
2013) interpreted effects in birds, mammals, amphibians, freshwater fish and 
invertebrates as ‘indicative of hormonal disruption and would tend to support the concern 
that mancozeb (as parent and/or complex form) and ETU may be potential endocrine 
disrupting compounds’. 
Exposure assessments 
Exposure assessment for the general population, sensitive subgroups, workers, 
bystanders and various environmental receptors are expected to vary with national or 
local circumstances. Typically estimated environmental exposures are derived from the 
results mandatory fate, transport and transformation tests combined with data on 
pesticide use, whilst dietary intakes are derived from MRLs or monitoring data (from field 
trials or market basket surveys) when available and food intake surveys. 
Risk assessments 
European Union 
The Theoretical Maximum Daily Intake (TMDI; excluding water and products of animal 
origin), based on MRLs and the FAO/WHO European Diet (August 1994), was 39 % of the 
ADI for a 60 kg adult and DG SANCO concluded that mancozeb fulfilled safety 
requirements (DG SANCO 2005).  
United States 
Aggregated risks from chronic exposure to both mancozeb and ETU via food and drinking 
water intake for the general population and sensitive subgroups were all found to be less 
100% of the cPAD and therefore were not considered of concern (USEPA 2005). 
Canada 
Aggregated risks from chronic exposure to both mancozeb and ETU via food and drinking 
water intake for the general population and sensitive subgroups were all found to be less 
100% of the ADI and therefore were not considered of concern. However, a lifetime 
aggregate cancer risk for ETU was 8 × 10-6 which was found to be of concern (Health 
Canada 2013). 
Health Canada (2013) considered that some of the toxicity observed in environmental 
receptors may be related to endocrine disruption and also subsequently found that 
mancozeb may pose a risk to beneficial arthropods used in Integrated Pest Management 
programs, birds, small wild mammals, and to aquatic organisms. ETU may also pose a 
risk to small wild mammals.  
The risk quotient calculated for chronic effects for amphibians on the thyroid histology did 
exceed the level of concern. However, this was deemed a highly conservative endpoint 
because it is unknown whether the observed histological changes to the thyroid will 
result in decreased survival. An endpoint for developmental effects in the forelegs of 
frogs following exposure to ETU is considered to be more severe and could result in the 
decreased survival of amphibians. When this endpoint is used to calculate the risk 
quotient the level of concern is not exceeded and Health Canada therefore concluded that 
amphibians are not at risk (Health Canada 2013). 




The potential for mixture effects is not addressed consistently by the various authorities. 
For the purpose of its reregistration eligibility decision, the USEPA had considered the 
possibility that mancozeb may act in concert with other dithiocarbamates. After a 
thorough review of relevant mechanistic data, the Agency reached the conclusion that 
mancozeb did not share a common mechanism with other substances and it was 
therefore not necessary to consider mixture effects. It nonetheless recognised that 
dithiocarbamates share a common metabolite, ETU, and its effects were considered 
(USEPA 2005). 
The European report made no mention of mixture effects at the time of publication (DG 
SANCO 2005). However, the European Food Standard Agency (EFSA) has since 
investigated the grouping of pesticides for the purpose of deriving MRLs. A methodology 
was developed resting on the assumption that pesticides causing the same specific 
phenomenological effects, can produce joint, cumulative toxicity – even in the absence of 
a similar mode of action. The application of the approach was carried out with thyroid 
disrupters and resulted in a much larger assessment group of around 100 active 
substances, including mancozeb (EFSA 2013). 
Health Canada refers to the possibility of mixture effect considering the only two ethylene 
bisdithiocarbamate fungicide registered for food use in Canada, mancozeb and metiram, 
nabam being registered for industrial uses only. Exposure to ETU in the environment or 
in occupational settings from non-pesticidal sources were not considered as they are 
regulated separately (Canadian Environmental Protection Act, 1999). Further, as the 
aggregate exposure from food and water to ETU derived from mancozeb was found to be 
of concern on its own due to carcinogenic risk, a cumulative risk assessment was 
considered redundant. 
Risk management options 
In the United States, the Reregistration Eligibility Decision details a number of restricted 
uses and protection measures related to residential or occupational exposure. The 
potential for endocrine disruption from the available human health and ecological effects 
data was considered. For human health risk assessment, thyroid effects are considered in 
the human health risk assessment. For possible hormonal effects in birds and mammals, 
it was suggested that mancozeb may be subject to additional testing and screening when 
the appropriate screening and/or testing protocols being considered under the Endocrine 
Disrupter Screening Program have been developed. Mancozeb was not included in list 1 
or list 2 of the EDSP. 
Health Canada has also proposed a number of risk management measures in relation to 
the risk to beneficial predatory arthropods, birds, small mammals and aquatic organisms 
ranging from labelling requirements to the implementation of spray buffer zones (Health 
Canada 2013). 
In the European Union, DG SANCO in its review report also recommended that Member 
States request additional studies for birds and mammals and developmental toxicity and 
that they consider risk mitigation measures for the protection of birds, mammals, aquatic 
organisms and non-target arthropods. Recent EU legislation has introduced endocrine 
disrupting properties as a hazard-based ‘‘cut-off’’ criterion for the approval of active 
substances as pesticides and biocides (Reg. (EC) No 1107/2009). Marx-Stölting et al. 
(2014) compared two options for the science-based criteria to decide whether a 
substance should be considered an endocrine disrupter with the interim criteria in place 
until a decision has been reached by the Commission. Mancozeb was one of the 
substances evaluated as part of this exercise and for which the evaluators’ opinion 
differed when additional elements such as potency were included. More recently, 
evidence for endocrine-disrupting properties of mancozeb were reviewed as part of a 
screening exercise related to the impact assessment of various options for science-based 
criteria required by European legislation. Mancozeb was found to be an endocrine 
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4.6 Case Study: Prochloraz, human health 
Summary 
Prochloraz is a broad-spectrum imidazole fungicide. It was first synthesized in mid and 
late 1970’s (PPDB, 2016) while The Boots Company presented and produced it 
commercially from 1980 (INCHEM, 2001).  
Prochloraz is widely used in gardening and agriculture. It is used on wheat, barley, 
mushrooms, cherries, turf on golf courses, and in flower production, for instance, in 
Ecuador, where roses are treated with prochloraz prior to export to the USA (Vinggaard 
et al. 2006). 
Its fungicidal activity is due to inhibition of 14 alpha- demethylase (CYP 51), an enzyme 
required for the synthesis of fungal cell walls. Prochloraz is recognized as an endocrine 
disrupter causing adverse effect on male reproductive development by multiple 
mechanisms of action in non-target species including inhibition of enzymes of 
steroidogenesis (CYP 19, CYP 17 and 5 α-reductase) and AR antagonism. Other possible 
mechanisms of action are ER antagonism and AhR agonism (OECD, 2012).  Prochloraz 
was one of the case studies used for the OECD GD 150 developed to evaluate whether 
the conclusions and next steps recommended in the guidance document for identification 
of ED was sensible and helpful when assessed in light of comprehensive datasets (OECD, 
2012). Prochloraz is on the European Union (EU) Prioritization List as Cat. 2 (potential).    
Prochloraz has earlier on been authorized for use as a pesticide in many parts of the 
world, and in the EU (apart from DK and Malta) the approval expires 31st December 
2021. The ADI for prochloraz on 0.01 mg/kg is based on the effects on a 2 year study in 
dogs. Plant protection products undergo broadly comparable registration process in all 
jurisdictions and the substance-specific monographs produced by the WHO/FAO Joint 
Meeting on Pesticide Residues (JMPR) play an important role in the harmonization of 
acceptable daily intakes (ADI = 0.01 mg/kg bw/day) for human health risk assessment. 
The JMPR report mentions that the intake range is 7-10% (% of maximum ADI).  
The potential for mixture effects of prochloraz and other anti-androgens has been shown 
in studies of developing rats. However, the cumulative risk does not appear to have been 
addressed by the various authorities. 
Scope of this case study 
This case study focuses on the endocrine disrupting effects of Prochloraz on male 
reproductive development in humans. Effects of Prochloraz on the environment are also 
relevant, but are considered to be outside the scope in this document.  
Discovery as an endocrine disruptor 
Prochloraz is an imidazole fungicide, and its regulatory toxicological data package has 
been primarily generated in the 1980s-1990s and in these studies the endocrine activity 
or the endocrine disrupting effects of prochloraz have not been in focus. Prochloraz has 
been tested in a full set of regulatory toxicological studies including two multi-generation 
reproductive toxicity studies, which was performed according or comparable to the US 
EPA OPPTS 870-3380, OECD TG 416 (1983) (EFSA conclusion, 2011). These guidelines, 
however, precede both OPPTS and OECD harmonization and lack specific parameters to 
identify anti-androgenicity (e.g., sperm parameter, onset of puberty) so the discovery of 
prochloraz as an ED was not part of regulatory testing. Besides these regulatory studies, 
prochloraz has been extensively studied in mode of action studies during the last 15 
years (Melching-Kollmuss et al. 2016). Screening studies have shown that prochloraz 
elicits multiple mechanisms of action in vitro, as it antagonises the androgen and the 
oestrogen receptor, agonises the Ah receptor and inhibits aromatase activity (Vinggaard 




Regulatory framework in selected jurisdictions 
European Union  
In 2008 the EU Commission decided not to include prochloraz (among a number of other 
active substances) in Annex I to Council Directive 91/414/EEC (EU, 2008). However, 
prochloraz was approved on 1 January 2012 by Commission Implementing Regulation 
(EU) No 1143/2011 as an active substance in accordance with Regulation (EC) No 
1107/2009, and is thus authorised for use as an active substance in pesticide products. It 
was a specific provision of the approval that the applicant was required to submit to the 
European Commission further studies as regards comparison and verification of the test 
material used in the mammalian toxicity and ecotoxicity dossiers against the specification 
of the technical material and further studies regarding the environmental risk assessment 
for the metal complexes of prochloraz by 31 December 2013.  
This EU approval expires 31st December 2021. At the EU Member State level it has been 
approved in 25 EU countries (except Malta and Denmark) (EU, 2016).  
United States of America 
The chemicals listed as U.S. EPA registered are those that can currently be legally used in 
the U.S., except in states where state laws are stricter than federal laws and prohibit 
such use. It is unclear whether any regulatory actions have been taken on prochloraz and 
whether it can be used legally in the USA (EPA, 2016). 
Japan 
The Food Safety Commission of Japan (FSCJ) has not conducted a risk assessment of 
prochloraz. Under the Law to Partially Revise the Food Sanitation Law (Law No. 55, 
2003), the Ministry of Health, Labour and Welfare (MHLW) introduced the positive list 
system for agricultural chemicals remaining in foods. This system prohibits the 
distribution of foods that contain agricultural chemicals above a certain level if MRLs have 
not been established. MRLs for prochloraz are established for the sum of residues of 
prochloraz prochloraz and each of N-folumyl-N-1-propyl-N-[2-(2,4,6-trichlorophenoxy) 
ethyl] urea and N-propyl-N-[2-(2,4,6-trichloro phenoxy) ethyl] urea, and 2,4,6-
trichlorophenol, which are individually calculated as prochloraz and is in the range of 
0.05-10 (JFCRF, 2015). 
China 
China operates a pesticide registration system under the Regulations on Pesticide 
Administration 2001. No substance-specific publicly available information in English could 
be retrieved during our online searches. 
Australia 
In Australia, 10 products with prochloraz as active ingredient are listed by the Australian 
Pesticides and Veterinary Medicines Authority (APVMA)(APVMA, 2016a). For most of the 
products an expiry date of 30/6 2017 is included. 
APVMA (Australian Pesticides and veterinary Medicines Authority) have nominated the 
triazoles fungicides and prioritised them for reconsideration but prochloraz is not included 
in this prioritisation (APVMA, 2016b). 
Assessment and measurement endpoints for hazard characterisations 
Prochloraz is a fungicide belonging to the imidazole group and acts as an inhibitor of 
ergosterol biosynthesis in fungi. Imidazole fungicides inhibit the activity of lanosterol 




been shown to react through several endocrine disrupting mechanisms, such as AR 
antagonist and can interfere with testosterone synthesis by inhibiting the CYP450 17a-
hydroxylase ⁄ 17,20-lyase as shown in vitro studies (Vinggaard et al., 2005, 2006). 
Moreover in vivo it can affect the development of several androgen-dependent tissues 
(Vinggaard et al., 2002; Vinggaard et al. 2005, Laier et al. 2006, Taxvig et al. 2008). 
Common features for the azole fungicides are that they increase gestational length and 
affect steroid hormone levels in foetuses and/or dams. In addition, studies indicate that 
prochloraz may also affect thyroid hormone levels and cause effects on the sexually 
dimorphic development of the brain (Vinggaard et al. 2005). In the majority of studies, 
male offspring, exposed in utero to prochloraz often showed no statistically significant 
changes in anogenital distance (AGD) with doses from 25-150 mg/kg but find significant 
nipple retention (NR) (Vinggaard et al. 2005; Christiansen et al. 2009; Noriega et al. 
2005 and Melching-Kollmuss et al. 2016). One study has found both a decrease in male 
AGD at 50 and 150 mg/kg and also increased NR (Laier et al. 2006). 
Assessment endpoints used to derive for points of departure (NOAELs) for prochloraz can 
be grouped into two broad categories, long-term studies on adult laboratory animals, and 
two-generation studies in rodents. 
In long-term studies, prochloraz induced liver weight increases, and this measurement 
endpoint was used to estimate NOAELs for the derivation of ADI values. 
Reproductive and developmental toxicity of prochloraz was also assessed in two-
generation toxicity studies. In these studies, reproductive outcomes were measured in 
terms of extended gestation lengths, dystocia and reduced live birth and viability indices.   
Assessment values and their derivation 
The lowest NOAELs from long-term studies were 0.9 mg/kg body weight/day (mg/kg 
bw/day) in dogs, 5.1 mg/kg bw/day in rats and 7.5 mg/kg bw/day in mice all increased 
liver weight and histopathology (EFSA conclusion 2011). The ADI (acceptable daily 
intake) of prochloraz is 0.01 mg/ kg bw which is based on the lowest NOAEL of 0.9 
mg/kg bw, derived in dogs based on liver weight increases (EFSA, 2011).  
Prochloraz was evaluated in two key two-generation toxicity studies from 1993 and 1982 
where overall reproductive performance was impaired following prochloraz administration 
to rats. Effects on reduction in body weight and body weight gain, increased liver weight 
and deaths were associated with dystocia and extended gestation length. Developmental 
toxicity was observed as reduced mean litter size, increased total litter loss, reduced live 
birth index, impaired growth and adverse effects on organ weights. In the 1993 study the 
agreed parental and reproductive NOAEL is 50 ppm (2.26 mg/kg bw/d), and the offspring 
NOAEL is 150 ppm (6.58 mg/kg bw/d).  In the study from 1983 the agreed parental 
NOAEL is 150 ppm (13 mg/kg bw/d), the reproductive NOAEL is 37.5 ppm (3.1 mg/kg 
bw/d), and the offspring NOAEL is 150 ppm (13 mg/kg bw/d. (EFSA, 2011).  
In the developmental toxicity studies, there was no evidence of teratogenicity, and the 
relevant maternal and developmental NOAELs are 25 mg/kg bw/d for the rat and 40 
mg/kg bw/d for the rabbit. Public literature reports effects of prochloraz on reduced 
anogenital distance (Vinggaard et al, 2005 in EFSA, 2011) and increased nipple retention 
(Christiansen et al. 2009 in EFSA, 2011) in rats, with the NOAEL for these effects being 
30 mg/kg bw/d and 5 mg/kg bw/d, respectively (EFSA, 2011).  The higher NOAELs in 
reproductive toxicity studies of prochloraz, reproductive toxicity is not the critical toxicity 
in the derivation of ADIs. Critical for the derivation of ADIs is toxicity to the liver in long-
term studies. Assessment values and the basis for their derivation are shown in the table 





Table 1. ADI(Acceptable daily intake), ARfD(Acute Reference dose) , AOEL (Acceptable 
Operator Exposure Level) 
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weights 
NOAEL of 2.5 
mg/kg bw/d (found 
in the 90-d dog 
study) with 70% 
correction for oral 
absorption AOEL = 
2.5/100 x 0.7= 
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evaluated by the 
FAO/WHO JMPR 
several times from 
1983- 2001. The 
2001 JMPR 
confirmed the ADI 
of 0.01 mg/kg bw/d 
and set an acute 
reference dose of 
0.1 mg/kg bw 
(JMPR 2001). 





In 2008, the average exposure to prochloraz in the general Danish population was 
estimated as 0.004 µg/kg bw/day (FVST, 2008), with a 95th percentile of 0.011 µg/kg 
bw/day (Jensen et al. 2013). 
In a research study, estimates for human intake of anti-androgenic chemicals (including 
prochloraz) were made and a TMDI (Theoretical Maximum Daily Intake) for France was 
set at 14 µg ⁄ kg d (Christiansen et al. 2012 referred to Menard et al., 2008).  





The overall conclusion from the evaluation made by DG SANCO is that it may be 
expected that plant protection products containing prochloraz will fulfil the safety 
requirements laid down in Article 5(1)(a) and (b) of Directive 91/414/EEC (EU, 2016). 
Estimates of acute dietary exposure of adults and children revealed that the Acute 
Reference Dose (ARfD) would not be exceeded (EU, 2016). 
The EFSA Draft Assessment Report (EFSA DAR, 2007) writes that the risk assessment 
carried out indicates that the estimated risk to the bystander will not exceed the AOEL 
(0.0175 mg/kg bw) under practical conditions of use.   
Japan 
The Food Safety Commission of Japan (FSCJ) has not conducted a risk assessment of 
prochloraz20. 
Mixture effects 
The potential for mixture effects of prochloraz and other anti-androgens has been shown 
in studies of developing rats. For example, a mixture of the pesticides epoxiconazole, 
mancozeb, prochloraz, tebuconazole and procymidone caused severe effects on gestation 
length, nipple retention and genital malformations at dose levels where the individual 
pesticides caused no or smaller effects when given alone (Hass et al. 2012). Generally, 
the mixture effect predictions based on dose-additivity were in good agreement with the 
observed effects.  
The potential for mixture effects is not directly addressed by the various authorities. 
However, the European Food Standard Agency (EFSA) has investigated the grouping of 
pesticides for the purpose of deriving MRLs. A methodology was developed resting on the 
assumption that pesticides causing the same specific phenomenological effects, can 
produce joint, cumulative toxicity – even in the absence of a similar mode of action. The 
application of the approach was carried out with anti-androgens in a scientific report 
submitted to EFSA and resulted in an assessment group of around 25 active substances 
(Nielsen et al. 2012. The assessment group does not include prochloraz as it was not 
included in Annex I of Council Directive 91/414/EEC (up to 31st of May 2009).  
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4.7 Case Study: Procymidone, human health 
Summary 
Procymidone is a dicarboximide fungicide. Procymidone is recognized as an endocrine 
disrupter causing adverse effect on male reproductive development due to AR 
antagonism. Earlier on, procymidone has been authorized for use as a pesticide in many 
parts of the world, but is no longer approved in the EU and the USA. The ADI for 
procymidone has been based on the effects on reproduction, such as infertility and 
abnormalities of the male sexual organs in adults and in pups. In the last decade, testing 
during sensitive windows of development in relation to endpoints reflective of anti-
androgenic effects (e.g. anogenital distance) and negative impacts on male reproductive 
development has begun. This has resulted in lower points of departure (NOAELs) with 
correspondingly lower ADIs in EU, Australia and Japan. In EU, the recognition of the 
severity of such effects has also lead to the lowest ADI due to the use of an additional 
assessment actor of 3. To reflect the decrease in the ADI, the Maximum Residue Limits 
(MRL) in food had to be lowered in EU. The various ADIs exist next to each other and the 
variation from the lowest to the highest is around 30 fold. Risk assessments of consumer 
intake in the EU and Australia have not signalled concerns. The potential for mixture 
effects of procymidone and other anti-androgens has been shown in studies of 
developing rats. However, the cumulative risk does not appear to have been addressed 
by the various authorities. 
Scope of this case study 
This case study focuses on the endocrine disrupting effects of procymidone on male 
reproductive development in humans. Effects of procymidone on the environment are 
also relevant, but this is outside the scope in this document. 
Discovery as an endocrine disruptor 
Procymidone is a dicarboximide fungicide. Procymidone was discovered as a reproductive 
toxicant during regulatory testing and the type of effects seen in male offspring, 
especially decreased anogenital distance and malformation of the external genitalia 
(hypospadias) clearly points to an anti-androgenic mode of action. This was supported by 
in vitro studies showing AR antagonism. The characteristics of procymidone were similar 
in assays for binding to androgen receptors in rats and humans and the concentrations 
required to inhibit activity by 50% (IC50) values for procymidone were similar to those of 
the anti-androgen prostate-cancer drug flutamide (JMPR 2005). 
Regulatory framework in selected jurisdictions 
European Union 
Procymidone had been authorized for use as a pesticide in EU, but the inclusion on the 
list of approved pesticides expired in 30 June 2008 and the authorization was withdrawn 
1 July 2008 (EU database 2016).  
Procymidone is classified as a toxic to reproduction in category 1B (May cause harm to 
the unborn child) and as a carcinogen in category 2 (Limited evidence of a carcinogenic 
effect). 
United States of America 
The chemicals listed as U.S. EPA registered are those that can currently be legally used in 
the U.S., except in states where state laws are stricter than federal laws and prohibit 





Canada (British Columbia) 
Health Canada sets maximum residue limits (MRLs) in food and MRLs for procymidone 
were established for wine, grapes and raisins in 2008. The MRLs are also calculated using 
the OECD MRL Calculator. Under NAFTA, Canada, the United States and Mexico are 
committed to resolving MRL discrepancies to the broadest extent possible. 
Japan 
Under the Law to Partially Revise the Food Sanitation Law (Law No. 55, 2003), the 
Ministry of Health, Labour and Welfare (MHLW) introduced the positive list system for 
agricultural chemicals remaining in foods. This system prohibits the distribution of foods 
that contain agricultural chemicals above a certain level if MRLs have not been 
established. MRLs for procymidone are established (MHLW 2016).  
China 
China operates a pesticide registration system under the Regulations on Pesticide 
Administration 2001. No substance specific publicly available information in English could 
be retrieved during our online searches. 
Australia 
In Australia, 18 products with procymidone as active ingredient are listed by the 
Australian Pesticides and Veterinary Medicines Authority (APVMA 2016). For most of the 
products an expiry date of 30/6 2017 is included, but for others the status is ‘approved’ 
and there is no information on expiry dates. 
Assessment and measurement endpoints for hazard characterisations 
The assessment endpoints used for hazard characterisations of procymidone were for 
carcinogenicity (testicular interstitial cell tumours) and for endpoints characteristic of 
reproductive toxicity, including infertility and abnormalites of the male sexual organs in 
adults and pups. Changes in anogenital distance, hypospadias, testicular atrophy and 
undescended testes, increased weight of the testes and decreased weight of the prostate, 
epididymis and seminal vesicles in pups were used in later studies of effects mediated by 
endocrine mechanisms.  
Assessment values and their derivation 
Procymidone was evaluated by the FAO/WHO JMPR in 1981, 1989, 1990, 1993, 1998 and 
2001. No ADIs were established in 1981 and 1982. In 1989, an ADI of 0–0.1 mg/kg bw 
was established based on the NOAEL of 12.5 mg/kg bw per day identified in studies of 
reproductive toxicity in rats. In 2001, the JMPR evaluation was (FAO 2001): “In a long-
term feeding study reported in rats, testicular interstitial cell and ovarian stromal 
hyperplasia, and an increased incidence of testicular interstitial cell tumours, were 
observed at 1000 and 2000 ppm. In a 2-generation study in rats, infertility and 
abnormalites of the male sexual organs were observed in adults and in pups at the 
highest dose level of 750 ppm. The JMPR evaluated that the effects on reproduction and 
the induction of testicular tumours in the long term rat study can be explained by the 
effects of procymidone on the endrocrine system. The JMPR allocated an ADI of 0 to 0.1 
mg/kg body weight for procymidone, based on sub-chronic effects in rats, mice and dogs 
and on chronic effects in mice and rats”. 
In 2007 in the EU, the toxicological profile of procymidone was investigated by the 
rapporteur Member State France in the framework of the peer review under Directive 
91/414/EEC and again in 2007 in view of the extension of the Annex I inclusion. An ADI 
of 0.025 mg/kg bw/day was previously assigned to procymidone (EC, 2007). France 




first peer review (France 2007). Member States and the European Commission confirmed 
that this toxicological reference value should be used for the risk assessment of MRLs 
although there was no formal adoption of these values by the Standing Committee on 
Food Chain and Animal Health (EFSA 2011).   
In the EFSA peer review, an ADI of 0.025 mg/kg bw/day was assigned, the value being 
based on the NOAEL for the rat multi-generation study, 2.5 mg/kg bw/day (50 ppm), and 
a safety factor of 100 (EFSA 2009). The effects noted at 250 ppm (12.5 mg/kg bw/day) 
in pups were: reduced anogenital distance, hypospadias, testicular atrophy and 
undescended testes. Considering the additional information submitted in the framework 
of the renewal of the Annex I inclusion, the RMS concluded that increased weight of the 
testes and decreased weight of the prostate, epididymis and seminal vesicles were seen 
even at 50 ppm. Thus, the following assessment factors were proposed: a 3-fold factor 
(LOAEL → NOEL), a 10-fold factor for interspecies variability, a 10-fold factor for 
intraspecies variability and a 3-fold factor for the severity of the effects giving a safety 
factor of 900 and an ADI of =  0.0028 mg/kg bw/day. If the 50 ppm level was regarded 
as a LOAEL, the use of a safety factor of 1000 would lead to a similar ADI of 0.0025 
mg/kg bw/day. 
In 2009, EFSA self-tasked to revise the previously performed risk assessment of MRLs 
established for procymidone because Member States and the European Commission 
agreed on lower toxicological reference values (EFSA 2009). EFSA proposed to lower the 
MRLs for 24 different food commodities in order to reduce the acute and/or consumer 
exposure to a level where no negative consumer health effects are expected. Thus, these 
MRLS are currently used in EU.  
In 2004, the Australian Government, Department of Health derived an ADI of 0.03 mg/kg 
bw/day for procymidone and this value still apply (Australian Government, Department of 
Health, 2016). 
In 2014, the Food Safety Commission of Japan (FSCJ) in 2014 derived an ADI for 
procymidone based on summary reports made by applicants and documents of the EU, 
JMPR and others (Food Safety Commission of Japan, 2014). The lowest no observed 
adverse effect level (NOAEL) was 3.5 mg/kg bw/day, obtained in a developmental 
toxicity study in rats. FSCJ specified an acceptable daily intake (ADI) of 0.035 mg/kg 
bw/day by applying a safety factor of 100 to the NOAEL. 
Assessment values and the basis for their derivation are shown in the table below. Earlier 
on, the ADI of 0.1 mg/kg bw/day for procymidone has been based on the effects on 
reproduction, such as infertility and abnormalities of the male sexual organs in adults and 
in pups (FAO (2001) and JMPR (1989-2005)). Many of the conventional studies of toxicity 
with procymidone were relatively old, were performed before the widespread use of GLP 
and some contained relatively limited information. Within the last decade, the ADI has 
decreased around 3-30 fold reflecting testing during sensitive windows of development 
combined with assessment of sensitive endpoints for anti-androgenic effects on male 
reproductive development (e.g. anogenital distance) as well as recognition in EU of the 






Table 1: Assessment values for procymidone and their derivation 
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The average exposure to procymidone in the general Danish population was in 2007 
calculated to 0.012 µg/kg bw/day (Danish Ministry of Food, 2007). Based on probabilistic 
methods the 95 percentile was calculated to 0.041 µg/kg bw/day (Jensen et al. 2013). 
Risk assessments 
A consumer risk assessment for procymidone was published by EFSA in 2011 (EFSA 




total intake values accounted for a maximum of 93% of the ADI in the subgroup of 
French toddlers. Also, no acute intake concerns were identified. 
Due to specific occupational health and safety concerns for women of child-bearing age, 
Food Standards Australia New Zealand (FSANZ) undertook a National Estimated Short 
Term Intake (NESTI) and a National Estimated Dietary Intake (NEDI) calculation to 
ascertain whether any public health and safety concerns existed from residues of 
procymidone for females aged 16 to 44 years (FSANZ 2007). 
The Australian Pesticides & Veterinary Medicines Authority (APVMA) has deleted the uses 
and MRLs for some specific commodities and withdrew the permits for others. The NEDI 
of residues (based on the MRL) in food was 40% of the acceptable daily intake (ADI) of 
0.03 mg/kg bw/day. Further, in later Australian Total Diet Surveys (ATDS) the estimated 
dietary exposure to Procymidone was less than 1% of the ADI for adult females 25-34 
years of age. On the basis of results from the NEDI and the results from the ATDSs, 
FSANZ considers that chronic dietary exposure to the potential residues associated with 
MRLs for Procymidone would not present a risk to the health and safety of women of 
child-bearing age. 
Mixture effects 
The potential for mixture effects of procymidone and other anti-androgens has been 
shown in studies of developing rats. For example, a mixture of the pesticides 
epoxiconazole, mancozeb, prochloraz, tebuconazole and procymidone caused severe 
effects on gestation length, nipple retention and genital malformations at dose levels 
where the individual pesticides caused no or smaller effects when given alone (Hass et al 
2012). Generally, the mixture effect predictions based on dose-additivity were in good 
agreement with the observed effects.  
The potential for mixture effects is not directly addressed by the various authorities. 
However, the European Food Standard Agency (EFSA) has investigated the grouping of 
pesticides for the purpose of deriving MRLs. A methodology was developed resting on the 
assumption that pesticides causing the same specific phenomenological effects, can 
produce joint, cumulative toxicity – even in the absence of a similar mode of action. The 
application of the approach was carried out with anti-androgens in a scientific report 
submitted to EFSA and resulted in an assessment group of around 25 active substances 
Nielsen et al 2012). The assessment group does not include procymidone as the focus 
was only on pesticides approved for use in EU, i.e. those included in Annex I of Council 
Directive 91/414/EEC (up to 31st of May 2009).  
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4.8 Case Study: Benzophenone-3 
Summary 
Benzophenone-3, also commonly referred to as oxybenzone, is a light absorber widely 
used in sunscreens, cosmetics, as well as plastics intended to come in contact with food. 
The present case study focused on its use in sunscreen lotions. The possibility that 
benzophenone-3 may affect the hormonal system was first raised when the National 
Toxicology Program in the United States published a report reviewing in vivo 
experimental evidence of the effects of benzophenone-3. The consistency of an effect on 
sperm density, estrous cycles and other parameters was thrown into doubt following the 
publication the following year of an industry sponsored study that did not find any effect. 
The ability of benzophenone-3 to bind with the estrogen receptor in vitro when several 
UV screens were tested in the MCF-7 proliferation assay and the uterotrophic assay. The 
Danish Centre for Endocrine Disrupters recently reviewed all publicly available 
epidemiological and (eco)toxicological data and concluded that benzophenone-3 would be 
considered a suspected endocrine disrupter (category 2a) if the criteria proposed by the 
Danish Government were applied. 
A major difference in the manner sunscreen ingredients are regulated in different 
jurisdictions is whether they are considered drugs/therapeutic goods (US, Canada, Japan, 
Australia) or cosmetics (EU, China). Nonetheless, all countries apply restriction for use in 
terms of the maximum concentration of benzophenone-3 allowed in the formulation of 
the product, although these vary from 5-15% by weight. The processes by which such 
restrictions are decided are rather opaque and apart from in Europe, our searches did not 
uncover any documentation of these decisions online. The opinion of the European 
Scientific Committee on Consumer Products did consider reproductive toxicity but not the 
estrogenic activity in Benzophenone as it had concluded in an earlier opinion that it did 
not endanger human health under current conditions of use. The point of departure to 
estimate the margin of exposure was derived from a teratogenicity study that only 
showed effects at the highest dose concomitant with signs of maternal toxicity. The 
margin of exposure was calculated as 112 which is greater than 100 and the use of 
benzophenone-3 at concentrations up to 6% by weight was considered safe for use. A 
large biomonitoring program in the United State showed that benzophenone-3 is 
bioavailable and exposure is widespread (97% of the sampled population). 
Benzophenone-3 is known to enhance the dermal absorption of other substances and 
there are some restrictions on formulations containing both benzophenone-3 and insect 
repellents. Investigation of the dermal absorption of a mixture of sunscreen ingredients 
including benzophenone-3 over a week in human volunteers observed no effect on 
endogenous reproductive hormone homeostasis. Beside stated restrictions with regards 
to benzophenone-3 concentration in product formulation, its use is generally considered 
safe and no further risk management options are recommended to protect human health. 
Scope of this case study 
Benzophenone-3, also commonly known as oxybenzone, is an ultraviolet (UV) light 
absorber. It is used to help prevent potential damage from sunlight exposure, often in 
combination with other benzophenones, in many consumer products including sunscreens 
but also other cosmetic products such as hairspray or nail varnish, in paints and inks, as 
well as in plastic intended to come in contact with food. The focus of this case study is on 
its use as an over-the counter sunscreen.  
As it is incompletely absorbed by skin, it pollutes surface and coastal waters directly or 
via sewage effluent discharges. Water pollution, bathing water quality, secondary 
poisoning through fish consumption and effects on coral reefs were considered beyond 




Discovery as an endocrine disruptor 
Benzophenone-3 occurs naturally in flower pigments. It has been synthesised and used 
commercially as a UV light absorber and stabiliser since the 1970’s. In 1992, the National 
Toxicology Program published a technical report on 2- and 13-week toxicity studies of 2-
hydroxy-4-methoxybenzophenone, also known as benzophenone-3 or oxybenzone 
(French, 1992). The report concluded that benzophenone-3 was a moderate reproductive 
toxicant at high dietary doses on the basis of observed increases in estrous cycle length 
and decreases in epididymal sperm density and suggested that such toxicity at least in 
females may operate via hormonal mechanisms. The summary of comments from peer 
reviewers reveals that the fact that the lack of a NOAEL for decreased epididymal sperm 
density in the 13-week dermal study in mice was subject to some debate. Mention was 
made of a subsequent study of the effect of topically applied benzophenone-3 on sperm 
production in another strain of mice, sponsored by the Cosmetic Toiletry and Fragrance 
Association, that failed to show statistically significant decreases in epididymal sperm 
density or any other effects on the reproductive system (Daston et al. 1993). It was 
deemed too difficult to compare the results of these toxicity studies with human exposure 
under conditions of used deemed safe at the time and this report did not lead to any 
revision of safe condition of use.  
The hormonal activity of benzophenone-3 was not investigated further until Schlumpf et 
al (2001), following reports of high concentrations reported in German fish, decided that 
their potential for bioaccumulation warranted that six frequently used UV filters be 
screened in vitro and in vivo for estrogenic activity. Benzophenone-3 was found to be an 
estrogen receptor agonist in vitro in MCF-7 breast cancer cells but showed only weak in 
vivo uterotrophic activity in the immature rat assay. This study prompted a request to 
the then European Scientific Committee on Cosmetic products and Non-Food Products 
intended for consumers (SCCNFP) to evaluate the possible estrogenic effects of organic 
UV filters (SCCNFP, 2001). It concluded that at least as far as benzophenone-3 is 
concerned, the results of Schlumpf et al were in line with those of another study carried 
out according to Good Laboratory Practice (GLP) standards commissioned by the 
cosmetic industry. Further, the Committee proposed that the weak estrogenic activity of 
benzophenone-3 in vivo was related to the fact that about 1% of the dose is metabolised 
to p-hydroxy-benzophenone in rats, itself a compound which might exhibit an estrogenic 
effect. Since then, benzophenone-3 has been screened in a large number of in vitro 
assays, most of which show estrogenic activity (there are however also studies that 
found no in vitro estrogenicity) but also other modes of action for this compound such as 
androgen and progesterone receptors antagonism and binding to the thyroid hormone 
receptor (Danish Centre on Endocrine Disrupters, 2012). Benzophenone-3 was included 
by ChemSec on the SINList 2.021 and the Danish Centre on Endocrine Disrupters 
categorised it as a suspected endocrine disrupter (category 2a) on the basis of an 
evaluation of results from human health, in vitro/vivo studies and studies in the 
environment and the Danish proposal for criteria (Danish Centre on Endocrine Disrupters, 
2012). 
Regulatory framework in selected jurisdictions 
International Cooperation on Cosmetics Regulation (ICCR) 
The ICCR is a voluntary international group of cosmetics regulatory authorities from 
Brazil, Canada, the European Union, Japan and the United States established in 2007. 
This group of regulatory authorities meet on an annual basis to discuss common issues 
on cosmetics safety and regulation. No information on sunscreen could be found on their 
website. 







Sunscreen products are cosmetics according to Regulation (EC) No 1223/2009. The 
safety of cosmetic products is in the EU based on the safety of the ingredients, the latter 
being evaluated by toxicological testing. Until recently, this was done by using 
experimental animals. This regulation introduced a ban on animal testing, making the 
use of validated alternative methods in toxicological testing compulsory. Only 
replacement methods are allowed. Via the combination of a testing and marketing ban, in 
vivo testing outside the EU was allowed for repeated dose toxicity (including skin 
sensitisation testing), developmental toxicity and toxicokinetics until 11 March 2013.  
For sunscreen products, there are also specific recommendations on efficacy claims22. 
Annex VI of the Cosmetics Regulation list UV filters allowed in cosmetic products. 
Benzophenone is authorised in concentrations up to 10% by weight. 
United States of America 
Sunscreen ingredients are regulated under the Federal Food, Drug, and Cosmetic Act 
(FD&C Act)23. Because the Food and Drug Agency (FDA) regulates sunscreen ingredients 
as drugs, each active ingredient must be approved before it can be allowed on the 
market under a Monograph process. The monograph process allows companies to avoid 
other more rigorous regulatory pathways. These monographs specify conditions whereby 
over-the-counter (OTC) drug ingredients are generally recognized as safe and effective. 
Historically, the human safety of sunscreen active ingredients contained in sunscreen 
products has been based on decades-long human experience, as well as preclinical and 
clinical safety testing.  
Benzophenone was first approved for use in OTC sunscreen in the Advanced Notice of 
Proposed Rulemaking in 1978 in concentrations up to 6% by weight. 
The Sunscreen Innovation Act (SIA) signed in November 2014 amends the FD & C Act to 
establish a process for the review and approval of OTC sunscreen active ingredients. The 
FDA published a draft guidance on sunscreens which describes the safety and efficacy 
requirements that each sunscreen ingredient will need to meet in order to be included in 
the OTC sunscreen monograph (FDA 2015). The FDA will publish the final guidance in 
late 2016.  
Australia 
UV filters can be regulated either as therapeutic goods or cosmetic sunscreens depending 
the stated (primary or secondary) purpose of the product and its efficacy, i.e.  its sun 
protection factor (SPF). Primary sunscreens, products used primarily for protection from 
UV radiation, with a SPF of 4 or more and moisturisers containing sunscreen with SPF 
greater than 15 are regulated as therapeutic goods by the Therapeutic Good 
Administration (TGA). Therapeutic sunscreens are required to be included in the 
Australian Register of Therapeutic Goods (ARTG) before they can legally be marketed in 
Australia. Most secondary sunscreens (those with a primary purpose other than 
sunscreening but that also contain sunscreening agents) are regulated as cosmetics. The 
regulators are the National Industrial Chemicals Notification and Assessment Scheme 
(NICNAS) and the Australian Competition and Consumer Commission (ACCC)24.  
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The Australian regulatory guidelines for sunscreens (ARGS) have been developed to 
provide guidance to sponsors and manufacturers, and to assist in the understanding of 
the regulatory requirements for sunscreens in Australia (TGA, 2016).  Benzophenone is 
listed in this guidance document as a permitted active ingredient for therapeutic 
sunscreens with a maximum concentration of 10% by weight. 
Canada 
Sunscreens can be classified either as natural health products or drugs depending on 
their medicinal ingredient (Health Canada, 2013). Accordingly, sunscreens will be subject 
to either the Food and Drug Regulations administered by the Therapeutic Products 
Directorate or the Natural Health Products Regulations administered by the Natural 
Health Products Directorate. Benzophenone-3 is listed as a drug medicinal ingredient and 
is authorised in concentrations up to 6% by weight. 
Under the auspices of the Canada-United States Regulatory Cooperation Council, Health 
Canada and U.S. Food and Drug Administration will coordinate and adjust their 
respective Over-the-Counter (OTC) monographs development processes for OTC drugs to 
reduce the regulatory burden on stakeholders. Health Canada is currently updating its 
approach to sunscreens, while the US FDA is due to issue its final guidance document on 
sunscreens at the end of 201625.  
Japan 
In Japan, cosmetics are regulated by the Ministry of Health, Labour and Welfare (MHLW) 
under the Pharmaceutical Affairs Law (PAL). For legal purposes, beauty products are 
divided into quasi-drugs and cosmetics. Sunscreens are classified as quasi-drugs, 
therefore, they require approval of their formulations, ingredients, use levels and 
functionalities, in addition to stability testing and a certificate showing no animal-derived 
materials were used (EU-Japan Centre for Industrial Co-operation, 2015).  
MHLW notification allows benzophenone-3 for cosmetic use in concentrations of up to 5% 
by weight. 
China 
In China, sunscreens are considered special use cosmetics and require a Hygiene license 
from China Food and Drug Administration (CFDA). Cosmetics need to be tested in CFDA-
accredited labs in China during the registration process even if they have been tested 
abroad or assessed. Hygiene safety tests include physio-chemical, microbiological and 
toxicological studies, which are mandatory for non-special use cosmetics. For special use 
cosmetics, such as sunscreen, human safety tests are also required26.  
The CFDA has published a consolidated Inventory of Existing Cosmetic Ingredients in 
China (2014) for public consultations27. Benzophenone-3 figures on this list and its 
maximum level of use already approved is 15% by weight. 
Assessment and measurement endpoints for hazard characterisations 












The publicly available documentation on standard information requirements for 
sunscreens focus on the evaluation of their efficacy rather than their safety. Maximum 
allowed concentration of the active ingredients are specified and as illustrated in the 
above section vary between 5-15% by weight. It is however unclear how and on the 
basis of which data these concentrations were derived. As benzophenone-3 has been 
used as a sunscreen ingredient for decades, it is possible that such values were mainly 
based on human experience and reports of allergic skin reactions. No safe level for 
benzophenone-3 in the body have been established. 
The only notable exception is the European Union where the Scientific Committee on 
Consumer Products (SCCP) reviewed the Submission I dossier on the UV-filter 
Benzophenone-3 first submitted by COLIPA, the European Cosmetics Toiletry and 
Perfumery Association, in December 2005, applying for a maximum allowed 
concentration up to 6%. In December 2006, SCCP adopted an opinion concluding that 
the data presented were insufficient to calculate the margin of safety of Benzophenone-3 
under the proposed conditions of use and requesting a dermal absorption study. 
The applicants resubmitted a dossier with the additional required information in 
December 2007 and the SCCP published a second opinion in December 2008 (SCCP, 
2008). The point of departure selected for its risk assessment was selected from a 
teratogenicity study in rats showing that benzophenone-3 caused some skeletal 
aberrations only at the highest dosage level (400 mg/kg bw/day), which also caused 
maternal toxicity. The NOAEL-value for maternal and developmental toxicity was 200 
mg/kg bw/day. The opinion of the European Scientific Committee on Consumer Products 
did consider reproductive toxicity but not the estrogenic activity in Benzophenone as it 
had concluded in an earlier opinion that it did not endanger human health under current 
conditions of use (SCCP, 2006). 
Exposure assessments 
United States of America 
Benzophenone-3 can be absorbed through human skin and excreted in the urine, mostly 
as a glucuronidated conjugate. The U.S. Center for Disease Control (CDC) National 
Health and Nutrition Examination Survey (NHANES) has been monitoring urinary 
benzophenone-3 levels in the general population over 6 years old since 2003 and found 
that it could be detected in 97% of samples (Calafat et al. 2008). The analysis showed 
that female participants had slightly higher urinary levels than males. The geometric 
mean and 95th percentile concentrations were 22.9 μg/L (22.2 μg/g creatinine) and 
1,040 μg/L (1,070 μg/g creatinine), respectively. 
European Union 
In their 2008 opinion, the SCCP considered the newly provided in vitro dermal absorption 
(then Draft OECD TG 428: Percutaneous Absorption: in vitro Method (2000)) study 
scientifically acceptable. It showed a mean dermal absorption level of 19.3 μg/cm² or 
3.1% of the applied dose for a sunscreen containing the maximum requested 
concentration of 6%. The mean value plus 2 standard deviations (9.9% [mean (3.1%) + 
2 SD (2*3.4%)]) was be used for the calculation of the systemic exposure dose for an 
adult weighing 60kg (SCCP, 2008) equal to 1.78 mg/kg bw/day. 
Risk assessments 
European Union 
On the basis of the hazard characterisation and exposure assessment described in the 
previous sections, the SCCP (2008) derived a margin of safety of 112. As this is above 




sunscreen products does not pose a risk to the health of the consumer, apart from its 
contact allergenic and photoallergenic potential. 
China 
Although no risk assessment was publicly available for benzophenone-3, the CFDA 
website states a safety risk assessment report is compulsory for the registration of 
domestic special cosmetics and imported cosmetics. There is however as yet no official 
guidance for the safety evaluation of cosmetic products in China and draft Guidelines on 
Safety Risk Assessment of Cosmetic Products have been compiled based on the Guidance 
for Safety Evaluation of Cosmetic Products in Europe. 
Consideration of mixture effects 
There is no routine requirement to consider the possibility of mixture effects. Nonetheless 
monographs generally mention ‘synergistic percutaneous permeation’, or the fact that 
benzophenone-3 can enhance the penetration of other chemicals such as insect 
repellents. A recent study investigating the dermal absorption of 10% of Benzophenone-3 
in a sunscreen formulation and 10% of other UV filters reported no effect on endogenous 
reproductive hormone levels in humans after topical application (Janjua et al. 2004). It is 
cited in the SCCP opinion (2008) as evidence that benzophenone-3 does have any effects 
on hormone homeostasis. 
Risk management options 
The use of benzophenone-3 as a sunscreen ingredient below the stated maximum 
concentrations is generally considered safe for human use and no further risk 
management options have been proposed. 
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4.9 Analysis of commonalities and differences in the regulatory status and in assessment values across the various legalities 
The eight case studies presented in this chapter show that endocrine disrupting 
chemicals are treated in a variety of ways in the different legalities that we examined. In 
this section, a summary and a comparison of the case study findings is given, with the 
aim of identifying the degree of commonalities and differences, and whether any 
differences are the result of scientific disputes or simply a reflection of the features of the 
respective regulatory systems in the various legalities. 
4.9.1 Discovery as endocrine disruptors 
The endocrine disrupting properties of five of the chemicals we considered were 
discovered in the context of scientific research activities; only three – two pesticides, 
prochloraz, procymidone and a cosmetic ingredient, benzophenone-3 – were identified 
through regulatory testing efforts. This may be due to the fact that pesticides and 
cosmetic ingredients are subject to rather extensive and relatively uniform regulation and 
testing across legislations, and also suggests that the framework of established 
regulatory testing is ill-equipped for identifying chemicals with endocrine disrupting 
properties. 
4.9.2 Regulatory status 
All the pesticides analysed in our case studies are subject to regulations and restrictions 
in all the legalities considered in this project, although there are important differences in 
detail: Procymidone is not authorised for use in the EU and the USA, but is used in Japan 
and Canada (we were unable to establish its regulatory status in China and Australia). 
Similar considerations apply to benzophenone which is either treated as a cosmetic 
ingredient, with the restrictions that implies, or as a drug (e.g. USA). The precise 
commonalities and differences are manifestations of the details of the respective 
regulatory systems which e.g. in the EU facilitate withdrawal of authorisation for 
placement on the market. 
The picture is much more varied for an industrial chemical such as bisphenol A. 
Restrictions apply in some legalities (e.g. EU and China), while in others, bisphenol A is 
essentially unregulated (USA, Canada, Japan, Australia). This is a reflection of differences 
in the regulatory regimes and of differences in the level of concern with which bisphenol 
A is treated (higher in the EU than anywhere else). 
The use of DEHP is restricted in the EU and the USA, but not in Canada, Japan or China. 
The regulatory status of nonylphenol varies considerably across the legalities we 
analysed, with water quality criteria implemented in the EU, the USA and Canada, but 
not in China, Japan and Australia. 
In contrast, the status of ethinylestradiol is rather uniform. With the exception of 
Canada, which has established water quality criteria, there are no environmental 
standards implemented in any of the other legislations. 
4.9.3 Assessment values 
The assessment values (acceptable daily intakes) that are applied for the pesticides 
considered in the case studies are rather uniform across all legislations apart from 
procymidone where the values vary by a factor of approximately 30. This appears to be a 
result of the internationally harmonised procedures of hazard characterisation that have 
evolved over the years in the area of pesticides. It is of note that the assessment values 
derived for prochloraz are based on toxicities unrelated to endocrine disruption. 
A similar, rather uniform picture emerges for DEHP where the assessment values utilised 
in the different countries and legislations do not differ much, with the exception of the EU 




Greater differences became obvious for the environmental standards used for 
ethinylestradiol and nonylphenol, and for bisphenol A. 
The water quality criteria (or equivalent) that are in use for risk assessments for 
ethinylestradiol vary by a factor of approximately 15. These differences are explained by 
the use of different experimental studies for the derivation of the values, and by the 
application of differing assessment factors. 
In the case of nonylphenol, the greater differences between the various assessment 
factors (factor of approximately 60) are due to the fact that their derivation was based 
on distinct chemical entities (linear or branched side chain), with quite different toxic 
properties. 
The greatest variations are apparent with bisphenol A where the assessment values in 
use internationally differ by no less than 10,000-fold. This is driven by the use of a 
variety of assessment endpoints, not all of which relate to endocrine disruption, and the 
application of widely differing assessment factors, reflecting differences in the evaluation 
of adversity, and a lack of scientific agreement about the basis for hazard 
characterisations.  
The Table below gives a summary of the case study findings. 
Table 1: Compilation of assessment values for case study substances 
Substance EU USA Canada Japan China Australia 
Ethinylestradiol 














































Substance EU USA Canada Japan China Australia 
Bisphenol A 
































0.06 0.044 - - - 
Mancozeb 
Discovery scientific studies 
Regulatory 
Status 




 0.05 0.008    
Prochloraz 
Discovery regulatory testing 
Regulatory 
Status 




0.01 0.01 0.01 0.01 0.01 0.01 
Substance EU USA Canada Japan China Australia 
Procymidone 
Discovery regulatory testing 
Regulatory 
Status 






- - 0.035 - - 
Benzophenone-3 
Discovery regulatory testing 
Regulatory 
Status 





In summary, the differences and commonalities in the different legalities in dealing with 
endocrine disruptors are mainly an expression of the different features of the respective 
legal systems. In some cases, differences in scientific approaches are also playing a role. 
The impact these differences have on the final outcome of the derivation of regulatory 
values (e.g. water quality standards, acceptable daily intakes and similar) varies from 




The differences in the respective assessment values could diminish if more consistent 
methods of hazard assessment were applied across the various legalities, with uniform, 
transparent and agreed criteria as to the selection of studies for hazard characterisations, 





5. THE INTERNATIONAL WORKSHOP ON COMMONALITIES AND DIFFERENCES IN APPROACHES FOR TESTING AND ASSESSMENT OF ENDOCRINE DISRUPTORS WITHIN THE EU AND AMONG RELEVANT TRADING PARTNERS 
5.1 Introduction 
This document is the report of a Workshop held on 19-20 September 2016 in Hotel 
Bloom in Brussels, in connection with the project Mapping commonalities and differences 
in approaches for testing and assessment of endocrine disruptors within the EU and 
among relevant international trading partners. 
This report describes the workshop objectives and agenda, and gives an account of 
workshop presentations, working group discussions and recommendations. 
The objective of the project Mapping commonalities and differences (…) itself is to 
compare approaches for the regulatory screening, testing and assessments of substances 
for the endocrine disrupting properties within the European Union (EU) and among 
relevant international trading partners, as well as the results of said approaches, in order 
to establish commonalities and differences and assess the drivers for these differences, 
with the following specific objectives: 
1. To gain an overview of regulatory screening, priority setting, testing and 
assessment approaches applied to identify and assess endocrine disruptors in EU Member 
State, at EU level and by relevant international trading partners (US, Canada, Australia, 
Japan, China) focusing in particular on case studies of application; 
2. To map out commonalities and differences in the screening, priority setting, 
testing and assessments approaches addressing the used methodologies, type of data 
considered, technical assessments of specific cases and interpretation of results of 
specific cases; 
3. To ascertain the extent to which differences are due to variations in scientific 
approaches or in different legislative frameworks and regulatory culture; 
4. To identify opportunities to foster international cooperation on scientific issues 
related to promoting chemical safety in regards to potential for endocrine disruption. 
5.1.1 Workshop objectives 
The following objectives were formulated for this workshop: 
1. To present to participants an overview of the field of endocrine disruption, 
2. To inform participants about project achievements thus far, 
3. To produce an overview of differences and commonalities in screening and testing 
in different legalities outside the EU, 
4. To investigate the scope for data sharing at the international level, 
5. To investigate commonalities and differences in setting priorities for screening and 
testing for endocrine disrupting properties, 
6. To consider international cooperation for research and horizon scanning for 
endocrine disruptors, 
7. To investigate the scope for harmonisation of hazard and risk assessment for 
endocrine disruptors at the international level. 





Objectives 4 – 7 were the topic of four working groups with the following thematic 
orientations, which were set up during the workshop: 
Working Group 1: The scope for data sharing on ED hazards and exposures at the 
international level 
Working Group 2: Setting priorities for screening and testing for ED properties – 
commonalities and differences and scope for common principles 
Working Group 3: Research needs and horizon scanning in the ED arena – prospects 
for international cooperation? 
Working Group 4: Harmonisation of hazard and risk assessment for endocrine 
disruptors at the international level – opportunities and limitations 
5.1.2 Workshop participants 
Invited workshop participants were from EU Member State competent authorities, 
competent authorities from the USA, Japan, China (unfortunately unable to attend) and 
Australia, and international experts. 
A list of participants can be found in Annex 1 of this report. 
5.1.3 Workshop agenda 
The workshop agenda can be found in Annex 2 of this report. 
5.1.4 Workshop materials 
To enable preparation for the workshop, participants received workshop materials in 
advance, prepared by the contractor. These materials consisted of: 
 An overview summary of legislative frameworks and approaches in different 
legalities, relevant to endocrine disruptors 
  Five case studies of hazard and risk assessments for specific endocrine disrupting 
chemicals in different legalities 
  Seven theses on commonalities and differences in approaches for testing and 
screening of endocrine disruptors, intended to trigger discussions at the workshop  
5.2 Workshop report: Summary of formal presentations 
In this section, a brief summary of the formal workshop presentations is given. The 
presentations are available in Annex 3 to this report. 
Prof Andreas Kortenkamp (Brunel University London): Milestones, discoveries and set-
backs in endocrine disruptor research – a potted history  
Andreas Kortenkamp began by sketching out the beginnings of endocrine disruptor 
research in the 1980s, with research into DES and the importance of timing of exposure. 
The 1990s saw by chance discoveries of important endocrine disrupting chemicals, 
including nonylphenol, tributyl tin, and steroidal estrogens as causing feminisation in fish. 
Research into the causes of deterioration of male reproductive health gave rise to the 
testicular dysgenesis hypothesis. By the mid 1990s, the importance of endocrine 
disruptors with estrogenic, anti-androgenic and thyroid disrupting modalities was 
established. 
Further underlining the importance of timing and windows of heightened susceptibility, 
the 2000s saw the establishment of the male programming window during pregnancy as 
the key period of susceptibility to anti-androgenic endocrine disruptors. This coincided 




developments unfolded in the area of thyroid research, as substances eliciting thyroid 
insufficiency in neonatal life were identified as risk factors for compromised brain 
development. Perchlorate, various UV filter substances and soy isoflavones were found to 
be thyroid disruptors. 
Endocrine disruptor research also uncovered issues of a more generic nature, applicable 
to many chemicals. Prominent are the issues of non-monotonic dose-response 
relationships, low dose effects and of combined exposures. 
More recent developments include the discovery of a number of chemicals inhibiting 
steroid modifying enzymes and the consequences of such inhibition, the importance of 
disruption of prostaglandin signalling as a new modality in endocrine disruption, which 
brought the issue of analgesics to the fore, the role of epigenetics, and the topic of 
differentiation of adipose tissue precursors and obesogens. 
Curiously neglected are the topics of progesterone signalling and female reproductive 
health. Regulatory testing and the development of test methods have not kept up with 
these developments. The focus is still on testing for estrogens, anti-androgens and 
thyroid disruptors. 
Prof Ulla Hass (Technical University of Denmark): Commonalities and differences - a 
summary of project outcomes thus far  
Ulla Hass summarised the work conducted for this project by the contractor thus far. On 
the basis of an overview of the current status of EDC regulation in the EU, USA, Japan, 
Canada, China and Australia, several commonalities and differences became apparent: 
A concern for endocrine disruptors is common to all jurisdictions considered, with a 
recognition of the need for testing and screening. Important differences concern the finer 
points of testing and screening, and of priority setting in the different jurisdictions: In 
some jurisdictions there is a strong focus on screening for endocrine activity without 
necessarily testing for adverse effects or vice versa. There are also differences 
concerning priority setting for testing and screening. The legal framework in the EU is 
based on production volume as a strong marker for priority setting, whereas in other 
jurisdictions (e.g. USA) endocrine activity or exposures are a strong stimulus. There are 
also differences concerning the issue of who should conduct testing – the manufacturer 
or governmental institutions? 
Common to many jurisdictions is the fact that the toxicity produced by endocrine 
disruptors is the subject of general chemical legislation, as well as specific regulatory 
domains (pesticides, food additives, pharmaceuticals etc.). Differences in approaches 
relate to the question as to whether additional regulatory approaches are needed to deal 
with endocrine disruptors, or whether they are adequately addressed by existing laws. 
There are also differences in relation to regulatory approaches, which range from soft 
voluntary agreements or recommendations to consumers to actual restrictions in the use 
of chemicals. 
In conclusion, there is common concern about endocrine disruptors. The differences that 
have become apparent in screening and testing approaches can be become significant 
strengths, if there is international cooperation. It is necessary to expand the focus of 
regulation beyond estrogens, antiandrogens and thyroid disruptors, and to move beyond 
high production volume chemicals to the large numbers of substances that have not been 
tested at all.     
Dr Patience Browne (USEPA and OECD): Prioritization and Screening Chemicals for 
Endocrine Bioactivity in the US 
Patience Browne traced the evolution of the USA EDSP from the first list (issued in 2009) 




exposures (67 substances), to the second list (revised in 2013) which was based on 
registration review schedule for pesticides and nationally regulated drinking water 
contaminants or unregulated chemicals. By exclusion of naturally occurring and 
untestable chemicals, the second list was revised to contain 109 chemicals. 
Computational tools and models are used in EDSP to rapidly prioritise chemicals for 
endocrine activity and for further testing, to contribute to the weight of evidence 
evaluation of a potential biological activity and to provide alternative data for specific 
screening assays. In connection with the ToxCast programme, these approaches were 
first developed and evaluated for estrogenic chemicals, but are to be rolled out for (anti)-
androgens and other endocrine modalities as well. 
The inclusion of computational approaches in screening activities relies on the successful 
identification of reference chemicals with proven activity. Reference chemicals are also 
needed for the evaluation of model performance. EDSP will develop additional predictive 
models for estrogens, (anti)androgens and thyroid disruptors by integrating more assays 
that are representative of key events in adverse outcome pathways. Similar approaches 
are developed for substances that interfere with steroidogenesis. 
To improve in vitro-in vivo extrapolations, current efforts are also focused on evaluating 
the impact of metabolism and bioactivation of endocrine active chemicals.   
Dr Jun Kanno (JBRC, NIHS, Japan): The Concept of “Signal Toxicity” for the Planning of 
Research and Testing of Endocrine Disrupting Chemicals - beyond EATS 
Jun Kanno expanded ideas of hormonal signalling and endocrine disruption into the 
concept of signal toxicity and demonstrated with original, unpublished data sets how 
these ideas can be harnessed for a more inclusive, comprehensive approach for 
endocrine disruptor testing beyond estrogens, (anti)androgens and thyroid disruptors. 
Dr Sharon Munn (DG Joint Research Centre): The EASIS data base (Endocrine Active 
Substances Information System) – an update  
Sharon Munn presented the history, structure, content and the evolution of the Endocrine 
Active Substances Information System (EASIS) data base at the Joint Research Centre. 
EASIS’s pre-history began in 1999 with the adoption of the EU Community Strategy for 
Endocrine Disruptors. One short-term action of the Strategy was to establish a priority 
list of substances for further evaluation of their role in endocrine disruption. This list 
(here termed the “DG ENV list”) was established between 2000 and 2006 and contains 
over 500 substances. It uses a categorisation system, with category 1 assigned to 
substances with in vivo evidence of endocrine disruption in at least one species, category 
2 for substances with in vitro evidence, and category 3 for cases with no evidence or no 
data. 
In 2010, a follow-up process began, with DG ENV requesting JRC to develop a new 
system, called EASIS. EASIS was to adhere to international standardised data models 
and allow the hosting of non-guideline test data (from in vitro, in silico and in vivo 
methods). Unlike the DG ENV list, EASIS does not categorise substances according to 
evidence of endocrine disruption. Because EASIS contains both positive and negative 
data, the mere presence of a substance in EASIS does not allow any conclusions as to its 
endocrine disrupting properties. EASIS is compatible with the OECD Harmonised 
Templates (OHT). 
EASIS’s content is currently evolving from a read-only data base for everyone, where JRC 
adds new data, to a system where third parties can be granted write access for the 




In summary, EASIS is a source of data relevant to the research community and to 
assessors of toxicity/ecotoxicity data with respect to the identification of endocrine 
disruptors. EASIS captures endocrine disruptor mode of action data, together with 
adverse effect data, in a structured knowledge base that follows the OHT. 
Dr Olwenn Martin (Brunel University London): Weighing and integrating evidence in 
hazard and risk assessment of endocrine disruptors  
Olwenn Martin presented preliminary findings from the contractor’s work and 
summarised recent developments in the field of evidence assessment and integration, 
especially for endocrine disruptors. 
On the basis of the case studies conducted by the contractor for specific endocrine 
disruptors in which commonalities and differences in testing and evaluation were 
analysed, it is possible to define some important issues for weighing and integrating 
evidence. 
It was notable that the endocrine disrupting properties of some chemicals were not 
detected through routine guideline testing. The effects were discovered accidentally. 
Common, uniform, and agreed criteria for the selection of studies relevant for the 
derivation of regulatory quality standards for endocrine disruptors (ADI, EQS, water 
quality standards etc.) are missing. There is a lack of transparency in the selection 
process. 
There is no consensus about what is to be considered an adverse effect relevant for 
endocrine disruption. 
To improve this state of affairs, it would be desirable to make the selection of studies for 
deriving regulatory values transparent. Clarity about value judgements inevitably 
involved in the definition of adversity is also needed. The incorporation of peer reviewed 
literature is important, as is the need to consider all the evidence accessible in the 
literature. 
These demands and requirements necessitate the adoption of systematic review 
protocols and methods for evidence integration and for judging data quality and reliability 
of studies that go beyond the familiar Klimisch scores. Olwenn Martin gave a summary of 
recent developments in these areas (the IARC system, GRADE, SYRINA and other 
decision tools such as from the OECD and EDSP). Endocrine disrupting chemicals present 
a difficult challenge to existing methodologies, as an assessment of adversity together 





5.3 Workshop report: Working group deliberations 
The formal workshop presentations were followed by working group discussions. This 
section of the report gives a summary of these discussions and the recommendations 
made in each group. 
Each working group elected a rapporteur and a member of the contractor’s project team 
was assigned to assist with record keeping, as follows: 
Working group 1: rapporteur - Dr Patience Browne, project team - Dr Olwenn Martin 
Working group 2: rapporteur - Dr Sharon Munn, project team - Prof Ulla Hass 
Working group 3: rapporteur - Dr Sander van der Linden, project team - Dr Sofie 
Christiansen 
Working group 4: rapporteur - Dr Henrik Holbech, project team - Prof Andreas 
Kortenkamp 
The presentations and summary slides from the working groups are available in Annex 4 
of this report.  
5.3.1 Working group 1: The scope for data sharing on ED hazards and exposures at the 
international level 
The discussions in this group focused on three topics relevant to the sharing of data at 
the international level: Copyright and proprietary data, reporting and data requirements, 
and biomonitoring data. For each of these topic areas, the group discussed 
commonalities, obstacles and solutions or opportunities for overcoming the obstacles. 
Copyright and proprietary data 
Common to all jurisdictions is that specific data may be requested for a substance if it 
presents concerns regarding endocrine disrupting properties. Summary hazard data can 
be shared at the international level, as can substance evaluations. This is particularly 
important for countries and jurisdictions that have not implemented data and information 
requirements and thus have to conduct regulation on the basis of data already available 
(as is the case e.g. in Canada). Exposure data are generally publicly available and can be 
readily shared. 
The group identified several obstacles to data sharing at the international level: The 
biggest problem is with sharing proprietary data that emanate from specific regulatory 
domains which place data and information requirements on registrants, as is the case 
with several EU regulations such as PPPR, BPR and REACH. These data can be shared 
within the EU, but not beyond. The group noted that several countries do not have data 
and information requirements implemented, and therefore depend on already available 
data (see above). 
The group saw significant opportunities in developing common guidance for hazard 
assessments of endocrine disruptors, which should include data from new methods and 
non-guideline studies. At a minimum, this guidance should be developed within the EU 
(EFSA, ECHA, to improve consistency between different regulatory domains), but also 
internationally, beyond the EU. 
It is also necessary to arrive at a common definition for endocrine disruptors. Although 




been criticised as lacking consistency28. There is large scope for international 
harmonisation. 
Reporting and data requirements 
Obstacles to better international sharing of data are language barriers, and the fact that 
many data are in non-standard templates, making them difficult to integrate into 
databases. 
The group noted that there are challenges and difficulties in the correct reporting of data, 
and the validation of existing data. There is little point in sharing data that are not 
validated. An issue raised was whether the existing OECD Harmonised Templates, which 
as such seem to be ideal for international data sharing, include the appropriate endpoints 
needed for the reporting of endocrine disrupting effects. 
To overcome these difficulties, agencies should be encouraged to use standard reporting 
formats for data on endocrine disrupting effects. Ideally, this requirement should extend 
to the realm of primary research, with funders requiring reporting in standardised 
formats. The same should apply also to scientific publishers who could make publication 
of data dependent on adherence to standardised data format. This would also help 
making data from non-guideline studies more useful for hazard- and risk assessment. 
Biomonitoring 
The group also discussed the possibilities of data sharing for exposure data, and focused 
on biomonitoring data. There are challenges in estimating correctly the external 
exposures that correspond to the various levels of endocrine disruptors measured in 
tissues and body fluids, and validation procedures are required before data can be shared 
internationally. 
The opportunity in this area is an international harmonisation of how biomonitoring data 
are gathered and interpreted. 
 
5.3.2 Working group 2: Setting priorities for screening and testing for ED properties – 
commonalities and differences and scope for common principles 
The group began their deliberations by discussing how priorities for screening and testing 
are developed in different countries and identified various commonalities: 
Common in Japan and the EU is a focus on using surrogates for exposures as an element 
in prioritisations. These are usually in examining production volumes and usage patterns 
of chemicals. Common to Japan and the EU is also that the literature or (in the EU) the 
submissions of registrants are reviewed for alerts for endocrine disrupting effects or 
endocrine disruptor modes of action. Screening is based on existing data, no new data 
are generated. In the EU, internationally validated screening assays for mode of action, 
such as those in the OECD Conceptual Framework, Level 2 or 3 are requested in some 
legislation (e.g. on plant protection products29), but only if there is evidence in 
mandatory in vivo studies long term toxicity and carcinogenicity, as well as reproductive 
toxicity30) or in the public literature31 that the active substance may have endocrine 
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 See https://chemicalwatch.com/14867/epa-urged-to-define-endocrine-disruptors-consistently 
29
 Regulation (EU) No 283/2013 points 5.8.3 and 8.2.3 and the associated Communication 2013/C 95/01 points 
5.8.3 and 8.2.3 
30




disrupting properties. Thus, these assays are not used for the screening of all active 
substances, but only for those substances where some alerts are highlighted in other in 
vivo mandatory studies. In themselves, they are not mandatory data requirements. In 
Japan, government-funded testing programmes are aligned to the OECD Conceptual 
Framework, with estrogenicity, (anti)androgenicity, thyroid disruption and 
steroidogenesis the focus of funding for testing. 
In the USA, the situation regarding prioritisation and screening efforts is slightly 
different. With the EDSP and ToxCast/Tox 21, there are government-funded high 
through-put schemes for the screening of substances, in addition to specific data 
requirements for registrants in the pesticide area. The USA also plans mixture testing 
using high through-put methods, for substances that affect the same pathways via 
similar modes of action, and also for substances that produce common adverse 
outcomes, but via different modes of action. 
In summary, the group realised that there were more commonalities than differences in 
the prioritisation for screening and testing for endocrine disruptors. They noted that the 
reporting of mode of action data, such as those from in vitro mode of action assays, are 
not core data requirements in any legislation, but may be triggered in some EU 
legislations if concern about endocrine disrupting properties arises from other toxicity 
testing (see above). 
The group elaborated several suggestions for a way forward at the international level: 
Essential is the sharing of data and assessments, and steps should be taken to facilitate 
this at the international level. Cooperation in terms of research funding was also seen as 
essential to avoid duplication of efforts. 
Looking to the future, the group saw the necessity of addressing mode of action data and 
adverse effects at the same time. The vision would be to use data from mode of action 
screens for the prediction of adverse effects. This will necessitate integration within an 
adverse outcome pathway framework, with the aim of establishing the degree of change 
required in an upstream key event to elicit adverse effects. 
The group made several recommendations, as follows: 
  Implement OECD Conceptual Framework Level 2 and 3 assays in data and 
information requirement directives 
  Provide guidance as to how the data generated are to be used for hazard and risk 
assessment (as is currently being done in the process of updating OECD guidance 
document 150) 
  Identify gaps in validated assays and prioritise, which should be filled (as is 
currently done at the OECD with guidance documents 97, 178 and others) 
  Translate assays developed in a research context into validated assays (aspects of 
this activity are ongoing at the OECD) 
  Explore the use of additional endpoints reflective of endocrine disruption in 
existing, validated assays 
  Generate priority lists of substances to be subjected to screening and testing  
  
5.3.3 Working group 3: Research needs and horizon scanning in the ED arena – 
prospects for international cooperation? 
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This group started the discussion with some research that has been reviewed by the 
OECD, and relevant projects for EDs, as outlined by the OECD, which concern: 
  Metabolism (not just for endocrine disruptors) 
  Thyroid disruption (with the development of adverse outcome pathways and 
prioritising assays for validation, as e.g. in the OECD thyroid scoping document) 
  Non-genotoxic carcinogens (validation and integration of test methods, to lead to 
an integrated approach to testing and assessment (IATA)32 
  Systematic uncertainty analysis of standard animal testing and assessment 
approaches to identify appropriate reference data and information for the 
validation of defined in vitro and in silico approaches and to identify benchmarks 
for the performance of the latter (e.g. initiated in OECD now for non-genotoxic 
carcinogenicity including ED and the derivation for a Point of Departure for risk 
assessment, but this is also needed for other areas). 
Specifically for endocrine disruptors, the need for a defined testing strategy was 
recognised, using in vitro and in silico methods, with the aim of helping the risk 
assessors worldwide with the interpretation of the data. Research that can underpin the 
development of such a testing strategy needs to be funded. 
Several aspects were discussed that could make the tools that would make up a testing 
strategy more useful. Risk assessors’ needs in terms of data and test requirements 
should be better communicated to scientists and test developers. This could be achieved 
by involving the agencies more in research programmes, especially in relation to the 
validation of test methods, as now described by several OECD documents, but also by 
research funding bodies supporting such grant applications. The group saw this as 
essential for international mutual acceptance. 
Generally, the group felt that research funding should be directed more towards a focus 
on regulatory science, as this would stimulate a better integration between science and 
regulation. An issue for debate was whether research funding should be directed towards 
the screening of many compounds for a limited number of endocrine-relevant pathways, 
or whether resources would be better allocated to the detailed and extensive 
characterisation of a few compounds in terms of their endocrine disrupting properties. 
One way of resolving this could be in building up the EU equivalent of the National 
Toxicology Programme in the USA. 
The group reached a consensus that the development and translation of adverse 
outcome pathways to defined approaches to testing and assessment for endocrine 
disruption should be a priority area in future research funding. Not only would this help in 
terms of providing an organising principle that would help the regulator understand 
several different sets of data, but it could also function as a central depository which 
would reflect the state of the science for a certain pathway or adverse outcome, and be 
reflective of the maturity of the adverse outcome pathway. 
The group also discussed the known publication bias towards positive findings. 
Publication of negative findings is important not only to prevent the funding of research 
programmes that turn out to be unsuccessful and fruitless, but also to put the positive 
data into perspective in weight of evidence assessments and systematic reviews. This 
dilemma could be addressed by obliging funded projects to make their data available, 
including negative results. Alternatively, or additionally, there could be funding for 
publishing the negative data in journals, e.g. a Journal of Confirmation Sciences, or a 
Journal of Negative Findings. 
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Several participants supported that more resources should be put towards researching 
novel pathways in endocrine disruption. On the other hand it was also raised that funding 
should focus on the OECD identified priority projects and to translating available 
knowledge for EATS pathways to defined in vitro and in silico approaches including 
kinetic modelling (QIVIVE) for regulatory application: At present testing and assessment 
for endocrine disruption relies largely on animal testing and this is prohibitive for the 
assessment of a larger number of substances and mixtures and for retesting chemicals 
according to progress in the development of scientific and toxicological understanding. 
The group identified another research need in the area of mixtures of endocrine 
disruptors. 
Finally, the research and assessment efforts spent on substances before they are put on 
the market should be complemented by some post-marketing research to confirm the 
initial exposure assessments, e.g. to confirm the hypothesis that chemicals do not appear 
in e.g. breast milk. Similar considerations apply to the post-market monitoring of 
endocrine-related effects in workers or environmental organisms exposed to 
agrochemicals. These efforts should be funded by the producers of chemicals. 
The group ended the discussions by considering whether the regulatory sector would be 
ready to utilise new research data. 
 
5.3.4 Working group 4: Harmonisation of hazard and risk assessment for endocrine 
disruptors at the international level – opportunities and limitations 
The group embraced the need for harmonisation of hazard and risk assessment for 
endocrine disruptors internationally, but stressed that even in the EU essential guidance 
for conducting such assessments is missing. There is great scope for developing such 
guidance jointly between ECHA and EFSA. 
The group discussed the possibility of harmonising hazard assessment approaches 
internationally, beyond the EU. To avoid “reinventing wheels”, this should borrow from 
principles of hazard identification and characterisation developed for carcinogens by 
IARC. However, the aspect of mode of action evaluation will have to be elaborated, 
considering that hazard assessment for endocrine disruptors requires consideration of 
adverse effects and endocrine related modes of action at the same time. 
As part of these efforts of harmonising hazard assessments, criteria for the selection of 
studies that can meaningfully be used in this process must be developed. These criteria 
should take into consideration the choice of endocrine related adverse endpoints, and 
also quality criteria. The harmonisation of hazard identification at the international level 
could find expression in the inclusion of an endocrine disruptor class in GHS. 
The group identified data availability as a bottleneck for harmonisation and noted that 
the EU does not use in vitro mode of action assays for the screening and testing, e.g. to 
establish endocrine relevant modes of action. The suggestion was made to ensure that 
relevant in vitro assays from the OECD Conceptual Framework Level 2 and further assays 
from level 3 are implemented in EU regulations for data and information requirements, 
e.g. in the context of pesticides, biocidal products and REACH. Such efforts should be 
based on careful consideration of which assays should be selected and should be 
embedded in developments of testing strategies, including decision trees for waiving 
further testing, should certain outcomes be negative, or to trigger earlier further testing 
in case of positive outcomes. 
Finally, institutional aspects of harmonisation were discussed. Various options were 




to the setting up of a body under the umbrella of UNEP or the use of OECD (EDTA AG and 
TFHA) as the platform for international institutionalisation.  
5.4 A summary of working group recommendations: The way forward 
In summary, all working groups saw a need for international cooperation and 
harmonisation in the area of endocrine disruptors. To achieve this goal, quite a few 
recommendations were made, often common to several working groups. 
In this section, a summary of these recommendations is drawn out from the account of 
the working group deliberations. The first two of these recommendations concern the 
“what?” of harmonisation, the remainder the “how?”. 
Recommendation 1: Develop international guidance for harmonised hazard 
identification and assessment of endocrine disruptors (articulated by working groups 1 
and 4) 
Elements of this guidance should be: 
  A common definition of endocrine disruptors, 
  The development of approaches that can assess adversity and endocrine-related 
modes of action at the same time,  
  The description of sets of tests essential for hazard assessment, 
  The elaboration of criteria for the selection of studies for hazard assessments, 
  The development of a standardised reporting format for data describing hazards, 
  The elaboration of quality criteria for studies and data sets, 
  The development of suitable weight of evidence approaches. 
 
There is also scope for developing hazard assessment guidance into one for risk 
assessment. 
 
Recommendation 2: Develop a strategy for the testing of endocrine disruptors 
(articulated by working group 2, and in parts by groups 3 and 4) 
This should entail: 
  The identification of gaps in internationally validated tests for endocrine 
disruption, with respect to endocrine disruptor effects not yet covered, 
  Consideration of additional endpoints of endocrine disruption that could be 
incorporated in existing tests, 
  The development of a staged testing strategy with a decision tree that would allow 
discontinuation of further testing in case of negative results (after thorough 
evaluation of all available information about the initial concern, data on similar 
substances and metabolic differences between species) and further testing in case 
of positive results, 
  An assessment of already existing scientific tests (as currently conducted at the 
OECD working group of National Coordinators), with a view of taking them 
forward into the validation process. 
 
The development of such a strategy could also be supported by the adverse outcome 




funding, especially for progressing OECD agreed priority areas towards regulatory 
applicability and the assessment of novel pathways and novel effects. 
 
Recommendation 3: Implement assays described in the OECD Conceptual Framework, 
Level 2 and 3 in legislations for data and information requirements (articulated by 
working groups 2 and 4) 
 
This was seen as essential to create the data necessary for judging whether chemicals 
induce adverse effects through endocrine-mediated modes of actions. However, it was 
also acknowledged that prior to this, testing strategies need to be established and 
harmonised that allow optimal use of the in vitro and in silico approaches (see working 
group 3). 
 
Recommendation 4: Create an institutional platform for international harmonisation of 
hazard and risk assessment for endocrine disruptors, and for the exchange of data and 
assessments (articulated by working groups 3 and 4) 
For international cooperation and harmonisation to become a reality, an appropriate 
institutional structure was seen as essential. Suggestions for realising this idea included: 
  The creation of an agency that is the IARC equivalent for endocrine disruptors, 
under the auspices of WHO, 
  As above, but under the umbrella of UNEP, 





6. POSSIBILITIES FOR FOSTERING INTERNATIONAL COOPERATION ON 
SCIENTIFIC ISSUES RELATED TO PROMOTING CHEMICAL SAFETY IN 
REGARDS TO THE POTENTIAL FOR ENDOCRINE DISRUPTION  
 
There is widespread recognition of the need for international cooperation on promoting 
chemical safety in relation to chemicals with endocrine disrupting properties. 
Furthermore, as has become apparent during the international workshop organised in 
connection with this project, there is considerable willingness among risk assessment 
practitioners in competent authorities to move towards an international harmonisation of 
approaches. This has found expression in the four recommendations from the workshop 
(see section 5.4). 
These recommendations concern the 
  development of international guidance for harmonised hazard assessment of 
endocrine disruptors, 
  development of a strategy for the testing of endocrine disruptors 
  implementation of existing tests and assays for the identification of endocrine 
disruptors, as described in the OECD Conceptual Framework, Level 2 and 3, and 
  creation of an institutional platform for international harmonisation of hazard and 
risk assessment for endocrine disruptors, and for the exchange of data and 
assessments 
The implementation of the last of these recommendations would appear to be essential 
to initiate the process of international harmonisation in the assessment of endocrine 
disruptors. However, it is beyond the scope of this project to elaborate the finer 







The inventory of completed and on-going activities in screening, priority setting, testing 
and assessment of chemicals for their endocrine disrupting properties in the EU 
(including within the Member States) and relevant international trading partners (US, 
Canada, Australia, Japan, China), as well as the expert consultation about ongoing 
activities showed that there is a common concern about the harmful effects of endocrine 
disrupting properties across all legalities. 
Despite this common concern, that there are significant differences relating to the 
question whether endocrine disrupting chemicals require dedicated regulatory systems 
and structures, or whether the adverse effects produced by endocrine disrupting 
chemicals can be dealt with adequately by regulating toxic effects within the existing 
regulatory structures. 
The eight case studies of ethinylestradiol and estradiol, nonylphenol, bisphenol A, di-
ethyl-hexyl phthalate (DEHP), mancozeb, prochloraz, procymidone and benzophenone-3 
support the conclusion that the framework of established regulatory testing is ill-
equipped for identifying chemicals with endocrine disrupting properties. 
It can also be concluded that there are benefits in the international harmonisation of the 
ways in which chemicals are dealt with. This is substantiated by the commonalties in 
which all the pesticides analysed in the case studies (mancozeb, prochloraz, and 
procymidone) are treated across all legalities. 
In contrast, there are considerable disparities in the ways in which industrial chemicals 
such as bisphenol A, nonylphenol and DEHP are handled in the different legalities. These 
are a reflection of differences in the regulatory regimes and of differences in the level of 
concern with which these chemicals are regarded. 
In conclusion, the differences and commonalities in dealing with endocrine disruptors in 
the various legalities are mainly an expression of the features of the respective legal 
systems and less so of differences in data interpretation. However, in some cases, 
including ethinylestradiol, nonylphenol and bisphenol A, diverging scientific approaches 
also play a role. The impact of these differences on the derivation of regulatory values 
(e.g. water quality standards, acceptable daily intakes and similar) can be considerable. 
It has also become apparent that the differences in the assessment values for specific 
chemicals could diminish if more consistent methods of hazard assessment were applied 
across the various legalities. This concerns the application of uniform, transparent and 
agreed criteria for the selection of studies for hazard characterisations, as well as for the 
choice of assessment factors. 
During the workshop which was organised in connection with this project, these 
conclusions were echoed among workshop participants. The need for international 
cooperation in promoting the chemical safety of chemicals with endocrine disrupting 
properties was recognised. There was also a willingness to move towards an international 
harmonisation of approaches, including internationally harmonised guidance for hazard 







This list encompasses the actual participants of the workshop and the people who 
express an interest in being kept informed. 
 
  
Country Name Institution email address
Australia Sneha Satya National Industrial Chemicals Notification and Assessment Scheme (NICNAS)neha.satya@nicnas.gov.au
Canada Tara Barton-Maclaren Health Canada tara.barton-maclaren@canada.ca
Canada John Prindiville Government of Canada john.prindiville@canada.ca
Japan Jun Kanno National Institute of Health Sciences jkanno@hh.iij4u.or.jp
Japan Kunihiko Yamazaki Ministry of the Environment KUNIHIKO_YAMAZAKI@env.go.jp
Japan Yukio Kawashima NUS kawasima@janus.co.jp
USA Patience Browne Environment Protection Agency Patience.BROWNE@oecd.org
USA Mark Miller National Institute of Environmental Health Sciencesmark.miller2@nih.gov 
USA Suzanne Fitzpatrick FDA suzanne.fitzpatrick@fda.hhs.gov
Austria Martin Paparella Umweltbundesamt martin.paparella@umweltbundesamt.at
Austria Simone Mühlegger Federal Ministry for Agriculture, Forestry, Environment and Water ManagementSimo e.Muehlegger@umweltbundesamt.at 
Belgium Martine Rohl FPS Public Health martine.rohl@environnement.belgique.be
Belgium Luc van Gaal Conseil Superieur de la Sante luc.van.gaal@uza.be
Denmark Pia Juul Nielsen Danish EPA pjn@mst.dk
Denmark Henrik Holbech University of South Denmark hol@biology.sdu.dk
Finland Jaana Palomaki Finnish Safety and Chemicals Agency (Tukes) jaana.palomaki@tukes.fi
France Christophe Rousselle ANSES Christophe.ROUSSELLE@anses.fr 
France Cecile Michel ANSES cecile.michel@anses.fr
Germany Roland Solecki Bundesinstitut fur Risikobewertung Roland.Solecki@bfr.bund.de
Germany Tobias Frische Umweltbundesamt tobias.frische@uba.de
Hungary Zoltan Marcsek National Institute of Chemical Safety (OKBI) marcsek.zoltan@okbi.antsz.hu
Ireland Alan Breen Department of Agriculture, Food and the Marine alan.breen@agriculture.gov.ie
Italy Alberto Mantovani Istituto Superiore di Sanita alberto.mantovani@iss.it
Italy Annamaria Colacci Arpae Emilia-Romagna acolacci@arpa.emr.it
Lithuania Agnė Janonytė Environmental Protection Agency a.janonyte@aaa.am.lt
Netherlands Betty Hakkert RIVM Betty.hakkert@rivm.nl
Norway Christine Bjorge Norwegian Environment Agency christine.bjorge@miljodir.no
Slovak Republik Karol Blesak Ministry of the Economy Karol.Blesak@mhsr.sk
Spain Jose Maria Navas INIA jmnavas@inia.es
Sweden Anna Beronius Karolinska Institutet anna.beronius@ki.se
Switzerland Petra Kunz Bundesamt für Umwelt BAFU petra.kunz@bafu.admin.ch
Switzerland Anne-Laure Demierre Bundesamt für Gesundheit BAG anne-laure.demierre@bag.admin.ch
United Kingdom Miriam Jacobs Public Health England miriam.jacobs@phe.gov.uk
Study Team Andreas Korternkamp Brunel University London andreas.kortenkamp@brunel.ac.uk
Study Team Olwenn Martin Brunel University London olwenn.martin@brunel.ac.uk
Study Team Ulla Hass DTU ulha@food.dtu.dk
Study Team Sofie Christiansen DTU sochr@food.dtu.dk
OECD Anne Gourmelon OECD anne.gourmelon@oecd.org
EU Bjorn Hansen DG ENV bjorn.hansen@ec.europa.eu
EU Kevin Flowers DG ENV kevin.flowers@ec.europa.eu
EU Maiken Rasmussen DG ENV maiken.rasmussen@ec.europa.eu
EU Peter Korytar DG ENV peter.korytar@ec.europa.eu
EU Sander van der Linden JRC sander.van-der-linden@ec.europa.eu
EU Sharon Munn JRC sharon.munn@ec.europa.eu
EU Georg Streck DG GROW georg.streck@ec.europa.eu
EU Hubert Deluyker EFSA Hubert.Deluyker@efsa.europa.eu
EU Karin Kilian DG ENV karin.kilian@ec.europa.eu
EU Sofie Norager DG RESEARCH sofie.norager@ec.europa.eu 
EU Tuomo Karjalainen DG RESEARCH Tuomo.KARJALAINEN@ec.europa.eu
EU Tobin Robinson EFSA tobin.robinson@efsa.europa.eu
EU Laura Fabrizi DG SANTE laura.fabrizi@ec.europa.eu 
EU Peter Lepper ECHA peter.lepper@echa.europa.eu 





International workshop on commonalities and differences in approaches for 
testing and assessment of endocrine disruptors within the EU and among 
relevant international trading partners 
19-20 September 2016, Hotel Bloom, Rue Royale 250, 1210 Bruxelles, Belgium 
Note on modus operandi during the workshop: 
Workshop discussions and deliberations will be conducted on the basis of detailed material and 
background documents which will be made available in advance (early Sept 2016)  
Registration and coffee breaks will take place on floor 1 in the meeting lounge, all plenary sessions 
take place in Meeting Room II, and working groups will take place in meeting rooms II and III. 
Free wifi is available (password: LOVE) 
Monday, 19 September 2016 
9:00 Arrival and registration  
9:30 Dr Bjorn Hansen (DG ENVI): Welcome from the European Commission 
9:45 Prof Andreas Kortenkamp (Brunel University London): Milestones, discoveries and set-backs 
in endocrine disrupter research – a potted history 
10:00 Discussion 
10:15 Prof Ulla Hass (Technical University of Denmark): Commonalities and differences - a 
summary of project outcomes thus far 
10:40 Discussion  
10:45 Dr Patience Browne (USEPA): Prioritization and Screening Chemicals for Endocrine 
Bioactivity in the US 
11:15 Discussion 
11:30 COFFEE BREAK 
12:00 Dr Jun Kanno (JBRC, NIHS, Japan): The Concept of “Signal Toxicity” for the Planning of 
Research and Testing of Endocrine Disrupting Chemicals - beyond EATS. 
12:30 Discussion 
12:45 LUNCH (Restaurant) 
14:00 Dr Sharon Munn (DG Joint Research Centre): The EASIS data base (Endocrine Active 





14:35 Dr Olwenn Martin (Brunel University London): Weighing and integrating evidence in hazard 
and risk assessment of endocrine disruptors 
15:00 Discussion 
15:05 Commonalities and differences in screening, testing, interpreting endocrine disruptors – 
General discussion: what is the problem and where is a way ahead? 
 Moderation: Prof Andreas Kortenkamp 
15:35 COFFEE 
16:00 Prof Andreas Kortenkamp (Brunel University London): Introduction to Working Groups: The 
Scope for International Collaboration 
 Assembly of 4 parallel running working groups on identifying the scope for international 
collaboration 
Working Group 1: The scope for data sharing on ED hazards and exposures at the international 
level 
Working Group 2: Setting priorities for screening and testing for ED properties – commonalities 
and differences and scope for common principles 
Working Group 3: Research needs and horizon scanning in the ED arena – prospects for 
international cooperation? 
Working Group 4: Harmonisation of hazard and risk assessment for endocrine disruptors at the 
international level – opportunities and limitations 







Tuesday, 20 September 2016 
9:00 Dr  Bjorn Hansen (DG ENVI): Introduction to Working groups: recap from day 1 
9:15 Working Groups resume 
10:30 COFFEE 
11:00 Presentation of results: from commonalities and differences to opportunities for 
collaboration 
 Moderation: Dr Bjorn Hansen (DG ENVI) 
11:00 Working Group 1 
11:30 Working Group 2 
12:00 Working Group 3 
12:30 LUNCH (Meeting Lounge) 
13:30 Working Group 4 
14:00 General discussion 
 Moderation: Dr Bjorn Hansen (DG ENVI) 
15:00 COFFEE 
15:30 Conclusions and wrap-up 
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from the delegations in non-EU countries 
(http://eeas.europa.eu/delegations/index_en.htm);  
by contacting the Europe Direct service (http://europa.eu/europedirect/index_en.htm) 
or calling 00 800 6 7 8 9 10 11 (freephone number from anywhere in the EU) (*). 
 
(*) The information given is free, as are most calls (though some operators, phone boxes or hotels may 
charge you). 
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• via EU Bookshop (http://bookshop.europa.eu). 
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• via one of the sales agents of the Publications Office of the European Union 
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